EMBASE Cardiac Update AutoAlert: EPICORE Cardiac Surgery Blogger2

Total documents retrieved: 90

Results Generated From:
Embase <1980 to 2024 Week 29>
Embase Weekly Updates (updates since 2024-07-12)

<1>
Accession Number
2032793584
Title
Factors Associated With Coronary Angiography Performed Within 6 Months of
Randomization to the Conservative Strategy in the ISCHEMIA Trial.
Source
Circulation: Cardiovascular Interventions. 17(6) (pp 457-473), 2024. Date
of Publication: 01 Jun 2024.
Author
Spertus J.A.; Broderick S.; Rockhold F.W.; Demchenko E.; Grossman G.B.;
Stone G.W.; Mancini G.B.J.; Hochman J.S.; Boden W.E.; Mavromatis K.; Doan
J.; Linefsky J.; Lee R.; Patel R.; Miller T.; Cho S.Y.; Milbrandt S.;
Shelstad D.; Banerjee S.; Kamath P.; Tejani I.; Reynolds H.R.; Newman
J.D.; Bangalore S.; Phillips L.M.; Saric M.; Abdul-Nour K.; Schley A.;
Golden H.; Stone P.H.; Osseni H.; Wiyarand C.; Douglass P.; Pomeroy H.;
Craft A.; Harvey B.; Jang J.J.; Anaya O.; Yee G.; Goold P.; Weitz S.;
Giovannone S.; Pritchard L.; Arnold S.; Gans R.; O'Keefe J.H.; Kennedy P.;
Shapiro M.D.; Ganesan S.; Schlichting D.; Naher A.; Fein S.A.; Stewart
W.L.; Torosoff M.T.; Salmi K.M.; Lyubarova R.; Mookherjee S.; Drzymalski
K.; McFalls E.O.; Garcia S.A.; Bertog S.C.; Johnson D.K.; Siddiqui R.A.;
Herrmann R.R.; Ishani A.; Hansen R.A.; Khouri M.G.; Arges K.; LeFevre M.;
Tomfohr J.; Goldberg J.L.; Byrne K.A.; Zappernick T.; Goldweit R.; Canada
S.; Kakade M.; Mieses P.; Cohen R.A.; Mirrer B.; Navarro V.; Rantinella
M.; Rodriguez J.; Mancilla O.; Winchester D.E.; Stinson S.; Kronenberg M.;
Weyand T.; Crook S.C.; Heitner J.F.; Ho J.; Khan S.; Mohamed M.; Dauber
I.M.; Soltau M.R.; Rose D.K.; Wimmer R.J.; Siegel K.E.; Derbyshire S.;
Cannan C.; Dixon M.; Leonard G.; Sudarshan S.; Heard C.; Gabriel V.;
Desire S.; Mehta P.K.; McDaniel M.; Rashid F.; Lerakis S.; Asier S.;
Quyyumi A.; Patel K.; Wenger N.K.; Hedgepeth C.M.; Gillis J.; Hurlburt H.;
Manocchia M.; Rosen A.; Moore S.; Congdon E.; Sahul Z.; Brandt G.;
Marchelletta N.; Wippler K.; Leung S.; Reda H.; Ziada K.; Setty S.;
Halverson K.E.; Roraff C.; Thorsen J.; Barua R.S.; Ojajuni A.; Olurinde
O.; Surineni K.; Hage F.; Valaiyapathi B.; Davies J.E.; Leesar M.; Heo J.;
Iskandrian A.; Al Solaiman F.; Dajani K.; Kartje C.M.; El-Hajjar M.;
Mesropian P.D.; Sacco J.; Rawlins M.; McCandless B.; Thomson J.; Orgera
M.; Sidhu M.S.; Rogge M.C.; Arif I.; Bunke J.; Kerr H.; Unterbrink K.;
Fannon J.; Burman C.; Trejo J.F.; Dubin M.F.; Fletcher G.; Lane G.E.;
Neeson L.M.; Parikh P.P.; Pollak P.M.; Shapiro B.P.; Landolfo K.;
Gemignani A.; Beaudry S.; O'Rourke D.; Meadows J.L.; Tirado S.A.; Halliday
J.; Julian P.; Call J.T.; Lane S.M.; Stanford J.L.; Hannan J.; Bojar R.;
Arsenault P.; Kumar D.; Sigel P.; Mukai J.; Martin E.T.; Brooks M.;
Vorobiof G.; Douangvila L.; Gevorgyan R.; Moor-Man A.; Ranjbaran F.; Smith
B.; Ohmart C.; Kinlay S.; Hamburger R.J.; Rocco T.P.; Ly S.; Bhatt D.L.;
Quinn M.C.; Croce K.; Temiyasathit S.; Quin J.A.; Do J.; Anumpa J.; Tobin
D.; Zenati M.; Faxon D.P.; Rayos G.; Langdon J.; Bayer M.W.; Seedhom A.;
O'Malley A.; Sullenberger L.; Orvis E.; Kumkumian G.; Murphy M.; Greenberg
A.; Iraola M.; Sedlis S.P.; Maranan L.C.; Donnino R.M.; Lorin J.;
Tamis-Holland J.E.; Malinay A.; Kornberg R.; Leber R.; Saba S.; Edillo
C.P.; Lee M.W.; Small D.R.; Nona W.; Alexander P.B.; Rehman I.; Badami U.;
Ostrander A.; Wasmiller S.; Marzo K.; Drewes W.; Patel D.; Robbins I.H.;
Levite H.A.; White J.M.; Shetty S.; Hallam A.; Patel M.; Hamroff G.S.;
Spooner B.J.; Hollenweger L.M.; Little R.W.; Little H.; Zimbelman B.D.;
Little T.; Lui C.Y.; Eskelson N.A.; Smith B.R.; Vezina D.P.; Khor L.L.;
Abraham J.D.; Bull D.A.; McKellar S.H.; Booth D.; Taul Y.; Kotter J.;
Rodgers C.; Abdel-Latif A.; Isaacs J.; Bulkley V.; Hu B.; Kaneshiro R.;
Labovitz A.J.; Berlowitz M.; Kirby B.J.; Rogal P.; Tran N.N.; McFarren C.;
Jahrsdorfer C.; Matar F.; Caldeira C.; Maron D.J.; Rodriguez F.; Yunis R.;
Schnittger I.; Patro J.; Fearon W.F.; Deedwania P.; Vega A.; Reddy K.;
Sweeny J.; Bloise-Adames H.; Jimenez S.; Vrestil N.S.; Bhandari R.;
Spizzieri C.; Schade D.; Yost R.; Hochberg C.P.; Beardsley P.; Fine D.;
Salerno W.D.; Tancredi J.; Arakelian P.; Mathus S.; O'Neill D.; Wyman R.;
Burkhardt J.; Hosino S.; Lubyanaya O.A.; Salas J.D.; Zarka A.; Aguirre M.;
Shah A.V.; Dhawan M.; Parra D.; Tran T.; Haldis T.; Fowler-Lehman K.;
Spitzer N.; Riedberger C.; Weick C.; Kohn J.A.; Girotra S.; Drum C.;
Miller-Cox K.; Ollinger A.; Almousalli O.; Capasso-Gulve E.; Loehr A.M.;
Mosley M.; Krishnam M.S.; Heydari S.; Mil-Liken J.C.; Lundeen A.M.; Patel
P.M.; Karanjah E.; Seto A.H.; Marfori W.C.; Harley K.T.; Hernandez-Rangel
E.; Gibson M.A.; Singh P.; Allen B.J.; Coram R.; Webb A.M.; Fridell E.;
Wilson H.; Thomas S.; Kim A.; Schwartz R.G.; Wilmot P.; Chen W.; El
Shahawy M.; Stevens R.; Stafford J.; Black L.; Abernethy W.B.; Hull A.B.;
Lim O.J.; Tucker H.C.; Putnam N.C.; Hall L.L.; Cauthren T.; Tucker T.;
Zurick A.; Horton H.; Orga J.; Meyer T.M.; White J.R.; Morford R.G.;
Baumann C.; Rutkin B.; Seeratan V.; Bokhari S.; Jimenez M.; Sokol S.I.;
Schultz C.; Meisner J.; Russo J.; Hamzeh I.; Misra A.; Huda Z.; Wall M.;
Boan A.; De Rosen V.L.; Alam M.; Turner M.C.; Hinton C.R.; Mulhearn T.J.;
Good A.P.; Archer B.A.; Dionne J.S.; Allardyce C.A.; Sikora L.N.; Czerniak
J.H.; Mull J.A.; Ferguson E.; Laube F.; Shammas N.W.; Shammas G.A.;
Christensen L.; Park H.; Chilton R.; Hecht J.; Nguyen P.K.; Vo D.; Hirsch
J.; Jezior M.; Bindeman J.; Salkind S.; Desimone L.-A.; Gordon P.C.;
Felix-Stern L.; Crain T.; Gomes J.; Gordon C.; Stenberg R.; Mann A.;
McCreary T.; Pedalino R.P.; Cobos S.E.; Dwyer R.R.; Espinosa D.; Quiles
K.J.; Wiesel J.; Juang G.J.; Gopaul C.; Hultberg K.; Huk T.; Hussain A.;
Al-Amoodi M.; Zambrano Y.; Rodriguez S.M.; Milner T.; Wohns D.; Mulder A.;
Van Oosterhout S.; Lader E.W.; Meyer M.; Mumma M.; Clapp N.L.; Barrentine
H.; Dharmarajan L.; Jose J.M.; Manchery J.; McGarvey J.F.X.; McKinney V.;
Schwarz L.; Downes T.R.; Kaczkowski S.M.; Luckasen G.J.; Jaskowiak A.J.;
Klitch J.; Cheong B.; Dees D.; Potluri S.; Vasquez P.; Mastouri R.A.;
Breall J.A.; Hannemann E.L.; Revtyak G.E.; Foltz J.M.; Bazeley J.W.;
DeRosa E.; Jorgenson B.; Riestenberg-Smith J.; Giedd K.; Old W.; Bariciano
R.; Burt F.; Sokhon K.; Waldron J.; Mayon M.; Gopal D.; Valeti U.S.;
Peichel G.A.; Kobashigawa J.; Starks B.; Garcia L.; Thottam M.; Anand A.;
Govindan S.C.; Raj J.; Nair R.G.; Ravindran R.; Rajalekshmi V.S.;
Manjunath C.N.; Nataraj N.; Moorthy N.; Nayak S.; Manjunath S.C.;
Mylarappa M.; Narayanappa S.; Pandit N.; Bajaj S.; Nath R.K.; Yadav V.;
Mishra G.; Dwivedi S.K.; Tewari R.; Narain V.S.; Mishra M.; Chandra S.;
Patel S.; Wander G.S.; Tandon R.; Ralhan S.; Kaur B.; Aslam N.; Gupta S.;
Pharmacy B.; Goyal A.; Bhargava B.; Suvarna C.; Karthikeyan G.;
Ramakrishnan S.; Seth S.; Yadav R.; Singh S.; Roy A.; Parakh N.; Verma
S.K.; Narang R.; Mishra S.; Naik N.; Sharma G.; Choudhary S.K.; Patel C.;
Gulati G.; Sharma S.; Bahl V.K.; Mathew A.; Kurian B.M.; Punnoose E.;
Gadkari M.A.; Karwa S.R.; Gadage S.; Kolhe S.; Pillay T.U.; Satheesh S.;
Vindhya R.J.; Jain P.; Seth A.; Meharwal Z.S.; Mathur A.; Verma A.; Bhatia
M.; Sachdeva A.; Devi T.I.; Jungla N.; Rani K.M.; Menon R.; Reddy M.S.;
Oomman A.; Sidh R.R.; Mao R.; Ramakrishnan T.; Solomon H.; Francis R.;
Priya V.P.; Khan S.P.; Preethi K.; Kumar N.; Grant P.; Hande S.; Sonawane
P.; Kachru R.; Dubey A.; Rawat K.; Kumar A.V.K.; Ganapathi S.; Jayakumar
K.; Vineeth C.P.; Sivadasanpillai H.; Chacko M.; Sasidharan B.; Babu S.;
Kapilamoorthy T.R.; Christopher J.; Reddy S.; Polamuri P.; Rani M.; Kaul
U.; Arambam P.; Singh B.; Senior R.; Fox K.A.A.; Carruthers K.; Elghamaz
A.; Gurunathan S.; Karogiannis N.; Young G.M.; Shah B.N.; Kinsey C.;
Trimlett R.H.J.; Kavalakkat R.; Rubens M.B.; Evans J.; Nicol E.D.; Hassan
I.; Mittal T.K.; Hampson R.; Gamma R.A.; Williams S.; Holland K.; Swan K.;
de Belder M.A.; Atkinson B.; Thambyrajah J.; Nageh T.; Kunhunny S.; Davies
J.R.; Lindsay S.J.; Atkinson C.; Kurian J.; Krannila C.; Jamil H.; Vinod
M.; Raheem O.; Hoye A.; Chaytor L.; Cox L.; Morrow J.; Rowe K.; Donnelly
P.; Kelly S.; Valecka B.; Regan S.; Turnbull D.; Chauhan A.; Fleming C.;
Ghosh A.; Gratrix K.; Preston S.; Barr C.; Cartwright A.; Alfakih K.;
Knighton A.; Byrne J.; Martin K.; Webb I.; Henriksen P.; Flint L.;
Harrison J.; OKane P.; Lake-Man N.; Ljubez A.; de Silva R.; Conway D.S.G.;
Wright J.; Exley D.; Sirker A.A.; Andiapen M.; Richards A.J.; Hoole S.P.;
Wong L.; Witherow F.N.; Munro M.J.; Harbinson M.; McEvoy M.; Walsh S.; Bao
B.; Brown C.; Douglas H.; Luckie M.; Charles T.; Kolakaluri L.; Phillips
H.; Sobolewska J.; Morby L.; Hallett K.; Corbett C.; Winstanley L.;
Jeetley P.; Smit A.; Patel N.; Kotecha T.; Travill C.; Gent S.; Karimullah
I.; Hussain N.; Al-Bustami M.; Braganza D.; Haines F.; Taaffe J.;
Henderson R.; Burton J.; Pointon K.; Colton M.; Naik S.; King R.; Mathew
T.; Brown A.; Docherty A.; Berry C.; McCloy L.; Collison D.; Robb K.;
Roditi G.; Paterson C.; Crawford W.; Kelly J.; McGregor L.; Moriarty A.J.;
Mackin A.; Glover J.D.; Knight J.P.; Pradhan J.; Mikhail G.; Bose T.;
Francis D.P.; Dzavik V.; Proietti A.; Brousseau M.; Corfias M.; Blaise P.;
Harvey L.; Diaz A.; Rheault P.; Barrero M.; Gagne C.-E.; Alarie P.;
Pepin-Dubois Y.; Arcand L.; Costa R.; Roy I.; Sia Y.T.; Montpetit E.;
Lemay C.; Gisbert A.; Gervais P.; Rheault A.; Drouin K.; Phaneuf D.C.;
Bergeron C.; Gosselin G.; Shelley C.; Masson C.; Garg P.; Carr S.; Bone
C.; Chow B.J.W.; Moga E.; Hessian R.C.; Kourzenkova J.; Beanlands R.S.;
Walter O.; Davies R.F.; Bainey K.R.; Hogg N.; Welsh S.; Bagai A.; Wald R.;
Goodman S.; Graham J.J.; Peterson M.; Bello O.; Chow C.-M.; Abramson B.;
Cheema A.N.; Syed I.; Vakani M.T.; Hussain M.; Kushniriuk K.; Cha J.; Otis
J.; Otis R.; Howarth A.G.; Seib M.M.; Rivest S.M.; Sandonato R.; Chow J.;
Starovoytov A.; Uchida N.; Meadows N.; Uxa A.; Asif N.; Tavares S.;
Galiwango P.; Bozek B.; Kassam S.; Shier M.; Mukherjee A.; Larmand L.-A.;
Ricci A.J.; Janmohamed A.; Hart B.; Lam A.; Marucci J.; Tai S.; Mehta S.;
Brons S.; Beck C.; Wong G.; Etherington K.; Arumairajah T.; Udell J.;
Aprile M.; Karlsson S.; Webber S.; Genereux P.; Mercure C.; Hameed A.;
Aedy N.; Daba L.; Farquharson F.; Siddiqui A.; Lopes R.D.; Hueb W.;
Takiuti M.E.; Rezende P.C.; Silva E.E.R.; Hueb A.C.; Smanio P.E.P.;
Caetano L.P.; de Quadros A.S.; Kalil R.A.K.; Deiro A.P.; da Costa Vieira
J.L.; Muller A.M.; Grossmann G.; de Moraes M.A.P.; de Oliveira P.P.;
Ascoli B.M.; Bridi L.; Poletti S.Z.; Savaris S.; Vitola J.V.; Cerci R.J.;
Zier S.S.; Farias F.R.; Veiga V.; Fernandes M.M.; Marin-Neto J.A.; Schmidt
A.; de Oliveira Lima Filho M.; da Cunha D.F.; Oliveira R.M.; Chierice
J.R.A.; Polanczyk C.A.; Rucatti G.G.; Furtado M.V.; Igansi F.; Smidt L.F.;
Haeffner M.P.; Carvalho A.C.; Almeida V.; Pucci G.; de Souza G.S.; Lyra
F.; Alves A.R.; Almeida M.; dos Santos V.; Dracoulakis M.D.A.; Oliveira
N.S.; Lima R.G.S.D.; Figueiredo E.; Azevedo B.E.P.; Caramori P.R.; Santos
M.B.; Germann A.; Gomes V.; Homem R.; Magedanz E.; Tumelero R.; Laimer R.;
Tognon A.; Dall'Orto F.; Mesquita C.T.; Santos R.P.; Colafranseschi A.S.;
Oliveira A.C.; Carvalho L.A.; Palazzo I.C.; Sousa A.S.; da Silva E.E.R.;
de Barros e Silva P.G.M.; Okada M.Y.; de Padua Silva Baptista L.; Batista
A.P.; Rodrigues M.J.; Rabaca A.N.; de Resende M.V.C.; Saraiva J.F.; Trama
L.M.; de Souza Ormundo C.T.; Vicente C.; Costantini C.; Pinheiro C.; Komar
D.; Ruzyllo W.; Demkow M.; Pracon R.; Kepka C.; Teresinska A.; Walesiak
O.; Kryczka K.; Malinowska K.; Henzel J.; Solecki M.; Kaczmarska E.;
Mazurek T.; Maksym J.; Wojtera K.; Fojt A.; Szczerba E.; Drozdz J.;
Czarniak B.; Frach M.; Szymczyk K.; Niedzwiecka I.; Sobczak S.; Ciurus T.;
Jakubowski P.; Misztal-Teodorczyk M.; Teodorczyk D.; Swiderek M.; Fratczak
A.; Wojtala E.; Szkopiak M.; Lebioda P.; Wlodarczyk M.; Plachcinska A.;
Kusmierek J.; Miller M.; Marciniak H.; Wojtczak-Soska K.; Luczak K.;
Tarchalski T.; Cichocka-Radwan A.; Szwed H.; Karwowski J.; Szulczyk G.A.;
Witkowski A.; Kukula K.; Celinska-Spodar M.; Zalewska J.; Gajos G.; Bury
K.; Pruszczyk P.; Labyk A.; Roik M.; Szramowska A.; Zdonczyk O.;
Loboz-Grudzien K.; Jaroch J.; Sokalski L.; Brzezinska B.; Lesiak M.;
Lanocha M.; Reczuch K.W.; Kolodziej A.; Kalarus Z.; Swiatkowski A.; Szulik
M.; Musial W.J.; Marcinkiewicz-Siemion M.; Bockeria O.; Bockeria L.;
Petrosyan K.; Kudzoeva Z.; Trifonova T.; Aripova N.; Chernyavskiy A.M.;
Naryshkin I.A.; Kretov E.I.; Kuleshova A.; Grazhdankin I.O.; Malaev D.;
Bershtein L.L.; Sayganov S.A.; Subbotina I.; Kuzmina-Krutetskaya A.M.;
Gumerova V.; Zbyshevskaya E.V.; Katamadze N.O.; Demchenko E.A.; Nikolaeva
O.B.; Kozlov P.S.; Kozulin V.Y.; Lubinskaya E.I.; Lopez-Sendon J.L.;
Lopez-Sendon J.; Fernandez-Figares V.; Castro A.; Salicio E.R.; Guzman G.;
Galeote G.; Valbuena S.; Peteiro J.; Martinez-Ruiz M.D.; Perez-Fernandez
R.; Blanco-Calvo M.; Cuenca-Castillo J.J.; Alonso-Alvarez E.; Flores-Rios
X.; Garcia-Gonzalez P.; Prada-Delgado O.; Barge-Caballero G.; Juanatey
J.R.G.; Amigo J.S.; Bayarri M.S.; Nunez V.P.; Sanchez R.O.; Alvarez B.C.;
Gil C.P.; Monzonis A.M.; Sionis A.; Martinez A.F.; Perales M.V.; Padro
J.M.; Penaranda A.S.; Picart J.G.; Iglesias A.G.; Marimon X.G.-M.; Llado
G.P.; Costa F.C.; Miro V.; Igual B.; Diez J.L.; Calvillo P.; Ortuno F.M.;
Chavarri M.V.; Giner M.Q.; Montolliu A.T.; Aniorte A.I.R.; Bermudez E.P.;
Caravaca J.M.R.; De La Morena G.; Blancas M.G.; Canavate O.; Guerrero S.;
Riera S.; Luena J.E.C.; Lasala M.; Fernandez-Aviles F.; Lorenzo M.;
Sobrino O.; Vazquez A.; Jiang L.; Chen J.; Dong H.; He P.; Xia C.; Yang
J.; Zhong Q.; Wu Y.; Tian Y.; Li D.; Ma Y.; Yang Y.; Ma X.; Yu Z.; Zhao
Q.; Ji Z.; Li C.; Zhu B.; Yang X.; Chen M.; Chi H.; Zhang J.; Lin W.; Jing
R.; Liu J.; Zeng H.; Zhou Q.; Xu C.; Li Z.; Xiong L.; Fu X.; Gao D.; Jiang
D.; Leng R.; Yuan Q.; Zhang L.; Bai Z.; Li J.; Qi J.; Wang F.; Wang H.;
Yang B.; Yue Z.; Zhang Z.; Wang S.; Dong Y.; Mao J.; Zhang B.; Cheng G.;
Li X.; Yao X.; Zhong N.; Zhou N.; Huang Y.; Zhou P.; Fang X.; Su W.; Zeng
Q.; Kunwu Y.; Peng Y.; Su X.; Wang C.; Zhao Y.; Li Q.; Geng Y.; Wang Y.;
Nie S.-P.; Fan J.-Y.; Feng S.-T.; Wang X.; Yan Y.; Zhang H.-M.; Yu Q.; Chi
L.; Liu F.; Chen H.; Jiang J.; Li H.; Wang J.; Han Y.; Xu L.; Zhang S.;
Liu Z.; Chen G.; Hu R.; Perna G.P.; Pietrucci F.; Marini M.; Gabrielli G.;
Provasoli S.; Di Donato A.; Verna E.; Monti L.; Nardi B.; Di Chiara A.;
Pezzetta F.; Mortara A.; Casali V.; Galvani M.; Attanasio C.; Ottani F.;
Sicuro M.; Leone G.; Pisano F.; Bare C.; Calabro P.; Fimiani F.; Formisano
T.; Tarantini G.; Barioli A.; Cucchini U.; Ramani F.; Andres A.L.; Racca
E.; Rolfo F.; Goletto C.; Briguori C.; De Micco F.; Amati R.; Di Marco S.;
Vergoni W.; Tricoli M.; Russo A.; Villella M.; Fanelli R.; Poh K.-K.; Chai
P.; Lau T.; Loh J.P.; Tay E.L.; Teoh K.; Tan S.-Y.V.; Teo L.L.; Sia W.C.;
Ong C.-C.; Leong A.W.; Wong R.C.; Loh P.-H.; Kofidis T.; Chan W.X.; Chan
K.H.; Foo D.; Yan L.H.; Kong J.L.K.; Er C.M.; Jafary F.-H.H.; Chua T.;
Ismail N.; Kyaw M.T.; Yip D.; Doerr R.; Stumpf J.; Grahl D.; Matschke K.;
Guenther F.; Simonis G.; Bonin K.; Kadalie C.T.; Sechtem U.; Wenzelburger
I.; Ong P.; Gruensfelder S.; Schulze P.C.; Goebel B.; Lenk K.; Nickenig
G.; Sinning J.-M.; Weber M.; Werner N.; Schuchlenz H.; Steinmaurer G.;
Weikl S.; Lang I.M.; Winter M.-P.; Andric T.; Huber K.; Maximilian T.;
Gabriele J.-K.; Claudia W.; Bernhard J.; Florian E.; Keltai M.; Vertes A.;
Sebo J.; Davidovits Z.; Matics L.; Varga A.; Agoston G.; Fontos G.; Dekany
G.; Merkely B.; Bartykowszki A.; Maurovich-Horvat P.; Kerecsen G.; Jakal
A.; Hinic S.; Djokic J.; Zdravkovic M.; Mudrenovic V.; Crnokrak B.;
Beleslin B.D.; Boskovic N.N.; Djordjevic-Dikic A.D.; Petrovic M.T.; Giga
V.L.; Dobric M.R.; Stepanovic J.J.; Markovic Z.Z.; Mladenovic A.S.;
Cemerlic-Adjic N.; Velicki L.; Pupic L.; Davidovic G.; Simovic S.M.; Vucic
R.; Dekleva M.N.; Martinovic M.S.; Stevanovic G.; Stankovic G.; Dobric M.;
Apostolovic S.; Martinovic S.S.; Stanojevic D.; Escobedo J.; de
Jesus-Perez R.; Juarez B.; Baleon-Espinosa R.; Campos-Santaolalla A.S.;
Duran-Cortes E.; Flores-Palacios J.M.; Garcia-Rincon A.; Jimenez-Santos
M.; Penafiel J.V.; Ortega-Ramirez J.A.; Valdespino-Estrada A.; Rosas E.A.;
Brassetti M.F.C.; Anaya D.A.V.; Garcia M.P.; Juarez I.E.C.; Rovalo M.M.;
Rodriguez E.D.M.; Selvanayagam J.B.; Rankin J.; Murphy D.; Lee S.; Joseph
M.X.; Thomas P.; Thambar S.T.; Chaplin M.D.; Boer S.C.; Beltrame J.F.;
Stansborough J.K.; Black M.; Hillis G.S.; Bonner M.M.; Ireland K.F.;
Venn-Edmonds C.; Steg P.-G.; Thobois C.; Thuaire C.; Tachot E.; Dutoiu T.;
Laure C.; Vassaliere C.; Steg P.G.; Abergel H.; Juliard J.-M.; Fuentes A.;
Slama M.S.; Eliahou L.; Mahmoud R.E.; Dubourg O.; Michaud P.; Nicollet E.;
Hadjih S.; Goube P.; Brito P.; Barone-Rochette G.; Furber A.; Cornet C.;
Biere L.; Rautureau J.; Juceviciene A.; Kalibataite-Rutkauskiene I.;
Keinaite L.; Laucevicius A.; Laukyte M.; Celutkiene J.; Mikolaitiene G.;
Smigelskaite A.; Tamasauskiene I.; Urboniene A.; Kedhi E.; Timmer J.;
Bouwhuis I.; Hermanides R.; Nijmeijer L.; Kaplan E.; Riezebos R.K.; Samadi
P.; Schoep J.J.M.; van Dongen E.; Janzen E.M.; Niehe S.R.; Suryapranata
H.; Ahoud S.; van Vugt S.; Ramos R.; Cacela D.; Santana A.; Fiarresga A.;
Sousa L.; Marques H.; Patricio L.; Selas M.; Bernanrdes L.; Silva F.; Rio
P.; Freixo C.; Carvalho R.; Ferreira R.; Silva T.; Rodrigues I.; Modas P.;
Portugal G.; Fragata J.; Pinto F.J.; Cabrita I.Z.; Menezes M.N.; Rocha A.;
Lopes G.C.; Figueiras F.P.; Almeida A.G.; Coelho A.; Silva P.C.; Capinha
M.; Nobre A.; Caetano M.I.; Francisco A.R.; Silva S.; Ferreira N.; Lopes
R.L.; Diaz R.; Guzman L.; Tinnirello V.; Figal J.C.; Mungo M.N.; Mendiz
O.; Cortes C.; Favaloro R.R.; Alvarez C.; Garcia M.; Courtis J.; Godoy V.;
Zeballos G.; Schiavi L.; Actis M.V.; Rubio M.; Scaro G.; Devlin G.P.; Low
L.; Fisher R.; Scales J.; Abercrombie K.; Stewart R.A.H.; Howell L.;
Patten C.; Benatar J.; Kedev S.; Mitevska I.P.; Kostovska E.S.; Pejkov H.;
Held C.; Eggers K.; Frostfelt G.; Bjorklund C.; Johnston N.; Andreasson
M.; Olsowka M.; Essermark M.; Akerblom A.; Soveri I.; Aspberg J.; Persson
L.; Beyar R.; Nikolsky E.; Sharir T.; Harel O.; Elian D.; Kerner A.;
Bentzvi M.; Massalha S.; Helmer L.; Fukuda K.; Ueda I.; Kohsaka S.; Fujita
J.; Yasuda S.; Furukawa A.; Nagai T.; Otsuka F.; Nishimura S.; Nakano S.;
Goetschalckx K.; Robesyn V.; Van de Werf F.; Claes K.; Hung C.-L.; Yang
Y.-H.; Yun C.-H.; Hou C.J.-Y.; Kuo J.-Y.; Yeh H.-I.; Hung T.-C.; Li J.-Y.;
Chien C.-Y.; Tsai C.-T.; Liu C.-C.; Yu F.-C.; Lin Y.-H.; Lan W.-R.; Yen
C.-H.; Tsai J.-P.; Sung K.-T.; Ntsekhe M.; Pandie S.; Philander C.;
Viljoen C.A.; Mtana N.; De Andrade M.; Maggioni A.P.; Moccetti T.; Anesini
A.; Rossi M.G.; Maspoli S.; Mombelli M.; Abdelhamid M.; Talaat A.; Adel
A.; Kamal A.; Mahrous H.; El Kaffas S.; El Fishawy H.; Pop C.; Claudia M.;
Popescu B.A.; Ginghina C.; Rosca M.; Deleanu D.; Beladan C.C.; Iliescu
V.A.; Al-Mallah M.H.; Zahrani S.; Aljzeeri A.; Najm H.; Alghamdi A.; Ramos
W.E.M.; Davila M.A.M.; Kuanprasert S.; Prommintikul A.; Nawarawong W.;
Khwakhong S.; Woragidpoonpol S.; Chaiyasri A.; Tepsuwan T.; Mekara W.;
Taksaudom N.; Kulthawong S.; Rimsukcharoenchai C.; Amaritakomol A.;
Euathrongchit J.; Wannasopha Y.; Yamwong S.; Panpunuan P.; Sritara P.;
Aramcharoen S.; Meemuk K.; White H.D.; Alsweiler C.; Khairuddin A.;
Mokhtar N.S.; Hadi H.A.; Basri N.A.; Yahaya S.A.; Yusnida I.; Hashim H.
Institution
(Pracon, Ruzyllo) National Institute of Cardiology, Warsaw, Poland
(Spertus) Saint Luke's Mid America Heart Institute, University of
Missouri-Kansas City, Durham, NC, United States
(Broderick, Rockhold) Duke Clinical Research Institute, Durham, NC, United
States
(Bangalore, Newman, Reynolds, Hochman) Cardiovascular Clinical Research
Center, New York University Grossman School of Medicine, Durham, NC,
United States
(Rockhold) Department of Biostatistics and Bioinformatics, Duke University
School of Medicine, Durham, NC, United States
(Demchenko) Almazov National Medical Research Centre, Saint Petersburg,
Russian Federation
(Nageh) Southend University Hospital, United Kingdom
(Grossman) Moinhos de Vento Hospital, Porto Alegre, Brazil
(Grossman) Cardionuclear Clinic, Porto Alegre, Brazil
(Mavromatis) Emory University, Atlanta VA Healthcare System, GA, United
States
(Manjunath) Sri Jayadeva Institute of Cardiovascular Sciences and
Research, Bengaluru, India
(Smanio) Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil
(Stone) Icahn School of Medicine at Mount Sinai, New York, NY, United
States
(Mancini) Center for Cardiovascular Innovation, The University of British
Columbia, Vancouver, Canada
(Boden) VA New England Healthcare System, Boston University School of
Medicine, MA, United States
(Maron) Department of Medicine, Stanford University, CA, United States
(Boden, Mavromatis, Doan) Atlanta VA Medical Center, Decatur, GA, United
States
(Linefsky, Lee, Patel, Miller, Cho) Mayo Clinic, Rochester, MN, United
States
(Milbrandt, Shelstad, Banerjee, Kamath) V.A. North Texas Health Care
System, Dallas, TX, United States
(Tejani) NYU Langone Medical Center-Bellevue Hospital, New York, NY,
United States
(Reynolds, Newman, Bangalore, Donnino, Phillips, Saric, Abdul-Nour,
Schley) Henry Ford Health System, Detroit, MI, United States
(Golden, Stone, Osseni) Brigham & Women's Hospital, Harvard Medical
School, Boston, MA, United States
(Wiyarand, Douglass, Pomeroy, Craft, Harvey, Jang, Anaya) Kaiser
Permanente San Jose, San Jose, CA, United States
(Yee, Goold, Weitz, Giovannone) Cardiology Associates of Schenectady P.C.,
Schenectady, NY, United States
(Pritchard, Arnold, Gans) Saint Luke's Hospital, Kansas City, MO, United
States
(O'Keefe, Kennedy, Shapiro, Ganesan) Oregon Health & Science University,
Portland, OR, United States
(Schlichting, Naher) Albany Medical Center Hospital, Albany, NY, United
States
(Fein, Stewart, Torosoff, Salmi, Lyubarova, Mookherjee, Drzymalski,
McFalls) Minneapolis VAMC, Minneapolis, MN, United States
(Garcia, Bertog, Johnson, Siddiqui, Herrmann, Ishani, Hansen, Khouri,
Arges) Duke University Medical Center, Durham, NC, United States
(LeFevre, Tomfohr, Goldberg, Byrne) Louis Stokes Cleveland Veterans
Affairs Medical Center, Cleveland, OH, United States
(Zappernick, Goldweit, Canada) Englewood Hospital and Medical Center,
Englewood, NJ, United States
(Kakade) NYU-HHC Woodhull Hospital, Brooklyn, NY, United States
(Mieses, Cohen, Mirrer, Navarro, Rantinella, Rodriguez, Mancilla,
Winchester, Stinson) Malcom Randall VAMC, Gainesville, FL, United States
(Kronenberg, Weyand) Vanderbilt University Medical Center, Nashville, TN,
United States
(Rogal, Crook, McFarren, Heitner, Ho) New York -Presbyterian/Brooklyn
Methodist Hospital, Brooklyn, NY, United States
(Khan, Mohamed, Dauber, Soltau) South Denver Cardiology Associates, P.C.,
Littleton, CO, United States
(Rose, Wimmer, Siegel, Derbyshire, Cannan, Dixon) Providence Heart and
Vascular Institute, Portland, OR, United States
(Leonard, Sudarshan, Heard) Wichita Falls Heart Clinic, Wichita Falls, TX,
United States
(Gabriel, Desire, Mehta) Emory University, Atlanta, GA, United States
(McDaniel, Rashid, Lerakis, Asier, Quyyumi, Patel, Wenger, Hedgepeth,
Gillis) Kent Hospital, Warwick, RI, United States
(Hurlburt, Manocchia, Rosen, Moore, Congdon, Sahul, Brandt) Michigan
Heart, PC, Ypsilanti, MI, United States
(Marchelletta, Wippler, Booth, Taul) University of Kentucky, Lexington,
KY, United States
(Leung, Isaacs, Abdel-Latif, Bulkley, Reda, Rodgers, Ziada, Setty,
Halverson) Gundersen Lutheran Medical Center, La Crosse, WI, United States
(Roraff, Thorsen, Barua, Ojajuni) Kansas City VA Medical Center, Kansas
City, MO, United States
(Olurinde, Surineni, Hage, Valaiyapathi) UAB Vascular Biology and
Hypertension Program, Birmingham, AL, United States
(Caldeira, Davies, Leesar, Heo, Iskandrian, Al Solaiman, Singh, Dajani,
Kartje) Loyola University Medical Center, Maywood, IL, United States
(El-Hajjar) Samuel Stratton VA Medical Center of Albany NY, Albany, NY,
United States
(Mesropian, Sacco, Rawlins, McCandless, Thomson, Orgera, Sidhu, Rogge)
Cincinnati VA Medical Center, Cincinnati, OH, United States
(Arif, Bunke, Kerr, Unterbrink, Fannon, Burman, Trejo, Dubin) Mayo Clinic
Florida, Jacksonville, FL, United States
(Fletcher, Lane, Neeson, Parikh, Pollak, Shapiro, Landolfo, Gemignani,
Beaudry) VAMC-White River Junction, White River Junction, VT, United
States
(O'Rourke, Meadows, Tirado) VA Connecticut Healthcare System, West Haven,
CT, United States
(Halliday, Julian, Call, Lane) Winchester Cardiology and Vascular
Medicine, PC, Winchester, VA, United States
(Stanford, Hannan) Saint Vincent Hospital, Worcester Medical Center,
Worcester, MA, United States
(Bojar, Arsenault, Kumar, Sigel, Mukai, Martin, Brooks) Oklahoma Heart
Institute, Tulsa, OK, United States
(Vorobiof, Douangvila) Ronald Reagan UCLA Medical Center, Los Angeles, CA,
United States
(Gevorgyan, Moor-Man, Ranjbaran) University of Washington Medical Center,
Seattle, WA, United States
(Smith, Ohmart, Kinlay) VA Boston Healthcare System, West Roxbury, MA,
United States
(Hamburger, Rocco, Ly, Bhatt, Quinn, Croce, Temiyasathit, Quin, Do,
Anumpa, Tobin, Zenati, Faxon, Rayos, Langdon) Daytona Heart Group, Daytona
Beach, FL, United States
(Bayer, Seedhom, O'Malley) Capital Cardiology Associates, Albany, NY,
United States
(Sullenberger, Orvis, Kumkumian, Murphy) NIH Heart Center, Suburban
Hospital, Bethesda, MD, United States
(Greenberg, Iraola, Sedlis, Maranan) VA New York Harbor Health Care
System, New York, NY, United States
(Donnino, Lorin, Tamis-Holland, Malinay) Mount Sinai Saint Luke's
Hospital, Ridgewood, NJ, United States
(Kornberg, Leber, Saba, Edillo) Providence - Providence Park Hospital,
Southfield, MI, United States
(Lee, Small, Nona, Alexander, Rehman, Badami, Ostrander) Covenant Medical
Center, Inc., Saginaw, MI, United States
(Wasmiller, Marzo, Drewes) NYU Winthrop, Mineola, NY, United States
(Patel, Robbins) AtlantiCare Regional Medical Center, Pomona, NJ, United
States
(Levite, White, Shetty, Hallam, Patel, Hamroff, Spooner) NYP Medical
Medical Group Hudson Valley Cardiology, Cortlandt Manor, NY, United States
(Hollenweger, Little, Little) Houston Heart & Vascular Associates,
Houston, TX, United States
(Zimbelman, Little, Lui, Eskelson) Salt Lake City VA Medical Center, Salt
Lake City, UT, United States
(Smith, Vezina, Khor, Abraham, Bull, McKellar, Booth, Taul) Lexington VA
Medical Center, Lexington, KY, United States
(Kotter, Rodgers, Abdel-Latif, Isaacs, Bulkley, Hu, Kaneshiro) Palo Alto
Medical Foundation Research Institute, Palo Alto, CA, United States
(Labovitz) University of South Florida, Tampa, FL, United States
(Berlowitz, Kirby, Rogal, Tran, McFarren, Jahrsdorfer, Matar, Caldeira,
Maron) Stanford University School of Medicine, Stanford, CA, United States
(Rodriguez, Yunis, Schnittger, Patro, Fearon, Deedwania, Vega) UCSF -
Fresno Community Regional Medical Center, Fresno, CA, United States
(Reddy, Sweeny, Bloise-Adames) Icahn School of Medicine at Mount Sinai,
New York, NY, United States
(Jimenez, Vrestil, Bhandari, Spizzieri, Schade) Holy Spirit Hospital
Cardiovascular Institute, Camp Hill, PA, United States
(Yost, Hochberg, Beardsley) Boston Medical Center, Boston, MA, United
States
(Fine, Salerno, Tancredi) Hackensack University Medical Center, Saddle
Brook, NJ, United States
(Arakelian, Mathus, O'Neill, Wyman, Burkhardt) Torrance Memorial Medical
Center, Torrance, CA, United States
(Hosino, Lubyanaya) Coastal Heart Medical Group, Santa Ana, CA, United
States
(Salas, Zarka, Aguirre, Shah, Dhawan, Parra, Tran, Haldis, Weick) Sanford
Health, Fargo, ND, United States
(Fowler-Lehman, Spitzer, Riedberger, Weick, Kohn) NYU New York Medical
Associates, New York, NY, United States
(Cobos, Quiles, Girotra, Drum) University of Iowa Hospitals and Clinics,
Iowa City, IA, United States
(Miller-Cox, Ollinger, Almousalli, Capasso-Gulve) Advanced Heart Care
Group, Fairview Heights, IL, United States
(Loehr, Mosley, Krishnam, Heydari) University of California Irvine Medical
Center, Orange, CA, United States
(Mil-Liken, Lundeen, Patel, Karanjah, Seto, Marfori, Harley,
Hernandez-Rangel, Gibson, Singh, Allen, Coram, Webb) University of
Louisville, Louisville, KY, United States
(Fridell, Wilson, Thomas, Kim) University of Rochester, Rochester, NY,
United States
(Schwartz, Wilmot, Chen, El Shahawy, Stevens) Cardiovascular Center of
Sarasota, Sarasota, FL, United States
(Stafford, Black) University of Maryland Medical Center, Baltimore, MD,
United States
(Abernethy, Hull) Asheville Cardiology Associates, Asheville, NC, United
States
(Lim, Tucker, Putnam, Hall, Cauthren, Tucker, Zurick, Horton) Saint Thomas
Hospital, Nashville, TN, United States
(Orga, Meyer, White) Stroobants Cardiovascular Center, Lynchburg, VA,
United States
(Morford, Baumann, Rutkin, Seeratan) Northwell Health - Manhasset,
Manhasset, NY, United States
(Bokhari, Jimenez) Columbia University Medical Center, New York, NY,
United States
(Sokol, Schultz) Jacobi Medical Center, Bronx, NY, United States
(Meisner, Russo, Hamzeh) Baylor College of Medicine, Houston, TX, United
States
(Misra, Huda, Wall, Boan, De Rosen, Alam, Turner, Hinton) Cardiovascular
Specialists of Southwest Louisiana, Lake Charles, LA, United States
(Mulhearn, Good, Archer) Ohio Health Grant Medical Center, Columbus, OH,
United States
(Dionne, Allardyce, Sikora, Czerniak, Mull, Ferguson, Laube, Shammas,
Shammas) Midwest Cardiovascular Research Foundation, Davenport, IA, United
States
(Christensen, Park, Chilton, Hecht) Audie Murphy V.A., San Antonio, TX,
United States
(Nguyen, Vo) VA Palo Alto Healthcare System, Palo Alto, CA, United States
(Hirsch, Jezior, Bindeman) Walter Reed National Military Medical Center,
Bethesda, MD, United States
(Salkind, Espinosa) Miriam Hospital, Providence, RI, United States
(Desimone, Gordon, Felix-Stern, Crain, Gomes, Gordon, Stenberg, Mann)
Conemaugh Valley Memorial Hospital, Johnstown, PA, United States
(McCreary, Pedalino, Cobos) NYU-HHC Kings County Hospital Center,
Brooklyn, NY, United States
(Dwyer, Espinosa, Quiles, Wiesel) New York University - Langone
Cardiovascular Associates, Flushing, NY, United States
(Juang, Gopaul) Coney Island Hospital, Brooklyn, NY, United States
(Hultberg, Huk, Hussain, Al-Amoodi, Zambrano) Yuma Regional Medical
Center, Yuma, AZ, United States
(Rodriguez, Milner, Wohns, Mulder) Spectrum Health, Grand Rapids, MI,
United States
(Van Oosterhout, Lader, Meyer) Mid Valley Cardiology, Kingston, NY, United
States
(Mumma, Clapp) Sarasota Memorial Hospital, Sarasota, FL, United States
(Barrentine, Dharmarajan, Jose) NYU-HHC Lincoln Medical and Mental Health
Center, Bronx, NY, United States
(Manchery, McGarvey, McKinney) Doylestown Health Cardiology, Doylestown,
PA, United States
(Schwarz, Downes, Kaczkowski) Medical Center of the Rockies, Loveland, CO,
United States
(Luckasen, Jaskowiak, Klitch, Cheong, Dees) Baylor St. Luke's Medical
Center, Houston, TX, United States
(Potluri, Vasquez) Baylor Research Institute, Legacy Heart Center, Plano,
TX, United States
(Mastouri) Indiana University, Krannert Institute of Cardiology,
Indianapolis, IN, United States
(Breall, Hannemann, Revtyak, Foltz, Bazeley, Li, DeRosa) HealthEast Saint
Joseph's Hospital, St. Paul, MN, United States
(Jorgenson, Riestenberg-Smith, Giedd) Beth Israel Medical Center, New
York, NY, United States
(Old, Bariciano) Cardiovascular Associates, Ltd., Chesapeake, VA, United
States
(Burt) Saint Luke's Hospital and Health Network, Bethlehem, PA, United
States
(Sokhon, Waldron) Medicus Alliance Clinical Research Org., Inc., Sugar
land, TX, United States
(Mayon, Gopal) The Heart Hospital Baylor, Plano, TX, United States
(Valeti, Peichel) University of Minnesota, Minneapolis, MN, United States
(Kobashigawa, Starks) Cedars Sinai Medical Center, Beverly Hills, CA,
United States
(Garcia, Thottam, Bhargava, Anand) Government Medical College, Calicut,
India
(Govindan, Raj, Nair, Ravindran, Rajalekshmi, Manjunath, Nataraj) Sri
Jayadeva Institute of Cardiovascular Sciences and Research, Bengaluru,
India
(Moorthy, Nayak, Manjunath, Mylarappa, Narayanappa, Pandit, Bajaj) Dr Ram
Manohar Lohia Hospital, New Delhi, India
(Nath, Yadav, Mishra, Dwivedi, Tewari) King George's Medical University,
Department of Cardiology, Lucknow, India
(Narain, Mishra, Chandra, Patel, Singh, Wander) Hero DMC Heart Institute,
Dayanand Medical College and Hospital, Ludhiana, India
(Tandon, Ralhan, Kaur, Aslam, Gupta, Pharmacy, Goyal, Bhargava, Suvarna)
All India Institute of Medical Sciences, New Delhi, India
(Karthikeyan, Ramakrishnan, Seth, Yadav, Singh, Roy, Parakh, Verma,
Narang, Mishra, Naik, Sharma, Choudhary, Patel, Gulati, Sharma, Bahl,
Mathew, Kurian) MOSC Medical College Hospital, Kolenchery, India
(Punnoose, Gadkari, Karwa) KEM Hospital Pune, Pune, India
(Gadage, Kolhe, Pillay, Satheesh, Vindhya) Jawaharlal Institute of
Postgraduate Medical Education & Research (JIPMER), Pondicherry, India
(Jain) Fortis Escort Heart Institute, New Delhi, India
(Seth, Meharwal, Mathur, Verma, Kaul, Bhatia, Sachdeva, Devi, Jungla,
Christopher, Rani) Gurunanak CARE Hospital, Hyderabad, India
(Menon, Reddy, Kumar, Preethi, Oomman, Sidh) Apollo Research and
Innovation, Chennai, India
(Mao, Ramakrishnan, Solomon, Francis, Naik, Priya) Apollo Research &
Innovations, Hyderabad, India
(Khan, Christopher, Preethi) CARE Nampally, Hyderabad, India
(Kumar, Grant, Hande) Ruby Hall Clinic, Grant Medical Foundation, Pune,
India
(Sonawane, Kachru, Dubey) Fortis Healthcare Fl.t Lt. Rajan Dhall Hospital,
New Delhi, India
(Rawat, Kumar) Sree Chitra Tirunal Institute for Medical Sciences and
Technology, Trivandrum, India
(Ganapathi, Jayakumar, Vineeth, Sivadasanpillai, Chacko, Sasidharan, Babu,
Kapilamoorthy, Christopher, Reddy) CARE Hospital, Hyderabad, India
(Polamuri, Rani, Kaul, Arambam) Batra Hospital and Medical Research Centre
(BHMRC), New Delhi, India
(Singh, Senior, Fox, Young, Carruthers) Northwick Park Hospital Harrow,
Royal Brompton Hospital London, Harrow, United Kingdom
(Elghamaz, Gurunathan, Karogiannis, Young, Shah, Kinsey, Trimlett,
Kavalakkat, Rubens, Evans, Nicol, Hassan, Mittal, Hampson, Gamma,
Williams) Broomfield Hospital, Chelmsford, United Kingdom
(Holland, Swan, de Belder, Atkinson) The James Cook University Hospital,
Middlesbrough, Middlesbrough, United Kingdom
(Thambyrajah, Nageh, Kunhunny) Southend University Hospital, Westcliffe on
Sea, United Kingdom
(Davies, Lindsay, Atkinson) Bradford Royal Infirmary, Bradford, United
Kingdom
(Kurian, Krannila, Jamil, Vinod, Raheem, Hoye, Chaytor) The University of
Hull, Castle Hill Hospital, Cottingham, United Kingdom
(Cox, Morrow, Rowe, Donnelly, Kelly) South Eastern Health and Social Care,
Belfast, United Kingdom
(Valecka, Regan, Turnbull, Chauhan, Fleming) Blackpool Teaching Hospitals,
Blackpool, United Kingdom
(Ghosh, Gratrix, Preston, Barr, Cartwright) Russells Hall Hospital,
Dudley, United Kingdom
(Alfakih, Knighton) King's College NHS Foundation Hospital, London, United
Kingdom
(Byrne, Martin, Webb, Henriksen, Flint) Royal Infirmary of Edinburgh,
Edinburgh, United Kingdom
(Harrison, OKane, Lake-Man) Royal Bournemouth Hospital, Bourneouth, United
Kingdom
(Ljubez, de Silva) Bedford Hospital NHS Trust, Bedford, United Kingdom
(Conway, Wright) Pinderfields Hospital, Wakefield, United Kingdom
(Exley, Sirker, Andiapen) University College London Hospitals NHS
Foundation Trust, London, United Kingdom
(Richards) BartsHealth NHS Trust, United Kingdom
(Hoole, Wong) Papworth Hospital, Cambridge, United Kingdom
(Witherow, Munro) Dorset County Hospital, Dorchester, United Kingdom
(Johnston, Bao) Belfast Trust, Belfast, United Kingdom
(Harbinson, Bao, McEvoy, Walsh, Bao, Brown, Douglas, Luckie, Charles)
Central Manchester University Hospital, Manchester, United Kingdom
(Kolakaluri, Phillips, Sobolewska, Morby) The Pennine Acute Hospitals NHS
Trust, Oldham, United Kingdom
(Hallett, Corbett, Winstanley, Jeetley, Smit) Royal Free London NHS
Foundation Trust, London, United Kingdom
(Patel, Kotecha, Travill, Gent) Luton and Dunstable University Hospital
NHS FT, Luton, United Kingdom
(Karimullah, Hussain, Al-Bustami, Braganza, Haines) Peterborough City
Hospital, Peterborough, United Kingdom
(Taaffe, Henderson, Burton) Nottingham University Hospitals, Nottingham,
United Kingdom
(Pointon, Colton, Naik, King, Mathew, Brown) University of Glasgow,
Clydebank, United Kingdom
(Docherty, Berry, McCloy, Collison, Robb, Roditi, Paterson, Crawford,
Kelly, McGregor, Moriarty, Mackin) Cardiovascular Research Unit, Craigavon
Area Hospital, Craigavon, United Kingdom
(Glover, Knight) Hampshire Hospitals NHS Foundation Trust, Basingstoke,
United Kingdom
(Pradhan, Mikhail, Bose) Imperial College Healthcare NHS Trust, London,
United Kingdom
(Francis, Dzavik, Goodman, Gosselin, Proietti) Montreal Heart Institute,
Montreal, QC, Canada
(Brousseau, Corfias, Blaise, Harvey, Diaz) Centre Hospitalier de Regional
Trois-Rivieres, Trois-Rivieres, QC, Canada
(Rheault, Barrero, Gagne, Alarie, Pepin-Dubois, Arcand, Costa, Roy, Sia,
Montpetit, Lemay, Gisbert, Gervais, Rheault, Drouin) CISSSL - Hopital
Pierre-Le Gardeur, Terrebonne, QC, Canada
(Phaneuf, Bergeron, Gosselin, Shelley, Masson, Garg, Carr) London Health
Sciences Centre, London, ON, Canada
(Bone, Chow, Moga) University of Ottawa Heart Institute, Ottawa, ON,
Canada
(Hessian, Kourzenkova, Beanlands, Walter, Davies, Bainey, Hogg) University
of Alberta, Edmonton, AB, Canada
(Welsh, Cheema) St. Michael's Hospital, Toronto, ON, Canada
(Bagai, Wald, Goodman, Kushniriuk, Graham, Hussain, Peterson, Bello, Chow,
Abramson, Cheema, Syed) Dixie Medical Group, Mississauga, ON, Canada
(Vakani, Hussain, Kushniriuk, Cha, Otis) Dr James Cha, Oshawa, ON, Canada
(Otis, Howarth, Seib) University of Calgary, Calgary, AB, Canada
(Rivest, Sandonato, Wong, Chow) Vancouver General Hospital, Vancouver, BC,
Canada
(Starovoytov, Uchida, Meadows, Uxa, Asif) University Health Network,
Toronto, ON, Canada
(Tavares, Galiwango, Bozek) Scarborough Cardiology Research, Scarborough,
ON, Canada
(Kassam, Shier, Mukherjee, Larmand, Ricci, Janmohamed, Hart, Lam, Marucci)
West Lincoln Memorial Hospital East Grimsby, ON, Canada
(Tai, Mehta, Brons) Hamilton General Hospital, Hamilton, ON, Canada
(Beck, Wong, Etherington, Arumairajah, Udell, Aprile) Women's College
Hospital, Toronto, ON, Canada
(Karlsson, Webber, Genereux, Mercure) Centre Integre Universitaire de
Sante et de Services Sociaux du Montreal, Montreal, QC, Canada
(Hameed, Aedy) Saint Catharines General Hospital, Catharines, ON, Canada
(Daba, Farquharson) Northwest GTA Cardiovascular and Heart Rhythm Program,
Vaughan, ON, Canada
(Siddiqui, Carvalho, Lopes, Hueb, Takiuti) Heart Institute (InCor),
University of Sao Paulo, Sao Paulo, Brazil
(Rezende, Silva, Hueb, Smanio, Caetano) Instituto Dante Pazzanese de
Cardiologia, Sao Paulo, Brazil
(de Quadros) Instituto de Cardiologia de Porto Alegre, Porto Alegre,
Brazil
(Kalil, Deiro, da Costa Vieira, Muller, Grossmann, de Moraes, de Oliveira,
Ascoli, Bridi, Poletti, Savaris, Vitola) Quanta Diagnostico & Terapia,
Curitiba, Brazil
(Cerci, Zier, Farias, Veiga, Fernandes, Marin-Neto) Hospital das Clinicas
da Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo,
Ribeirao Preto, Brazil
(Schmidt, de Oliveira Lima Filho, da Cunha, Oliveira, Chierice, Polanczyk,
Rucatti) Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil
(Furtado, Igansi, Smidt, Haeffner, Carvalho, Almeida) Unifesp - Hospital
Sao Paulo, Sao Paulo, Brazil
(Pucci, de Souza, Lyra, Alves, Almeida) Fundacao Bahiana de Cardilogia,
Salvador, Brazil
(dos Santos, Dracoulakis, Oliveira) Hospital da Bahia, Salvador, Brazil
(Lima, Figueiredo, Azevedo) Hospital Lifecenter, Belo Horizonte, Brazil
(Caramori, Santos) Hospital Sao Lucas da Pontificia Universidade Catolica
do Rio Grande do Sol, Porto Alegre, Brazil
(Germann, Gomes, Homem, Magedanz, Tumelero, Laimer) Hospital Sao Vicente
de Paulo Fundo, Brazil
(Tognon, Dall'Orto) Hospital Maternidade e Pronto Socorro Santa Lucia,
Pocos de Caldas, Brazil
(Mesquita, Santos) Hospital Pro-Cardiaco Botafogo, Brazil
(Colafranseschi, Oliveira, Carvalho, Palazzo, Sousa, da Silva) Hospital
TotalCor, Sao Paulo, Brazil
(de Barros e Silva, Okada, de Padua Silva Baptista, Batista, Rodrigues,
Rabaca, de Resende, Saraiva, Trama) Hospital Celso Pierro, Sao Paulo,
Brazil
(Silva, de Souza Ormundo, Vicente, Costantini, Pinheiro, Pracon) Hospital
Cardiologico Costantini, Curitiba, Brazil
(Komar, Ruzyllo, Szwed, Demkow, Pracon) Coronary and Structural Heart
Diseases Department, Institute of Cardiology, Warsaw, Poland
(Kepka, Teresinska, Walesiak, Kryczka, Malinowska, Henzel, Solecki,
Kaczmarska, Mazurek, Maksym) Medical University of Warsaw, Warszawa,
Poland
(Wojtera, Fojt, Szczerba, Drozdz) Cardiology Clinic, Medical University in
Lodz, Lodz, Poland
(Czarniak, Frach, Szymczyk, Niedzwiecka, Sobczak, Ciurus, Jakubowski,
Misztal-Teodorczyk, Teodorczyk, Swiderek, Fratczak, Wojtala, Szkopiak,
Lebioda, Wlodarczyk, Plachcinska, Kusmierek, Miller, Marciniak,
Wojtczak-Soska, Luczak, Tarchalski, Cichocka-Radwan, Szwed, Karwowski)
National Institute of Cardiology, Warsaw, Warsaw, Poland
(Szulczyk, Witkowski) Department of Interventional Cardiology & Angiology,
Institute of Cardiology, Warsaw, Poland
(Kukula, Celinska-Spodar, Zalewska, Gajos) Department of Coronary Disease,
John Paul II Hospital, Jagiellonian University Medical College, Krakow,
Poland
(Bury, Pruszczyk, Labyk) Department of Internal Medicine and Cardiology,
Infant Jesus Teaching Hospital, Medical University of Warsaw, Warszawa,
Poland
(Roik, Szramowska, Zdonczyk, Loboz-Grudzien, Jaroch) T.Marciniak Hospital,
Wroclaw, Poland
(Sokalski, Brzezinska, Lesiak) Szpital Kliniczny Przemienienia Panskiego,
Poznan, Poland
(Lanocha, Reczuch, Kolodziej) Military Hospital, Medical University,
Wroclaw, Poland
(Kalarus) Medical University of Silesia, School of Medicine, The Division
of Dentistry, Department of Cardiology, Congenital Heart Diseases and
Electrotherapy, Silesian Center for Heart Diseases, Zabrze, Poland
(Swiatkowski, Szulik, Musial, Marcinkiewicz-Siemion) University Hospital
in Bialystok, Bialystok, Poland
(Bockeria, Bockeria) National Medical Research Center for Cardiovascuar
Surgery, Moscow, Russian Federation
(Petrosyan, Kudzoeva, Trifonova, Aripova, Chernyavskiy, Naryshkin)
E.Meshalkin National Medical Research Center, The Ministry of Health of
the Russian Federation, Novosibirsk, Russian Federation
(Kretov, Kuleshova, Grazhdankin, Malaev, Bershtein) North-Western State
Medical University, Saint Petersburg, Russian Federation
(Sayganov, Subbotina, Kuzmina-Krutetskaya, Gumerova, Zbyshevskaya,
Katamadze, Demchenko, Nikolaeva) Federal Almazov North-West Medical
Research Centre, Saint Petersburg, Russian Federation
(Kozlov, Kozulin, Lubinskaya, Lopez-Sendon, Castro, Lopez-Sendon,
Fernandez-Figares) Hospital La Paz. IdiPaz, Madrid, Spain
(Castro, Salicio, Guzman, Galeote, Valbuena, Peteiro) Complexo
Hospitalario Universitario A Coruna (CHUAC) Sergas, Department of
Cardiology, INIBIC A Coruna. CIBER-CV., Universidad de A Coruna, A Coruna,
Spain
(Martinez-Ruiz, Perez-Fernandez, Blanco-Calvo, Cuenca-Castillo,
Alonso-Alvarez, Flores-Rios, Garcia-Gonzalez, Prada-Delgado,
Barge-Caballero, Juanatey, Amigo) Hospital Clinico Universitario de
Santiago, Santiago de Compostela, Spain
(Bayarri, Nunez, Sanchez, Alvarez, Gil, Monzonis, Sionis, Martinez)
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
(Perales, Padro, Penaranda, Picart, Iglesias, Marimon, Llado, Costa, Miro,
Igual) Hospital Universitario y Politecnico La Fe, Valencia, Spain
(Diez, Calvillo, Ortuno) HUVA, Hospital Clinico Universitario Virgen De La
Arrixaca, Murcia, Spain
(Chavarri, Giner, Montolliu, Aniorte, Bermudez, Caravaca, De La Morena,
Blancas, Canavate) Hospital De Bellvitge, Barcelona, Spain
(Guerrero, Riera, Luena, Luena) Hospital Universitario Miguel Servet,
Zaragoza, Spain
(Lasala, Fernandez-Aviles, Lorenzo) Hospital General Universitario
Gregorio Maranon, Madrid, Spain
(Sobrino, Vazquez, Jiang, Chen, Dong) Guangdong General Hospital,
Guangzhou, China
(He, Xia, Yang, Zhong, Wu, Tian) Chinese Academy of Medical Sciences,
Fuwai Hospital, Beijing, China
(Li) First Affiliated Hospital of Xinjiang Medical University, Urumqi,
China
(Ma, Li, Yang, Ma, Yu, Zhao, Ji, Li) Tangshan Gongren Hospital, Tangshan,
China
(Zhang, Zhao, Zhu, Yang, Chen) Beijing Chao-yang Hospital, Capital Medical
University, Beijing, China
(Chi, Wang, Zhang, Lin, Jing) TEDA International Cardiovascular Hospital,
Tianjing, China
(Liu, Zeng, Zhou) Tongji Medical College, Wuhan, China
(Xu, Li, Li, Xiong, Fu, Gao) The First Affiliated Hospital of Zhengzhou
University, Zhengzhou, China
(Jiang, Leng, Wang, Yuan, Zhang, Yang, Bai) Shanxi Cardiovascular
Hospital, Taiyuan, China
(Li, Qi, Wang, Wang, Yang, Yue, Zhang, Wang, Dong) Qingdao Fuwai Hospital,
Qingdao, China
(Mao, Zhang, Cheng, Li) Shanxi Provincial People's Hospital, Xian, China
(Yao, Zhong, Zhou, Zhao, Huang) The Second Affiliated Hospital of
Zhengzhou University, Zhengzhou, China
(Zhou, Fang, Su) Liangxiang Hospital, Beijing, Fangshan District, Beijing,
China
(Zeng, Kunwu) Wuhan Union Hospital, Tongji Medical College, Huazhong
Science and Tech University, Wuhan, China
(Peng, Su, Su, Wang) Wuhan Asia Heart Hospital, Wuhan, China
(Zhao, Li, Geng) Affiliated Hospital of Jining Medical University, Jining,
China
(Wang, Nie, Fan) Beijing Anzhen Hospital, Beijing, China
(Feng, Wang, Yan, Zhang, Yu, Chi) Affiliated Zhongshan Hospital of Dalian
University, Dalian, China
(Liu, Wang, Chen) The Second Affiliated Hospital Zhejiang University
School of Medicine, Hangzhou, China
(Jiang, Li, Wang, Han) Peking Union Medical College Hospital, Beijing,
China
(Xu, Zhang, Liu, Liu, Chen, Hu, Maggioni, Perna, Pietrucci) Cardiology and
CCU - Ospedali Riuniti Ancona, Ancona, Italy
(Marini, Gabrielli, Provasoli, Di Donato) Ospedale di Circolo e Fondazione
Macchi, Varese, Italy
(Verna, Monti) Humanitas Research Hospital, Rozzano (MI), Rozzano, Italy
(Nardi, Di Chiara, Pezzetta) Azienda Servizi Sanitaria n.3 Alto
Friuli-Collinare-Medio Friuli, Tolmezzo, Italy
(Mortara, Casali) Policlinico di Monza, Monza, MB, Monza, Italy
(Galvani, Attanasio) Ospedale "G.B. Morgagni - L. Pierantoni" Forli (AUSL
della Romagna), Forli, Italy
(Ottani, Sicuro, Leone) Ospedale Regionale Umberto Parini, Aosta, Italy
(Pisano, Bare, Calabro, Fimiani) AORN Dei Colli "V. Monaldi" UOC
Cardiologia Universita della Campania "L.Vanvitelli", Napoli, Italy
(Formisano, Tarantini, Barioli) University of Padua- Cardiology Clinic,
Padua, Italy
(Cucchini, Ramani, Andres, Racca, Rolfo) Azienda Ospedaliera S. Croce e
Carle, Cuneo, Italy
(Goletto, Briguori, De Micco) Clinica Mediterranea, Naples, Italy
(Amati, Di Marco) UO Cardiologia Ospedale SS Cosma e Damiano, Pescia,
Italy
(Vergoni, Tricoli, Russo, Villella) IRCCS "Casa Sollievo della
Sofferenza", San Giovanni Rotondo, Italy
(Fanelli, White, Alsweiler, Poh) National University Heart Center
Singapore, Singapore, Singapore
(Chai, Lau, Loh, Tay, Teoh, Tan, Teo, Sia, Ong, Leong, Wong, Loh, Kofidis,
Chan, Chan, Foo, Yan) Tan Tock Seng Hospital, Singapore, Singapore
(Kong, Er, Jafary, Chua, Ismail) National Heart Centre Singapore,
Singapore, Singapore
(Kyaw, Yip, Doerr) Praxisklinik Herz und Gefaesse, Dresden, Germany
(Stumpf, Grahl, Matschke, Guenther, Simonis, Bonin, Kadalie, Sechtem,
Wenzelburger) Robert-Bosch-Krankenhaus, Stuttgart, Germany
(Ong, Gruensfelder, Schulze) University Hospital Jena, Jena, Germany
(Goebel, Lenk, Nickenig, Sinning) Universitatsklinikum Bonn, Bonn, Germany
(Weber, Werner, Lang, Huber, Schuchlenz, Steinmaurer) LKH Graz West, Graz,
Austria
(Weikl, Lang, Winter) Medical University of Vienna, Department of
Cardiology, Vienna, Austria
(Andric) Wilhelminen Hospital Vienna, Vienna, Austria
(Huber, Maximilian, Gabriele, Claudia, Bernhard, Florian, Keltai, Vertes,
Sebo) Eszszk- Szent Istvan Hospital, Budapest, Hungary
(Davidovits, Matics, Varga, Agoston) University of Szeged, Szeged, Hungary
(Fontos, Dekany) George Gottsegen National Institute of Cardiology,
Budapest, Hungary
(Merkely, Bartykowszki) Heart and Vascular Center, Semmelweis University,
Budapest, Hungary
(Maurovich-Horvat, Kerecsen, Jakal) Military Hospital, Budapest, Budapest,
Hungary
(Hinic, Djokic) University Hospital Center Bezanijska Kosa, Belgrade,
Serbia
(Zdravkovic, Mudrenovic, Crnokrak, Beleslin) Faculty of Medicine,
University of Belgrade, Cardiology Clinic, Clinical Center of Serbia,
Belgrade, Serbia
(Boskovic, Djordjevic-Dikic, Petrovic, Giga, Dobric, Stepanovic, Markovic,
Mladenovic, Cemerlic-Adjic, Velicki) Institute of Cardiovascular Diseases
Vojvodina, Sremska Kamenica, Serbia
(Pupic, Davidovic, Simovic) Clinical Center Kragujevac, Kragujevac, Serbia
(Vucic, Dekleva, Martinovic) University Clinical Hospital Zvezdara,
Belgrade, Serbia
(Stevanovic, Stankovic, Dobric) Clinical Center of Serbia, Belgrade,
Serbia
(Apostolovic, Martinovic) Clinic for Cardiovascular Diseases, Clinical
Center Nis, Nis, Serbia
(Stanojevic, Escobedo, de Jesus-Perez, Juarez) Instituto Mexicano del
Seguro Social, Mexico
(Baleon-Espinosa, Campos-Santaolalla, Duran-Cortes, Flores-Palacios,
Garcia-Rincon, Jimenez-Santos, Penafiel, Ortega-Ramirez,
Valdespino-Estrada, Rosas, Brassetti, Selvanayagam) Instituto Nacional de
Cardiologia "Ignacio Chavez", Mexico City, Mexico
(Anaya, Garcia, Juarez, Rovalo, Rodriguez, Selvanayagam, Rankin, Murphy,
Lee) Flinders Medical Centre, Adelaide, Australia
(Joseph, Thomas, Thambar, Chaplin) John Hunter Hospital, New Lambton
Heights, Australia
(Boer, Beltrame, Stansborough) The Queen Elizabeth Hospital, Woodville
South, Australia
(Black, Hillis, Bonner) Royal Perth Hospital, Perth, Australia
(Ireland, Venn-Edmonds, Steg, Abergel, Juliard, Thobois) C.H. Louis
Pasteur, Chartres, France
(Thuaire, Tachot, Dutoiu, Laure, Vassaliere, Steg, Abergel) Bichat
Hospital, Paris, France
(Juliard, Fuentes, Slama, Eliahou) Antoine-Beclere Hospital, Clamart
Cedex, France
(Mahmoud, Dubourg) Ambroise Pare Hospital, Boulogne, France
(Michaud, Nicollet, Hadjih) Centre Hospitalier Sud Francilien,
Corbeil-Essonnes Cedex, France
(Goube, Brito, Barone-Rochette, Barone-Rochette) Grenoble University
Hospital, Grenoble, France
(Furber, Cornet) Centre Hospitalier Universitaire d'Angers, Angers Cedex
9, France
(Biere, Rautureau, Juceviciene) Vilnius University Hospital Santariskes
Clinic, Vilnius, Lithuania
(Kalibataite-Rutkauskiene, Keinaite, Laucevicius, Laukyte, Celutkiene,
Mikolaitiene, Smigelskaite, Tamasauskiene, Urboniene, Kedhi) Isala
Klinieken, Zwolle, Netherlands
(Timmer, Bouwhuis, Hermanides, Nijmeijer, Kaplan, Riezebos) Cardio
Research Hartcentrum OLVG, Amsterdam, Netherlands
(Samadi, Schoep, van Dongen, Janzen, Niehe, Suryapranata, Ahoud)
Radboudumc, Nijmegen, Netherlands
(van Vugt, Ramos) Hospital de Santa Marta, Lisbon, Portugal
(Cacela, Santana, Fiarresga, Sousa, Marques, Patricio, Selas, Bernanrdes,
Silva, Rio, Freixo, Carvalho, Ferreira, Silva, Rodrigues, Modas, Portugal,
Fragata, Pinto, Cabrita) Santa Maria University Hospital, Cardiology
Department, CHLN, Lisbon, Portugal
(Menezes, Rocha, Lopes, Figueiras, Almeida, Coelho, Silva, Capinha, Nobre,
Caetano, Francisco, Silva, Ferreira) Centro Hospitalar de Vila Nova de
Gaia/Espinho, EPE, Vila Nova de Gaia, Portugal
(Lopes, Diaz, Guzman, Tinnirello) Instituto Medico DAMIC, Cordoba,
Argentina
(Figal, Mungo) Fundacion Favaloro, Ciudad Autonoma de Buenos Aires,
Argentina
(Mendiz, Cortes, Favaloro, Alvarez, Garcia) Hospital Italiano Regional del
Sur Bahia Blanca, Bahia Blanca, Argentina
(Courtis, Godoy) Clinica Romagosa and Clinica De La Familia, Cordoba,
Spain
(Zeballos, Schiavi, Actis) Clinica Del Prado, Cordoba, Spain
(Rubio) Clinica Privada Velez Sarsfield, Cordoba, Spain
(Scaro, Devlin, Low) Waikato Hospital, Hamilton, New Zealand
(Fisher, Scales, Abercrombie, Stewart) Auckland City Hospital, Auckland,
New Zealand
(Howell, Patten, Benatar, Kedev, Held) University Clinic of Cardiology,
Skopje, North Macedonia
(Mitevska, Kostovska, Pejkov, Held) Uppsala University, Uppsala, Sweden
(Eggers, Frostfelt, Bjorklund, Johnston, Andreasson, Olsowka, Essermark,
Akerblom, Soveri, Aspberg, Persson, Sharir) Karolinska Institutet,
Danderyd Hospital, Stockholm, Sweden
(Beyar, Nikolsky, Sharir, Harel) Assuta Medical Centers, Tel-Aviv, Israel
(Elian, Kerner, Bentzvi) Rambam Medical Center, Haifa, Israel
(Massalha, Helmer, Kohsaka, Fukuda, Ueda) Keio University, Shinjuku-ku,
Japan
(Kohsaka, Fujita, Yasuda, Furukawa) National Cerebral and Cardiovascular
Center, Kanae Hirase, RN, -4, Suita-shi, Japan
(Nagai, Otsuka, Nishimura, Nakano) Saitama Medical University, Hidaka,
Japan
(Van de Werf, Goetschalckx, Robesyn) University Hospital Leuven, Leuven,
Belgium
(Van de Werf, Claes, Hung, Yang) Mackay Memorial Hospital, Taipei City,
Taiwan (Republic of China)
(Yun, Hou, Kuo, Yeh, Hung, Li, Chien, Tsai, Liu, Yu, Lin, Lan, Yen, Tsai,
Sung, Ntsekhe) Groote Schuur Hospital, University of Cape Town, Cape Town,
South Africa
(Pandie, Philander, Viljoen, Mtana, De Andrade, Maggioni, Moccetti,
Anesini) Cardiocentro, Lugano, Switzerland
(Rossi, Maspoli, Mombelli, Abdelhamid, Talaat) Cairo University, Cairo,
Egypt
(Adel, Kamal, Mahrous, El Kaffas, El Fishawy, Pop) Emergency County
Hospital Baia Mare, Bucharest, Romania
(Claudia, Popescu) Emergency Institute of Cardiovascular Diseases ''Prof.
Dr. C. C. Iliescu'', Bucharest, Romania
(Ginghina, Rosca, Deleanu, Beladan, Iliescu, Al-Mallah, Zahrani) King
AbdulAziz Cardiac Center, Central Province, Saudi Arabia
(Aljzeeri, Najm, Alghamdi, Ramos) Instituto Neuro Cardiovascular De Las
Americas, Mirafloes, Peru
(Davila, Kuanprasert) Maharaj Nakorn Chiang Mai Hospital, Chiang Mai,
Thailand
(Prommintikul, Nawarawong, Khwakhong, Woragidpoonpol, Chaiyasri, Tepsuwan,
Mekara, Taksaudom, Kulthawong, Rimsukcharoenchai, Amaritakomol,
Euathrongchit, Wannasopha, Yamwong, Panpunuan) Ramathibodi Hospital,
Bangkok, Thailand
(Sritara, Aramcharoen, Meemuk, White, Alsweiler, Khairuddin, Mokhtar)
Institut Jantung Negara, Kuala Lumpur, Malaysia
Publisher
Lippincott Williams and Wilkins
Abstract
BACKGROUND: ISCHEMIA (International Study of Comparative Health
Effectiveness With Medical and Invasive Approaches) did not find an
overall reduction in cardiovascular events with an initial invasive versus
conservative management strategy in chronic coronary disease; however,
there were conservative strategy participants who underwent invasive
coronary angiography early postrandomization (within 6 months).
Identifying factors associated with angiography in conservative strategy
participants will inform clinical decision-making in patients with chronic
coronary disease. <br/>METHOD(S): Factors independently associated with
angiography performed within 6 months of randomization were identified
using Fine and Gray proportional subdistribution hazard models, including
demographics, region of randomization, medical history, risk factor
control, symptoms, ischemia severity, coronary anatomy based on
protocol-mandated coronary computed tomography angiography, and medication
use. <br/>RESULT(S): Among 2591 conservative strategy participants,
angiography within 6 months of randomization occurred in 8.7% (4.7% for a
suspected primary end point event, 1.6% for persistent symptoms, and 2.6%
due to protocol nonadherence) and was associated with the following
baseline characteristics: enrollment in Europe versus Asia (hazard ratio
[HR], 1.81 [95% CI, 1.14-2.86]), daily and weekly versus no angina (HR,
5.97 [95% CI, 2.78-12.86] and 2.63 [95% CI, 1.51-4.58], respectively),
poor to fair versus good to excellent health status (HR, 2.02 [95% CI,
1.23-3.32]) assessed with Seattle Angina Questionnaire, and new/more
frequent angina prerandomization (HR, 1.80 [95% CI, 1.34-2.40]). Baseline
low-density lipoprotein cholesterol <70 mg/dL was associated with a lower
risk of angiography (HR, 0.65 [95% CI, 0.46-0.91) but not baseline
ischemia severity nor the presence of multivessel or proximal left
anterior descending artery stenosis >70% on coronary computed tomography
angiography. <br/>CONCLUSION(S): Among ISCHEMIA participants randomized to
the conservative strategy, angiography within 6 months of randomization
was performed in <10% of patients. It was associated with frequent or
increasing baseline angina and poor quality of life but not with objective
markers of disease severity. Well-controlled baseline low-density
lipoprotein cholesterol was associated with a reduced likelihood of
angiography. These findings point to the importance of a comprehensive
assessment of symptoms and a review of guideline-directed medical therapy
goals when deciding the initial treatment strategy for chronic coronary
disease. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique
identifier: NCT01471522. GRAPHIC ABSTRACT: A graphic abstract is available
for this article.<br/>Copyright &#xa9; 2024 American Heart Association,
Inc.

<2>
Accession Number
2030553695
Title
Effect of empagliflozin on total myocardial infarction events by type and
additional coronary outcomes: insights from the randomized EMPA-REG
OUTCOME trial.
Source
Cardiovascular Diabetology. 23(1) (no pagination), 2024. Article Number:
248. Date of Publication: December 2024.
Author
Fitchett D.; Zinman B.; Inzucchi S.E.; Wanner C.; Anker S.D.; Pocock S.;
Mattheus M.; Vedin O.; Lund S.S.
Institution
(Fitchett) Division of Cardiology, St Michael's Hospital, University of
Toronto, Toronto, ON, Canada
(Zinman) Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital,
University of Toronto, Toronto, ON, Canada
(Inzucchi) Section of Endocrinology, Yale University School of Medicine,
New Haven, CT, United States
(Wanner) Wurzburg University Clinic, Wurzburg, Germany
(Anker) Department of Cardiology (CVK) and Berlin Institute of Health
Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular
Research (DZHK) Partner Site Berlin, Charite Universitatsmedizin Berlin,
Berlin, Germany
(Anker) Institute of Heart Diseases, Wroclaw Medical University, Wroclaw,
Poland
(Pocock) Department of Medical Statistics, London School of Hygiene & amp;
Tropical Medicine, London, United Kingdom
(Mattheus) Boehringer Ingelheim Pharma GmbH & amp; Co. KG, Ingelheim,
Germany
(Vedin) Boehringer Ingelheim AB, Stockholm, Sweden
(Lund) Boehringer Ingelheim International GmbH, Ingelheim, Germany
Publisher
BioMed Central Ltd
Abstract
Background: The effect of empagliflozin, a sodium-glucose-co-transporter-2
inhibitor, on risk for myocardial infarction has not been fully
characterized. <br/>Method(s): This study comprised prespecified and
post-hoc analyses of the EMPA-REG OUTCOME trial in which 7020 people with
type 2 diabetes (T2D) and cardiovascular disease [mostly atherosclerotic
(ASCVD)] were randomized to empagliflozin or placebo and followed for a
median 3.1 years. We assessed the effect of empagliflozin on total (first
plus recurrent) events of centrally adjudicated fatal and non-fatal
myocardial infarction (MI) using a negative binomial model with robust
confidence intervals (CI) that preserves randomization and accounts for
the within-patient correlation of multiple events. Post hoc, we analyzed
types of MI: type 1 (related to plaque-rupture/thrombus), type 2
(myocardial supply-demand imbalance), type 3 (sudden-death related, i.e.
fatal MI), type 4 (percutaneous coronary intervention-related), and type 5
(coronary artery bypass graft-related). MIs could be assigned to > 1 type.
<br/>Result(s): There were 421 total MIs (including recurrent); 299, 86,
26, 19, and 1 were classified as type 1, 2, 3, 4, and 5 events,
respectively. Overall, empagliflozin reduced the risk of total MI events
by 21% [rate ratio for empagliflozin vs. placebo, 0.79 (95% CI,
0.620-0.998), P = 0.0486], largely driven by its effect on type 1 [rate
ratio, 0.79 (95% CI, 0.61-1.04)] and type 2 MIs [rate ratio, 0.67 (95% CI,
0.41-1.10)]. <br/>Conclusion(s): In T2D patients with ASCVD, empagliflozin
reduced the risk of MIs, with consistent effects across the two most
common etiologies, i.e. type 1 and 2. Trail Registration: URL:
https://www.clinicaltrials.gov; Unique identifier:
NCT01131676.<br/>Copyright &#xa9; The Author(s) 2024.

<3>
Accession Number
2025698490
Title
Multicentre, randomised, double-blind, parallel controlled trial to
investigate timing of platelet inhibition after coronary artery bypass
grafting: TOP-CABG trial study.
Source
BMJ Open. 13(6) (no pagination), 2023. Article Number: e070823. Date of
Publication: 29 Jun 2023.
Author
Yuan X.; Chu Q.; Chen K.; Wang Y.; Zhang L.; Zheng Y.; Hu S.
Institution
(Yuan, Chu, Chen, Hu) State Key Laboratory of Cardiovascular Disease,
Fuwai Hospital, National Centre for Cardiovascular Diseases, Chinese
Academy of Medical Sciences, Peking Union Medical College, Beijing, China
(Yuan, Chu, Chen, Hu) Department of Cardiac Surgery, Fuwai Hospital,
Chinese Academy of Medical Science, Peking Union Medical College, Beijing,
China
(Wang, Zhang) National Clinical Research Centre of Cardiovascular
Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital,
National Centre for Cardiovascular Diseases, Chinese Academy of Medical
Sciences, Peking Union Medical College, Beijing, China
(Zheng) Department of Pharmacy, Fuwai Hospital, Chinese Academy of Medical
Science, Peking Union Medical College, Beijing, China
Publisher
BMJ Publishing Group
Abstract
Introduction Dual antiplatelet therapy (DAPT), referred to as the
combination of aspirin and P2Y 12 receptor antagonist (clopidogrel or
ticagrelor), potentially improves patency of saphenous vein grafts (SVG)
after coronary artery bypass grafting (CABG), while it is further proposed
that DAPT potentially increases bleeding risk. Compared with DAPT,
de-escalated DAPT (De-DAPT) is an effective antiplatelet strategy for
acute coronary syndrome treatment, which significantly reduces the risk of
bleeding without increasing the incidence of major adverse cardiovascular
events. However, insufficient evidence is available to determine the
timing of DAPT after CABG. Methods and analysisEthics and dissemination
The Ethics Committee in Fuwai hospital approved this study (2022-1774).
Fifteen centres agreed to participate the TOP-CABG trial, and the study
has been approved in these 15 centres by whose ethics committee. The
results of the trial will be submitted for publication in a peer-reviewed
journal. Trial registration number NCT05380063.<br/>Copyright &#xa9;
Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No
commercial re-use. See rights and permissions. Published by BMJ.

<4>
Accession Number
2033325900
Title
Managing surgical relapse risk in acquired thrombotic thrombocytopenic
purpura: a systematic review.
Source
Research and Practice in Thrombosis and Haemostasis. 8(5) (no pagination),
2024. Article Number: 102478. Date of Publication: July 2024.
Author
Pinheiro Maux Lessa M.; Soares Ferreira Junior A.; Graton M.; Simon E.;
Ledbetter L.; Onwuemene O.A.
Institution
(Pinheiro Maux Lessa, Soares Ferreira Junior) Department of Medicine,
Faculdade de Medicina de Sao Jose do Rio Preto, Sao Jose do Rio Preto, Sao
Paulo, Brazil
(Soares Ferreira Junior) General and Applied Biology Program, Institute of
Biosciences (IBB), Sao Paulo State University (UNESP), Botucatu, Brazil
(Graton, Simon, Ledbetter) Duke University Medical Center Library, Durham,
NC, United States
(Onwuemene) Division of Hematology, Department of Medicine, Duke
University School of Medicine, Durham, NC, United States
Publisher
Elsevier B.V.

<5>
Accession Number
2033281359
Title
TRISCEND II: Novel Randomized Trial Design for Transcatheter Tricuspid
Valve Replacement.
Source
American Journal of Cardiology. 225 (pp 171-177), 2024. Date of
Publication: 15 Aug 2024.
Author
Grayburn P.A.; Kodali S.K.; Hahn R.T.; Lurz P.; Thourani V.H.;
Kozorovitsky E.R.; Gilmore S.Y.; Vinekar C.; Zhang B.; Boulware K.;
Krzmarzick A.M.; Nguyen D.; Vu M.T.; Feldman T.; Mack M.J.; Leon M.B.
Institution
(Grayburn, Mack) Baylor Scott and White: The Heart Hospital Plano, Plano,
Texas, United States
(Grayburn) Baylor Scott and White Research Institute Cardiac Imaging Core
Laboratory, Plano, Texas, United States
(Kodali, Hahn, Leon) Columbia University Irving Medical Center, New York,
New York, United States
(Lurz) University Medical Centre Mainz, Mainz, Germany
(Thourani) Piedmont Heart Institute, Atlanta, Georgia, United States
(Kozorovitsky, Gilmore, Vinekar, Zhang, Boulware, Krzmarzick, Nguyen, Vu,
Feldman) Edwards Lifesciences, Irvine, California, United States
Publisher
Elsevier Inc.
Abstract
Severe tricuspid regurgitation remains largely undertreated given limited
treatment options. Transcatheter tricuspid valve interventions have
emerged as a promising therapy for these patients, and the TRISCEND II
pivotal trial is the first randomized controlled trial to evaluate
transcatheter tricuspid valve replacement (TTVR). The TRISCEND II pivotal
trial studies the transcatheter EVOQUE (Edwards Lifesciences, Irvine,
California) tricuspid valve replacement system using a United States Food
and Drug Administration Breakthrough Device Designation-a program intended
to provide timely access to medical devices by speeding up development,
assessment, and review. The TRISCEND II trial is a prospective,
multicenter trial that randomizes patients with symptomatic severe
tricuspid regurgitation to treatment with either TTVR in conjunction with
optimal medical therapy or optimal medical therapy alone. The trial's
novel 2-phase design evaluates 30-day safety and 6-month effectiveness end
points for the first 150 patients in the initial phase and a 1-year safety
and effectiveness end point for the full cohort of 400 patients in the
second phase. The TRISCEND II trial's 2-phase trial design provided an
opportunity for early review and led to the first commercial approval of a
TTVR system. In conclusion, the design of the TRISCEND II trial will
likely inform future transcatheter tricuspid device trials.<br/>Copyright
&#xa9; 2024 Elsevier Inc.

<6>
Accession Number
2033268720
Title
Weekly journal scan: intravascular imaging to guide percutaneous coronary
intervention - ready for prime time?.
Source
European Heart Journal. 45(25) (pp 2183-2185), 2024. Date of Publication:
01 Jul 2024.
Author
Vergallo R.; Patrono C.
Institution
(Vergallo) Interventional Cardiology Unit, Cardiothoracic and Vascular
Department (DICATOV), Irccs Ospedale Policlinico San Martino, Largo R.
Benzi, 10, Genova 16132, Italy
(Vergallo) Department of Internal Medicine and Medical Specialties (DIMI),
Universita di Genova, Viale Benedetto XV, 6, Genova 16132, Italy
(Patrono) Department of Cardiovascular and Pulmonary Sciences, Catholic
University School of Medicine, Rome, Italy
(Patrono) Center of Excellence on Ageing, Cast, 'G. d'Annunzio' University
School of Medicine, Chieti, Italy
Publisher
Oxford University Press

<7>
Accession Number
2033267162
Title
Cannulation selection in relation to deep learning-based algorithm for the
detection of thoracic aortic calcifications.
Source
European Journal of Cardio-thoracic Surgery. 66(1) (no pagination), 2024.
Article Number: ezae260. Date of Publication: 01 Jul 2024.
Author
Condello I.; Nasso G.
Institution
(Condello, Nasso) Department of Cardiac Surgery, Anthea Hospital, Bari,
Italy
Publisher
European Association for Cardio-Thoracic Surgery

<8>
Accession Number
2033049036
Title
Comparison of Cryoballoon vs. Pulsed Field Ablation in Patients with
Symptomatic Paroxysmal Atrial Fibrillation (SINGLE SHOT CHAMPION): Study
protocol for a randomized controlled trial.
Source
Heart Rhythm O2. 5(7) (pp 460-467), 2024. Date of Publication: July 2024.
Author
Maurhofer J.; Kueffer T.; Knecht S.; Thalmann G.; Badertscher P.;
Kozhuharov N.; Krisai P.; Jufer C.; Iqbal S.U.R.; Heg D.; Servatius H.;
Tanner H.; Kuhne M.; Roten L.; Sticherling C.; Reichlin T.
Institution
(Maurhofer, Kueffer, Thalmann, Kozhuharov, Jufer, Iqbal, Servatius,
Tanner, Roten, Reichlin) Department of Cardiology, Inselspital -
University Hospital Bern, University of Bern, Bern, Switzerland
(Knecht, Badertscher, Krisai, Kuhne, Sticherling) Department of
Cardiology, University Hospital Basel, University of Basel, Basel,
Switzerland
(Heg) Department of Clinical Research, University of Bern, Bern,
Switzerland
Publisher
Elsevier B.V.
Abstract
Background: Single-shot devices are increasingly used for pulmonary vein
isolation (PVI) in atrial fibrillation (AF). The Arctic Front cryoballoon
is the most frequently used single-shot technology. A recently developed
novel pulsed field ablation (PFA) device (FARAPULSE) has been introduced
with the aim to improve procedural safety and efficacy. <br/>Objective(s):
This study will compare the novel FARAPULSE PFA device and the Arctic
Front cryoballoon for first PVI in patients with symptomatic paroxysmal
AF. <br/>Method(s): SINGLE SHOT CHAMPION is a multicenter, randomized
controlled trial with blinded endpoint adjudication by an independent
clinical events committee. Overall, 210 patients with paroxysmal AF
undergoing their PVI are randomized 1:1 between PFA and cryoballoon
ablation. Continuous rhythm monitoring with an implantable cardiac monitor
is performed in all patients. <br/>Result(s): The primary endpoint is time
to first recurrence of any atrial tachyarrhythmia (AF and/or organized
atrial tachyarrhythmia) lasting >=120 seconds and identified by the
implantable cardiac monitor within 91 and 365 days postablation. The
composite procedural safety endpoint includes cardiac tamponade requiring
drainage, persistent phrenic nerve palsy, vascular complications requiring
intervention, stroke/transient ischemic attack, atrioesophageal fistula,
and death occurring during or up to 30 days after the procedure. Key
secondary endpoints include (1) increase in high-sensitivity troponin on
day 1 postablation, (2) analysis of postablation 3-dimensional
electroanatomic mapping (first 25 patients per study group), (3) AF
burden, and (4) quality-of-life changes. <br/>Conclusion(s): SINGLE SHOT
CHAMPION will evaluate the efficacy and safety of PVI using the novel
FARAPULSE PFA for patients with symptomatic paroxysmal AF.<br/>Copyright
&#xa9; 2024 Heart Rhythm Society

<9>
Accession Number
2032346040
Title
Reactivation of Trypanosoma cruzi infection in immunosuppressed patients:
a systematic review and meta-analysis.
Source
Clinical Microbiology and Infection. 30(8) (pp 980-988), 2024. Date of
Publication: August 2024.
Author
Antequera A.; Molin-Veglia A.D.; Lopez-Alcalde J.; Alvarez-Diaz N.; Muriel
A.; Munoz J.
Institution
(Antequera, Molin-Veglia, Munoz) Barcelona Institute for Global Health,
Hospital Clinic Universitat de Barcelona (UB), Barcelona, Spain
(Lopez-Alcalde) Faculty of Health Sciences, Universidad Francisco de
Vitoria, Pozuelo de Alarcon, Spain
(Lopez-Alcalde, Muriel) Clinical Biostatistics Unit, Instituto Ramon y
Cajal de Investigacion Sanitaria, Madrid, Spain
(Lopez-Alcalde, Muriel) CIBERESP, Madrid, Spain
(Lopez-Alcalde) Institute for Complementary and Integrative Medicine,
University Hospital Zurich and University Zurich, Zurich, Switzerland
(Alvarez-Diaz) Medical Library, Hospital Universitario Ramon y Cajal,
Irycis, Madrid, Spain
(Muriel) Department of Nursing and Physiotherapy, Universidad Alcala de
Henares, Alcala de Henares, Spain
Publisher
Elsevier B.V.
Abstract
Background: The risk of Trypanosoma cruzi reactivation is poorly
understood. Previous studies evaluating the risk of reactivation report
imprecise findings, and recommendations for monitoring and management from
clinical guidelines rely on consensus opinion. <br/>Objective(s): We
conducted a systematic review and meta-analysis to estimate the cumulative
T. cruzi reactivation incidence in immunosuppressed adults, summarize the
available evidence on prognostic factors for reactivation, and examine its
prognostic effect on mortality. Data sources: MEDLINE, Embase, LILACS,
Clinical Trials, and CENTRAL from inception to 4 July 2022. Study
eligibility criteria: Studies reporting the incidence of T. cruzi
reactivation. <br/>Participant(s): Immunosuppressed adults chronically
infected by T. cruzi. <br/>Method(s): Two authors independently extracted
data (including, but not limited to, incidence data, reactivation
definition, follow-up, treatment, monitoring schedule, examined prognostic
factors) and evaluated the risk of bias. We pooled cumulative incidence
using a random-effects model. <br/>Result(s): Twenty-two studies (806
participants) were included. The overall pooled incidence of T. cruzi
reactivation was 27% (95% CI, 19-36), with the highest pooled proportion
in the sub-group of transplant recipients (36%; 95% CI, 25-48). The
highest risk period was in the first 6 months after transplant (32%; 95%
CI, 17-58), decreasing drastically the number of new cases later. People
living with HIV and patients with autoimmune diseases experienced
significantly lower cumulative reactivation incidences (17%; 95% CI, 8-29
and 18%; 95% CI, 9-29, respectively). A single study explored the
independent effect of benznidazole and found benefits for preventing
reactivations. No studies evaluated the independent association between
reactivation and mortality, while sensitivity analysis results using
unadjusted estimates were inconclusive. The heterogeneity of diagnostic
algorithms was substantial. <br/>Conclusion(s): Reactivation occurs in
three out of ten T. cruzi-seropositive immunosuppressed adults. These
findings can assist clinicians and panel guidelines in tailoring
monitoring schedules. There is a great need for an accurate definition of
reactivation and targeted monitoring.<br/>Copyright &#xa9; 2024 The
Authors

<10>
Accession Number
2031183225
Title
Utility of coronary revascularization in patients with ischemic left
ventricular dysfunction.
Source
Cardiovascular Revascularization Medicine. 65 (pp 88-97), 2024. Date of
Publication: August 2024.
Author
Al-Sadawi M.; Tao M.; Dhaliwal S.; Radakrishnan A.; Liu Y.; Gier C.;
Masson R.; Rahman T.; Tam E.; Mann N.
Institution
(Al-Sadawi) Division of Cardiology, University of Michigan Hospital, Ann
Arbor, MI, United States
(Tao, Dhaliwal, Radakrishnan, Liu, Gier, Masson, Rahman, Tam, Mann)
Department of Medicine, Division of Cardiology, Stony Brook University
Hospital, Stony Brook, NY, United States
Publisher
Elsevier Inc.
Abstract
Background: Revascularization in patients with left ventricular (LV)
dysfunction has been a subject of ongoing uncertainty and conflicting
results. This is further complicated by factors including viability,
severity of LV dysfunction, and method of revascularization using
percutaneous coronary intervention (PCI) versus coronary-artery bypass
grafting (CABG). <br/>Objective(s): The purpose of this meta-analysis is
to evaluate the association of coronary revascularization with outcomes in
patients with ischemic LV dysfunction. <br/>Method(s): A literature search
was conducted for studies reporting on cardiovascular outcomes after
revascularization compared to optimal medical therapy (OMT) in patients
with ischemic LV dysfunction. <br/>Result(s): A total of 23 studies with
10,110 participants met inclusion criteria. Revascularization was
significantly associated with lower all-cause mortality and CV mortality
compared to OMT. The association was statistically significant regardless
of severity of LV dysfunction or method of revascularization. Subgroup
analysis demonstrated that revascularization was significantly associated
with lower all-cause and CV mortality compared to OMT for patients with
viable myocardium and mixed cohorts with variable viability, but not
patients without viable myocardium. Revascularization was not associated
with a significant difference in risk of heart failure (HF)
hospitalization or acute myocardial infarction (AMI) compared to OMT.
<br/>Conclusion(s): Revascularization in patients with ischemic LV
dysfunction is associated with lower risk of all-cause and CV mortality
independent of severity of LV dysfunction or method of revascularization.
Revascularization is not associated with lower risk of mortality in
patients without evidence of viable myocardium and is not associated with
lower risk of AMI or HF hospitalization.<br/>Copyright &#xa9; 2024
Elsevier Inc.

<11>
Accession Number
2030557187
Title
The effect of escitalopram in treating mild to moderate depressive
disorder and improving the quality of life in patients undergoing coronary
artery bypass grafting - a double-blind randomized clinical trial.
Source
Frontiers in Psychiatry. 15 (no pagination), 2024. Article Number:
1342754. Date of Publication: 2024.
Author
Baradaran A.; Ardakani M.R.K.; Bateni F.S.; Asadian-Koohestani F.; Vahedi
M.; Aein A.; Shahmansouri N.; Sadighi G.
Institution
(Baradaran) Cardiovascular Department of Firouzabadi Hospital, Iran
University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Ardakani, Bateni, Asadian-Koohestani, Sadighi) Psychosis Research Center,
University of Social Welfare and Rehabilitation Sciences, Tehran, Iran,
Islamic Republic of
(Vahedi) Substance Abuse and Dependence Research Center, University of
Social Welfare and Rehabilitation Sciences, Tehran, Iran, Islamic Republic
of
(Aein) Department of Health Promotion and Education, School of Public
Health, Tehran University of Medical Sciences, Tehran, Iran, Islamic
Republic of
(Shahmansouri) Psychosomatic research center, Tehran University of Medical
Sciences, Tehran, Iran, Islamic Republic of
Publisher
Frontiers Media SA
Abstract
Introduction: Chronic depression and anxiety can be a risk factor for
coronary aArtery bypass grafting (CABG) and is an emerging factor after
coronary artery disease when the patient is admitted to the hospital and
after surgery. We aimed to assess the effect of Escitalopram in treating
mild to moderate depressive disorder and improving the quality of life in
patients undergoing CABG. <br/>Method(s): In this randomized clinical
trial, 50 patients undergoing CABG referred to Tehran Heart Hospital from
January 2021 to May 2021 and were suffering from mild to moderate
depression were randomly assigned to one of the two groups of Escitalopram
or placebo. The level of depression was assessed based on Beck's
depression inventory and the quality-of-life status and its domains were
assessed based on the SF-36 questionnaire in 2 groups. Measurements were
obtained at baseline and at four and eight weeks after treatment.
Chi-square, Fisher's exact, paired, and Wilcoxon tests or ANOVA were used
as appropriate. <br/>Result(s): There was no significant difference
between the level of depression between the two study groups at baseline
(P=0.312). There was no significant difference between the quality of life
and its domains in the two study groups at baseline (P=0.607). However,
the most important effect of Escitalopram was reducing depression scores
in the intervention group at weeks 4 and 8 after treatment compared to the
placebo group (P<0.001). The quality of life and its domains were
significantly higher in the Escitalopram group eight weeks after treatment
(P=0.004). The amount of drug side effects at 2 and 4 weeks after
treatment had no significant difference between the groups (P>0.05).
<br/>Conclusion(s): Escitalopram was effective in treating mild to
moderate depressive disorder and improving quality of life in patients
undergoing CABG. Clinical trial registration:
https://irct.behdasht.gov.ir/, identifier
IRCT20140126016374N2.<br/>Copyright &#xa9; 2024 Baradaran, Ardakani,
Bateni, Asadian-Koohestani, Vahedi, Aein, Shahmansouri and Sadighi.

<12>
Accession Number
2030314915
Title
Comparing different postoperative sedation strategies for patients in the
intensive care unit after cardiac surgery: A systematic review of
randomized controlled trials and network meta-analysis.
Source
Basic and Clinical Pharmacology and Toxicology. 135(2) (pp 180-194), 2024.
Date of Publication: August 2024.
Author
Hu Q.; Liu X.; Xiang Y.; Lei X.; Yu H.; Liu L.; Feng J.
Institution
(Hu, Lei) Department of Critical Care Medicine, The Affiliated Hospital,
Southwest Medical University, Luzhou, China
(Liu) The Third Central Clinical College, Tianjin Medical University,
Tianjin, China
(Liu, Yu, Liu, Feng) Department of Anesthesiology, The Affiliated
Hospital, Southwest Medical University, Luzhou, China
(Liu, Liu, Feng) Anesthesiology and Critical Care Medicine Key Laboratory
of Luzhou, The Affiliated Hospital, Southwest Medical University, Luzhou,
China
(Xiang) Department of Biochemistry and Molecular Biology, School of Basic
Medical Sciences, Southwest Medical University, Luzhou, China
Publisher
John Wiley and Sons Inc
Abstract
Background: Various postoperative sedation protocols with different
anaesthetics lead to profound effects on the outcomes for post-cardiac
surgery patients. However, a comprehensive analysis of optimal
postoperative sedation strategies for patients in the intensive care unit
(ICU) after cardiac surgery is lacking. <br/>Method(s): We systematically
searched for randomized controlled trials (RCTs) in databases including
PubMed and Embase. The primary outcome measured the duration of mechanical
ventilation (MV) in the ICU, and the secondary outcome encompassed the
length of stay (LOS) in the ICU and hospital and the monitoring adverse
events. <br/>Result(s): The literature included 18 RCTs (1652 patients)
with 13 sedation regimens. Dexmedetomidine plus ketamine and sevoflurane
were associated with a significantly reduced duration of MV when compared
with propofol. Our results also suggested that dexmedetomidine plus
ketamine may associated with a shorter LOS in ICU, and sevoflurane
associated with a shorter LOS in the hospital, respectively.
<br/>Conclusion(s): The combination of dexmedetomidine and ketamine seems
to be a better option for adult patients needing sedation after cardiac
surgery, and the incidence of side effects is lower with dexmedetomidine.
These findings have potential implications for medication management in
the perioperative pharmacotherapy of cardiac surgery
patients.<br/>Copyright &#xa9; 2024 Nordic Association for the Publication
of BCPT (former Nordic Pharmacological Society). Published by John Wiley &
Sons Ltd.

<13>
Accession Number
644678155
Title
Twenty percent human albumin solution fluid bolus administration therapy
in patients after cardiac surgery-II: a multicentre randomised controlled
trial.
Source
Intensive care medicine. 50(7) (pp 1075-1085), 2024. Date of Publication:
01 Jul 2024.
Author
Wigmore G.J.; Deane A.M.; Presneill J.J.; Eastwood G.; Serpa Neto A.;
Maiden M.J.; Bihari S.; Baker R.A.; Bennetts J.S.; Ghanpur R.; Anstey
J.R.; Raman J.; Bellomo R.
Institution
(Wigmore, Deane, Presneill, Serpa Neto, Maiden, Bellomo) Department of
Critical Care, Melbourne Medical School, Faculty of Medicine, Dentistry
and Health Sciences, University of Melbourne, Melbourne, VIC, Australia
(Wigmore) Department of Anaesthesia and Pain Medicine, Western Health,
Melbourne, VIC, Australia
(Deane, Presneill, Maiden, Anstey, Bellomo) Department of Intensive Care,
Royal Melbourne Hospital, Melbourne, VIC, Australia
(Presneill, Serpa Neto, Bellomo) Australian and New Zealand Intensive Care
Research Centre (ANZIC-RC), School of Public Health and Preventive
Medicine, Monash University, Melbourne, VIC, Australia
(Eastwood, Serpa Neto, Raman, Bellomo) Department of Intensive Care,
Austin Hospital, Melbourne, VIC, Australia
(Serpa Neto) Department of Critical Care Medicine, Hospital Israelita
Albert Einstein, Sao Paulo, Brazil
(Maiden) Intensive Care Unit, Barwon Health, Geelong, VIC, Australia
(Bihari) College of Medicine and Public Health, Flinders University,
Adelaide, SA, Australia
(Bihari) Department of ICCU, Flinders Medical Centre, Adelaide, SA,
Australia
(Baker, Bennetts) Flinders Medical Centre and College of Medicine and
Public Health Flinders University, Cardiothoracic Quality and Outcomes,
Adelaide, SA, Australia
(Ghanpur) Department of Intensive Care, Warringal Private Hospital,
Melbourne, VIC, Australia
(Raman) University of Melbourne, Melbourne, VIC, Australia
(Raman) St. Vincent's Hospital, Melbourne, VIC, Australia
(Bellomo) Data Analytics Research and Evaluation Centre, Austin Hospital,
Melbourne, VIC, Australia
Abstract
PURPOSE: After cardiac surgery, fluid bolus therapy (FBT) with 20% human
albumin may facilitate less fluid and vasopressor administration than FBT
with crystalloids. We aimed to determine whether, after cardiac surgery,
FBT with 20% albumin reduces the duration of vasopressor therapy compared
with crystalloid FBT. <br/>METHOD(S): We conducted a multicentre,
parallel-group, open-label, randomised clinical trial in six intensive
care units (ICUs) involving cardiac surgery patients deemed to require
FBT. We randomised 240 patients to receive up to 400 mL of 20% albumin/day
as FBT, followed by 4% albumin for any subsequent FBT on that day, or to
crystalloid FBT for at least the first 1000 mL, with use of crystalloid or
4% albumin FBT thereafter. The primary outcome was the cumulative duration
of vasopressor therapy. Secondary outcomes included fluid balance.
<br/>RESULT(S): Of 480 randomised patients, 466 provided consent and
contributed to the primary outcome (mean age 65 years; median EuroSCORE II
1.4). The cumulative median duration of vasopressor therapy was 7
(interquartile range [IQR] 0-19.6) hours with 20% albumin and 10.8 (IQR
0-22.8) hours with crystalloids (difference -3.8 h, 95% confidence
interval [CI] -8 to 0.4; P=0.08). Day one fluid balance was less with 20%
albumin FBT (mean difference -701 mL, 95% CI -872 to -530).
<br/>CONCLUSION(S): In patients after cardiac surgery, when compared to a
crystalloid-based FBT, 20% albumin FBT was associated with a reduced
positive fluid balance but did not significantly reduce the duration of
vasopressor therapy.<br/>Copyright &#xa9; 2024. The Author(s).

<14>
Accession Number
644382542
Title
Non-ST-elevation acute coronary syndromes with previous coronary artery
bypass grafting: a meta-analysis of invasive vs. conservative management.
Source
European heart journal. 45(27) (pp 2380-2391), 2024. Date of Publication:
12 Jul 2024.
Author
Kelham M.; Vyas R.; Ramaseshan R.; Rathod K.; de Winter R.J.; de Winter
R.W.; Bendz B.; Thiele H.; Hirlekar G.; Morici N.; Myat A.; Michalis L.K.;
Sanchis J.; Kunadian V.; Berry C.; Mathur A.; Jones D.A.
Institution
(Kelham, Ramaseshan, Rathod, Mathur, Jones) Centre for Cardiovascular
Medicine and Devices, Faculty of Medicine & Dentistry, Queen Mary
University of London, London, United Kingdom
(Kelham, Vyas, Ramaseshan, Rathod, Mathur, Jones) Barts Interventional
Group, Barts Heart Centre, Barts Health NHS Trust, West Smithfield,
London, UK
(de Winter) Department of Cardiology Heart Center, Universiteit van
Amsterdam, Amsterdam, Netherlands
(de Winter) Department of Cardiology, Vrije Universiteit Amsterdam,
Amsterdam, Netherlands
(Bendz) Department of Cardiology, Oslo University Hospital and Institute
of Clinical Medicine, University of Oslo, Oslo, Norway
(Thiele) Heart Center Leipzig at University of Leipzig and Leipzig Heart
Science, Leipzig, Germany
(Hirlekar) Department of Cardiology, Sahlgrenska University Hospital,
Gothenburg, Sweden
(Morici) IRCCS S. Maria Nascente-Fondazione Don Carlo Gnocchi ONLUS,
Milan, Italy
(Myat) Medical Director (Cardiology), London, United Kingdom
(Michalis) 2nd Department of Cardiology, Faculty of Medicine, School of
Health Sciences, University of Ioannina and University Hospital of
Ioannina, University Campus, Ioannina 45110, Greece
(Sanchis) Cardiology Department, University Clinic Hospital of Valencia,
INCLIVA University of Valencia, Valencia, Spain
(Kunadian) Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne
Hospitals NHS Foundation Trust and Translational and Clinical Research
Institute, Faculty of Medical Sciences, Newcastle University, Newcastle
upon Tyne, United Kingdom
(Berry) British Heart Foundation Cardiovascular Research Centre,
University of Glasgow, Glasgow, United Kingdom
(Mathur, Jones) NIHR Barts Biomedical Research Centre, Queen Mary
University of London, Charterhouse Square, London, United Kingdom
Abstract
BACKGROUND AND AIMS: A routine invasive strategy is recommended in the
management of higher risk patients with non-ST-elevation acute coronary
syndromes (NSTE-ACSs). However, patients with previous coronary artery
bypass graft (CABG) surgery were excluded from key trials that informed
these guidelines. Thus, the benefit of a routine invasive strategy is less
certain in this specific subgroup. <br/>METHOD(S): A systematic review and
meta-analysis of randomized controlled trials (RCTs) was conducted. A
comprehensive search was performed of PubMed, EMBASE, Cochrane, and
ClinicalTrials.gov. Eligible studies were RCTs of routine invasive vs. a
conservative or selective invasive strategy in patients presenting with
NSTE-ACS that included patients with previous CABG. Summary data were
collected from the authors of each trial if not previously published.
Outcomes assessed were all-cause mortality, cardiac mortality, myocardial
infarction, and cardiac-related hospitalization. Using a random-effects
model, risk ratios (RRs) with 95% confidence intervals (CIs) were
calculated. <br/>RESULT(S): Summary data were obtained from 11 RCTs,
including previously unpublished subgroup outcomes of nine trials,
comprising 897 patients with previous CABG (477 routine invasive, 420
conservative/selective invasive) followed up for a weighted mean of 2.0
(range 0.5-10) years. A routine invasive strategy did not reduce all-cause
mortality (RR 1.12, 95% CI 0.97-1.29), cardiac mortality (RR 1.05, 95% CI
0.70-1.58), myocardial infarction (RR 0.90, 95% CI 0.65-1.23), or
cardiac-related hospitalization (RR 1.05, 95% CI 0.78-1.40).
<br/>CONCLUSION(S): This is the first meta-analysis assessing the effect
of a routine invasive strategy in patients with prior CABG who present
with NSTE-ACS. The results confirm the under-representation of this
patient group in RCTs of invasive management in NSTE-ACS and suggest that
there is no benefit to a routine invasive strategy compared to a
conservative approach with regard to major adverse cardiac events. These
findings should be validated in an adequately powered RCT.<br/>Copyright
&#xa9; The Author(s) 2024. Published by Oxford University Press on behalf
of the European Society of Cardiology.

<15>
Accession Number
2033299030
Title
Effect of Preoperative Recombinant Human Erythropoietin on the Need for
Blood Transfusion and Surgical Outcomes in Adult Patients Undergoing
Cardiac Surgery: A Systematic Review and Meta-Analysis with Trial
Sequential Analysis.
Source
Journal of Cardiothoracic and Vascular Anesthesia. (no pagination), 2024.
Date of Publication: 2024.
Author
Hakim S.M.; Ahmad A.H.M.; Amer A.M.
Institution
(Hakim, Ahmad, Amer) Department of Anesthesiology, Intensive Care and Pain
Management, Ain Shams University Faculty of Medicine, Cairo, Egypt
Publisher
W.B. Saunders
Abstract
This study aimed to examine the value of preoperative recombinant human
erythropoietin (rhEPO) administration to adults undergoing elective
cardiac surgery. Databases were searched for randomized controlled trials
(RCTs) comparing rhEPO plus standard treatment versus standard treatment
only. Primary outcomes were the need for and volume of homologous blood
transfusion (HBT). Secondary outcomes were the lengths of intensive care
unit (ICU) and hospital stay and the incidence of major adverse events.
There was very low certainty that rhEPO is associated with a reduction in
the need for HBT, with a number needed to treat of 5.6 (95% confidence
interval [CI], 3.9-12.5), and low certainty that it is associated with a
moderate reduction in HBT volume (Hedges g = -0.55; 95% CI, -0.79 to
-0.32). Meta-regression revealed that studies with a higher proportion of
females or older patients demonstrated less benefit of rhEPO in terms of
reduced consumption of HBT. Trial sequential analysis showed that rhEPO
was superior to standard treatment only for reducing the need for and
volume of HBT. Regarding secondary outcomes, there was moderate certainty
that rhEPO is associated with a limited reduction in the length of ICU
(Hedges g = -0.10; 95% CI, -0.19 to -0.01) and hospital stay (Hedges g =
-0.13; 95% CI = -0.25 to -0.02), and low certainty for increased risk of
myocardial infarction, with a number needed to harm of 36.1 (95% CI,
17.9-127.4). More well-designed, adequately powered RCTs are needed to
draw conclusions regarding the value of rhEPO.<br/>Copyright &#xa9; 2024
Elsevier Inc.

<16>
Accession Number
2033224434
Title
Total Intravenous Anesthesia Is Preferred Over Volatile Agents in Cardiac
Surgery.
Source
Journal of Cardiothoracic and Vascular Anesthesia. (no pagination), 2024.
Date of Publication: 2024.
Author
Smeltz A.M.; Serrano R.A.
Institution
(Smeltz, Serrano) University of North Carolina School of Medicine, Chapel
Hill, NC, United States
Publisher
W.B. Saunders
Abstract
The choice of maintenance anesthetic during cardiopulmonary bypass has
been a subject of ongoing debate. Systematic reviews on the topic have so
far failed to demonstrate a difference between volatile agents and total
intravenous anesthesia (TIVA) in terms of mortality, myocardial injury,
and neurological outcomes. Studies using animal models and noncardiac
surgical populations suggest numerous mechanisms whereby TIVA has been
associated with more favorable outcomes. However, even if the different
anesthetic methods are assumed to equivalent in terms of patient outcomes
in the context of cardiac surgery, additional factors, namely variables of
occupational exposure and environmental impact, strongly support the
preferred use of TIVA.<br/>Copyright &#xa9; 2024 Elsevier Inc.

<17>
Accession Number
2030553115
Title
Comments on Elmitwalli et al 'Use of high-flow nasal cannula versus other
noninvasive ventilation techniques or conventional oxygen therapy for
respiratory support after pediatric cardiac surgery: A systematic review
and meta-analysis'.
Source
Paediatric Anaesthesia. (no pagination), 2024. Date of Publication: 2024.
Author
Murphy T.; Beringer R.
Institution
(Murphy, Beringer) Department of Paediatric Cardiac Anaesthesia, Bristol
Royal Hospital for Children, Bristol, United Kingdom
Publisher
John Wiley and Sons Inc

<18>
Accession Number
2033353237
Title
Reporting Minority Race and Ethnicity in Cardiovascular and Thoracic
Journals.
Source
Journal of Surgical Research. 301 (pp 352-358), 2024. Date of Publication:
September 2024.
Author
Khedr S.; Hong J.; Forter-Chee-A-Tow N.; Cygiel G.; Heffernan D.S.; Lee
B.E.; Chao S.Y.
Institution
(Khedr, Hong, Forter-Chee-A-Tow, Cygiel, Chao) Department of General
Surgery, New York Presbyterian-Queens, Queens, New York, United States
(Chao) Department of Surgery, Weill Cornell Medicine, New York, New York,
United States
(Heffernan) Department of Surgery, Brown University, Providence, Rhode
Island, United States
(Lee) Department of Cardiothoracic Surgery, Weill Cornell Medicine, New
York, New York, United States
Publisher
Academic Press Inc.
Abstract
Introduction: Currently, there is no mandatory standard for reporting race
and ethnicity in medical journals, presenting significant barriers to
studying disparities in medical outcomes. We seek to investigate whether
greater recent awareness of diversity and inclusion reflects in reporting
of race and ethnicity by peer-reviewed cardiothoracic articles.
<br/>Method(s): Pubmed was queried for clinical outcomes articles
published from January 2017 to June 2023 in the Journal of Thoracic and
Cardiovascular Surgery, Annals of Thoracic Surgery, Journal of Heart and
Lung Transplantation, and CHEST Journal. Basic science, translational
studies, and international studies were excluded. SAS Studio was used for
statistical analysis. <br/>Result(s): 817 papers were reviewed, 378
reported race/ethnicity with 354 (93%) reporting White, 267 (71%)
reporting Black, 128 (34%) reporting Hispanic, and 119 (31%) reporting
Asian. Over 8-y, there were no statistically significant changes in
percent of articles that included White (odds ratio 0.808 95% confidence
interval [0.624-1.047], P = 0.1068), Black (1.125 [0.984-1.288], P =
0.0857), or Asian (1.096 [0.960-1.250], P = 0.1751) groups. Hispanics were
more likely to be reported in recent years (1.147 [1.006-1.307], P =
0.0397). Subset analysis was performed on cardiac (n = 157) and thoracic
articles (n = 157) with no significant trends for race reporting in these
subsets. <br/>Conclusion(s): Minorities remain underrepresented in
reported patient populations in peer-reviewed cardiothoracic journals.
Future efforts should prioritize accurately representing these populations
in the literature. Inaccurate data and exclusion of minority populations
can contribute to disparities observed in overall outcomes.<br/>Copyright
&#xa9; 2024 Elsevier Inc.

<19>
Accession Number
2033295742
Title
Erratum: Multicentre, randomised, double-blind, parallel controlled trial
to investigate timing of platelet inhibition after coronary artery bypass
grafting: TOPCABG trial study (BMJ Open (2023) 13 (e070823) DOI:
10.1136/bmjopen-2022-070823).
Source
BMJ Open. 14(7) (no pagination), 2024. Article Number: e070823.corr1. Date
of Publication: 11 Jul 2024.
Author
Anonymous
Publisher
BMJ Publishing Group
Abstract
This article has been corrected since it was published online. The Sample
size has been updated from "Primary efficacy endpoint: patency in De-DAPT
group is non-inferior to DAPT group. We assumed that the 1-year SVG
occlusion rate would be 10% with De-DAPT and DAPT and non-inferiority
margin would be 3.0%." to "Primary efficacy endpoint: patency in De-DAPT
group is non-inferior to DAPT group. We assumed that the 1-year SVG
occlusion rate would be 10% with DAPT and non-inferiority margin would be
3.5%."<br/>Copyright &#xa9; Author(s) (or their employer(s)) 2024. Re-use
permitted under CC BY-NC. No commercial re-use. See rights and
permissions. Published by BMJ.

<20>
Accession Number
2033216169
Title
Effects of ciprofol infusion on hemodynamics during induction and
maintenance of anesthesia and on postoperative recovery in patients
undergoing thoracoscopic lobectomy: Study protocol for a randomized,
controlled trial.
Source
PLoS ONE. 19(7 July) (no pagination), 2024. Article Number: e0305478. Date
of Publication: July 2024.
Author
Guo N.; Cao J.; Duan M.; Zhou F.; Wang W.; Xu L.; Wei C.; Song X.
Institution
(Guo, Cao, Duan, Zhou, Wang, Song) Department of Anesthesiology, The First
Affiliated Hospital of Shandong First Medical University, Shandong
Provincial Qianfoshan Hospital, Jinan, China
(Guo, Cao, Duan, Zhou, Wang, Song) Shandong Institute of Anesthesia and
Respiratory Critical Medicine, Ji nan, China
(Guo, Cao, Duan, Zhou, Wang, Song) Shandong Provincial Clinical Research
Center for Anesthesiology, Ji nan, China
(Xu, Wei) Department of Nursing, The First Affiliated Hospital of Shandong
First Medical University, Shandong Provincial Qianfoshan Hospital, Ji nan,
China
Publisher
Public Library of Science
Abstract
Introduction Ciprofol, a new candidate drug, is effective and safe for the
maintenance of anesthesia in non-cardiothoracic and non-neurological
elective surgery. However, few studies have been conducted on general
anesthesia using ciprofol in patients undergoing thoracoscopic lobectomy.
Therefore, this study aims to observe the effects of ciprofol on
hemodynamics and on postoperative recovery in patients undergoing
thoracoscopic lobectomy. Methods and analysis This randomized controlled
trial will include 136 patients aged 18 E5 years undergoing elective
thoracoscopic lobectomy between April 2023 and December 2024. The
participants will be randomly assigned to the propofol or ciprofol group.
The primary outcome to be assessed is the hemodynamic fluctuation during
the induction and maintenance of anesthesia. The secondary outcomes
involve quality of anesthesia induction and quality of recovery from
anesthesia. The former includes TLOC (time to loss of consciousness), the
use of vasoactive agents, the incidence of injection pain, body movement,
muscle twitching and coughing during induction of anesthesia. The latter
includes TROC (time to recovery of consciousness), post anesthesia care
unit (PACU) time, incidence of postoperative nausea and vomiting (PONV),
postoperative agitation, intraoperative awareness and quality of recovery
(QoR) score. Discussion A number of clinical trials have confirmed that
ciprofol, as a new sedative-hypnotic agent, has advantages of better
tolerance, higher sedation satisfaction score, and lower incidence of
adverse reactions, especially in reducing the incidence of injection pain.
But considering that ciprofol was recently developed, limited data are
available regarding its use for general anesthesia. This study aims to
investigate the effects of ciprofol on hemodynamics and on postoperative
recovery of patients undergoing thoracoscopic lobectomy. The results of
this study may provide evidence for the safe application of ciprofol, a
new choice of general anesthetic for thoracic surgery.<br/>Copyright
&#xa9; 2024 Garzon-Alfaro et al. This is an open access article
distributed under the terms of the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are credited.

<21>
Accession Number
2033381456
Title
Revascularisation in Left Ventricular Systolic Dysfunction: A
Meta-analysis of Kaplan-Meier Reconstructed Individual Patient Data.
Source
Canadian Journal of Cardiology. (no pagination), 2024. Date of
Publication: 2024.
Author
Lee G.; Malik A.; Vervoort D.; Tam D.Y.; Marquis-Gravel G.; Redfors B.;
Gaudino M.; Fremes S.E.
Institution
(Lee, Malik, Fremes) Division of Cardiac Surgery, University of Toronto,
Toronto, ON, Canada
(Vervoort, Fremes) Institute of Health Policy, Management and Evaluation,
University of Toronto, Toronto, ON, Canada
(Tam) Cedars-Sinai Medical Center, Los Angeles, CA, United States
(Marquis-Gravel) Montreal Heart Institute and Universite de Montreal,
Montreal, Quebec, Canada
(Redfors) Department of Cardiology, Sahlgrenska University Hospital,
Gothenburg, Sweden
(Gaudino) Department of Cardiothoracic Surgery, Weill Cornell Medicine,
New York, NY, United States
Publisher
Elsevier Inc.
Abstract
Background: Coronary artery disease is a common cause of ischemic left
ventricular systolic dysfunction (LVSD), for which the optimal
revascularisation strategy remains unclear. We aimed to determine whether
percutaneous coronary intervention (PCI) or coronary artery bypass
grafting (CABG) results in greater survival advantage in patients with
LVSD. <br/>Method(s): Study-level (SLMA) and reconstructed individual
patient data (rIPDMA) meta-analyses from Kaplan-Meier (KM) survival curves
were performed. A systematic search of Medline, Embase, and Cochrane
Library was conducted for observational and randomised studies published
after 2010 that compared PCI and CABG in patients with left ventricular
ejection fraction <= 40%. The primary outcome was all-cause mortality at
longest follow-up. The secondary outcomes were myocardial infarction (MI),
stroke, repeated revascularisation, cardiovascular mortality, and major
adverse cardiovascular and cerebrovascular events (MACCE) at longest
follow-up. <br/>Result(s): Fourteen studies (11 observational, 3
randomised, 13,063 patients) were eligible for the SLMA. Seven contained
digitisable KM curves from which individual patient data could be
reconstructed. Study-level analysis found PCI to be associated with
increased all-cause mortality (hazard ratio [HR] 1.41, 95% confidence
interval [CI] 1.18-1.69), MI (HR 2.10, 95% CI 1.62-2.72), repeated
revascularisation (HR 2.39, 95% CI 1.37-4.17), and MACCE (HR 1.58, 95% CI
1.23-2.03), without significant differences in stroke (HR 0.86, 95% CI
0.39-1.92) or cardiovascular mortality (HR 1.42, 95% CI 0.78-2.59). In the
rIPDMA, PCI resulted in increased all-cause mortality (HR 1.57, 95% CI
1.34-1.87) and repeated revascularisation (HR 3.63, 95% CI 3.12-4.21) but
overall lower risk of stroke (HR 0.62, 95% CI 0.39-0.99) owing to fewer
events during initial follow-up. <br/>Conclusion(s): In patients with
ischemic LVSD, PCI was associated with higher risk of all-cause mortality
and repeated revascularisation than CABG, but lower risk of short-term
stroke. (PROSPERO: CRD42021291408)<br/>Copyright &#xa9; 2024 Canadian
Cardiovascular Society

<22>
Accession Number
2033297785
Title
Transcatheter edge-to-edge mitral valve repair for severe heart failure in
a young woman with polymyositis: A case report.
Source
Journal of Cardiology Cases. (no pagination), 2024. Date of Publication:
2024.
Author
Fujii M.; Onishi T.; Yamamoto H.; Takahashi N.; Takaya T.; Kawai H.
Institution
(Fujii, Onishi, Yamamoto, Takahashi, Takaya, Kawai) Division of
Cardiovascular Medicine, Hyogo Prefectural Harima-Himeji General Medical
Center, Hyogo, Himeji, Japan
Publisher
Elsevier Ltd
Abstract
Polymyositis (PM) and dermatomyositis (DM) are chronic inflammatory muscle
disorders characterized by muscle weakness and fatigue. They are
histopathologically defined by inflammatory cell infiltrates in the
skeletal muscle. In a recent meta-analysis, the incidence of
cardiovascular complications in patients with PM/DM ranged from 9 to 72 %,
with heart failure being the most commonly reported heart disease. In
cases of heart failure accompanied by severe mitral regurgitation that is
refractory due to guideline-directed medical therapy, the transcatheter
edge-to-edge mitral valve repair (TEER) procedure using the MitraClip
(Abbott Vascular, Santa Clara, CA, USA) offers an alternative therapeutic
approach. We present a pioneering case report describing the successful
application of TEER in a young woman with drug-refractory heart failure
due to cardiovascular involvement in PM. Learning objective: * In
polymyositis (PM)/ dermatomyositis (DM), the most commonly reported
clinical heart disorder is heart failure, with some cases attributed to
mitral regurgitation. * Patients suffering from systemic inflammatory
diseases such as PM/DM often face high surgical risk, and the MitraClip is
an effective treatment modality.<br/>Copyright &#xa9; 2024 Elsevier Ltd

<23>
Accession Number
2030599688
Title
Natural history of initially asymptomatic severe aortic stenosis: a
one-stage meta-analysis.
Source
Clinical Research in Cardiology. (no pagination), 2024. Date of
Publication: 2024.
Author
Tan J.T.A.; He G.S.; Chia J.L.L.; Tan G.Q.X.; Teo Y.N.; Teo Y.H.; Syn
N.L.; Chai P.; Wong R.C.C.; Yeo T.-C.; Kong W.K.F.; Poh K.-K.; Sia C.-H.
Institution
(Tan, He, Chia, Tan, Teo, Syn, Chai, Wong, Yeo, Kong, Poh, Sia) Department
of Medicine, Yong Loo Lin School of Medicine, National University of
Singapore, Singapore, Singapore
(Teo) Department of Medicine, National University Hospital, Singapore,
Singapore
(Chai, Wong, Yeo, Kong, Poh, Sia) Department of Cardiology, National
University Heart Centre Singapore, 1E Kent Ridge Road, NUHS Tower Block
Level 9, Singapore 119228, Singapore
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Background: Current guidelines on the management strategy for patients
with asymptomatic severe aortic stenosis (AS) remain unclear. This
uncertainty stems from the lack of data regarding the natural history of
these patients. To address this gap, we performed a systematic review and
meta-analysis examining the natural history of asymptomatic severe AS
patients receiving conservative treatment. <br/>Method(s): The PubMed,
Cochrane, and Embase databases were searched from inception to 24 January
2024 using the keywords "asymptomatic" AND "aortic" AND "stenosis". We
included studies examining patients with asymptomatic severe AS. In
interventional trials, only data from conservatively managed arms were
collected. A one-stage meta-analysis was conducted using individual
patient data reconstructed from published Kaplan-Meier curves. Sensitivity
analysis was performed for major adverse cardiovascular outcomes in
patients who remained asymptomatic throughout follow-up. <br/>Result(s): A
total of 46 studies were included (n = 9545). The median time to the
development of symptoms was 1.11 years (95% CI 0.90-1.53). 49.36%
(40.85-58.59) of patients who were asymptomatic had suffered a major
adverse cardiovascular event by 5 years. The median event-free time for
heart failure hospitalization (HFH) was 5.50 years (95% CI 5.14-5.91) with
36.34% (95% CI 33.34-39.41) of patients experiencing an HFH by year 5. By
5 years, 79.81% (95% CI 69.26-88.58) of patients developed symptoms
(angina, dyspnoea, syncope and others) and 12.36% (95% CI 10.01-15.22) of
patients died of cardiovascular causes. For all-cause mortality, the
median survival time was 9.15 years (95% CI 8.50-9.96) with 39.43% (CI
33.41-36.40) of patients dying by 5 years. The median time to AVR was 4.77
years (95% CI 4.39-5.17), with 52.64% (95% CI 49.85-55.48) of patients
requiring an AVR by 5 years. <br/>Conclusion(s): Our results reveal poor
cardiovascular outcomes for patients with asymptomatic severe AS on
conservative treatment. A significant proportion eventually requires an
AVR. Further research is needed to determine if early intervention with
AVR is more effective than conservative treatment.<br/>Copyright &#xa9;
Springer-Verlag GmbH Germany, part of Springer Nature 2024.

<24>
Accession Number
2033191142
Title
Digital health intervention in patients undergoing cardiac rehabilitation:
systematic review and meta-analysis.
Source
F1000Research. 13 (no pagination), 2024. Article Number: 596. Date of
Publication: 2024.
Author
Harbi A.S.; Soh K.L.; Yubbu P.B.; Soh K.G.
Institution
(Harbi, Soh) Department of Nursing, Faculty of Medicine & Health Sciences,
University Putra Malaysia, Selangor, Serdang 43400, Malaysia
(Yubbu) Department of Paediatrics, Faculty of Medicine & Health Sciences,
University Putra Malaysia, Selangor, Serdang 43400, Malaysia
(Soh) Department of Sport Studies, Faculty of Educational Studies,
University Putra Malaysia, Selangor, Serdang 43400, Malaysia
Publisher
F1000 Research Ltd
Abstract
Background: Cardiovascular disease (CVD) continues to be the foremost
mortality internationally. Cardiac rehabilitation has proven as an
effective program in reducing CVD burden. Participation in cardiac
rehabilitation programs is very low. Digital health intervention emerged
as an alternative method to deliver Cardiac rehabilitation. This review
aimed to investigate the impact of digital health intervention on the
outcomes of interest Methods: the following databases: PubMed, CINAHL,
Scopus, and Cochrane Library have been searched to retrieve randomized
controlled trials that examine the impact of digital health intervention
on blood pressure, body mass index, lipid profile, blood glucose,
Six-Minute Walk Test, and peak oxygen consumption. filters were set to
include studies published in English between 2000-2023. <br/>Result(s):
Nineteen studies were included in this review. Six-Minute Walk Test (MD =
16.70; 95% CI: 6.00 to 27.39, p = 0.000) and maximal oxygen consumption
(SMD = 0.27; 95% CI: 0.08 to 0.45, p = 0.004) significantly improved
following digital health intervention, after employing the sensitivity
analysis significant improvement was observed in systolic (MD = -2.54; 95%
CI: -4.98 to -0.11, p = 0.04) and diastolic blood pressure (SMD = -2.0182;
95% CI: -3.9436 to -0.0928, p = 0.04) favoring experimental groups.
Subgroup analysis revealed significant improvement in quality of life
after three months of follow-up (SMD = 0.18; 95% CI: 0.05 to 0.31, p =
0.00), no significant differences have been observed in body mass index,
lipid profile, and blood glucose. <br/>Conclusion(s): The findings
emphasize the significant impact of digital vs CBCR or usual care on
physical capacity, blood pressure, and quality of life. Despite the
non-statistically significant differences in body mass index and lipid
profile, the comparable effect between the two methods suggests the
superiority of digital over CBCR or usual care due to its convenient
nature, accessibility, and cost-effectiveness.<br/>Copyright: &#xa9; 2024
Harbi AS et al.

<25>
Accession Number
2033183674
Title
Efficacy of N-acetylcysteine for Prevention of Postoperative Atrial
Fibrillation Following Coronary Artery Bypass Grafting: A Systematic
Review and Meta-Analysis of Randomized Controlled Trials.
Source
Reviews in Cardiovascular Medicine. 25(7) (no pagination), 2024. Date of
Publication: 2024.
Author
Hanafy D.A.; Willim H.A.; Suwatri W.T.; Sani A.A.; Khouw H.; Susanti E.I.;
Sugisman
Institution
(Hanafy, Willim, Suwatri, Sani, Khouw, Susanti, Sugisman) Department of
Cardiothoracic and Vascular Surgery, Division of Adult Cardiac Surgery,
National Cardiovascular Center Harapan Kita, Faculty of Medicine,
University of Indonesia, Jakarta 10430, Indonesia
Publisher
IMR Press Limited
Abstract
Background: As the prevalence of coronary artery disease rises, the demand
for coronary artery bypass grafting (CABG) increases. A common
complication after CABG is postoperative atrial fibrillation (POAF), which
is linked to adverse clinical outcomes. N-acetylcysteine (NAC), an
antioxidant, may mitigate oxidative stress and reduce the incidence of
POAF. This meta-analysis aims to investigate the efficacy of NAC in
preventing POAF after CABG. <br/>Method(s): The meta-analysis was
conducted following Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines. We systematically searched multiple
databases, including PubMed, Cochrane Library, ProQuest, and
ScienceDirect, to identify relevant randomized controlled trials (RCTs).
The intervention groups received perioperative NAC therapy, while the
control groups received a placebo. The outcomes assessed were POAF
incidence, all-cause mortality, and hospital length of stay (LOS). Review
Manager 5.3 was used to conduct the meta-analysis. <br/>Result(s): Eleven
RCTs involving 648 patients were included. The NAC group comprised 326
patients, while the control group comprised 322 patients. In the pooled
analysis, patients in the NAC group had a significantly lower incidence of
POAF (odds ratios (OR) = 0.57; 95% confidence intervals (CI) = 0.33 to
0.97; p = 0.04) and a shorter hospital LOS (weighted mean differences
(WMD) = -0.66; 95% CI = -1.22 to -0.10; p = 0.02) compared to the control
group. However, there was no significant difference in all-cause
mortality. <br/>Conclusion(s): The perioperative administration of NAC can
effectively reduce the incidence of POAF and hospital LOS in CABG
patients. However, larger RCTs are needed to confirm these
findings.<br/>Copyright: &#xa9; 2024 The Author(s).

<26>
Accession Number
2033287322
Title
Transfusion strategy trials excluding patients transfused outside the
trial study period are more likely to report a trend favoring restrictive
strategies: a meta-analysis.
Source
Journal of Clinical Epidemiology. 173 (no pagination), 2024. Article
Number: 111441. Date of Publication: September 2024.
Author
Trentino K.M.; Shander A.; Gross I.; Farmer S.L.
Institution
(Trentino) Medical School, The University of Western Australia, Perth,
Australia
(Trentino) Community and Virtual Care, East Metropolitan Health Service,
Perth, Australia
(Shander) TeamHealth Department of Anesthesiology and Critical Care,
Englewood Health, Englewood, NJ, United States
(Gross) Discipline of Surgery, Medical School, The University of Western
Australia, Perth, WA, Australia
(Gross) Department of Medicine, Emeritus, Northern Light Eastern Maine
Medical Center, Bangor, ME, United States
(Farmer) Department of Haematology, Royal Perth Hospital, Perth, WA,
Australia
(Farmer) Discipline of Surgery, Medical School, The University of Western
Australia, Perth, WA, Australia
Publisher
Elsevier Inc.
Abstract
Objectives: Some large, randomized trials investigating red cell
transfusion strategies have significant numbers of transfusions
administered outside the trial study period. We sought to investigate the
potential impact of this methodological issue. Study Design and Setting:
Meta-analysis of randomized controlled trials (RCTs) comparing liberal vs
restrictive transfusion strategies in cardiac surgery and acute myocardial
infarction patients. The outcome of interest was 30-day or in-hospital
mortality. <br/>Result(s): In cardiac surgery, the pooled risk ratio for
mortality was 0.83 (95% confidence interval [CI] 0.62-1.12, P = .22) times
lower in the restrictive group when compared to the liberal group in
trials applying a transfusion strategy throughout the patient's entire
perioperative period, and 1.33 (95% CI 0.84-2.11, P = .22) times higher in
the restrictive group in trials not applying transfusion strategies
throughout the entire perioperative period. When combined, the risk ratio
for mortality was 0.98 (95% CI 0.73-1.32, P = .89). In patients with acute
myocardial infarction, the risk ratio for mortality was 0.72 (95% CI
0.40-1.28, P = .26) times lower in the restrictive group when compared to
the liberal group in 1 trial excluding patients administered the
intervention prerandomization and 1.19 (95% CI 0.96-1.47, P = .11) times
higher in the restrictive group in 1 trial including patients receiving
the intervention prerandomization. When combined the risk ratio for
mortality was 1.00 (0.62-1.59, P = .99). <br/>Conclusion(s): Though not
statistically significant, there was a consistent difference in trends
between RCTs administering significant numbers of transfusion outside the
trial study period compared to those that did not. The implications of our
results may extend to RCTs in other settings that ignore if and how
frequently an investigated therapy is administered outside the trial
window.<br/>Copyright &#xa9; 2024 The Author(s)

<27>
Accession Number
2033272613
Title
Valve-in-Valve Transcatheter Aortic Valve Replacement Versus Redo-Surgical
Aortic Valve Replacement in Patients With Aortic Stenosis: A Systematic
Review and Meta-analysis.
Source
American Journal of Cardiology. 225 (pp 151-159), 2024. Date of
Publication: 15 Aug 2024.
Author
Nasir M.M.; Ikram A.; Usman M.; Sarwar J.; Ahmed J.; Hamza M.; Farhan
S.A.; Siddiqi R.; Qadar L.T.; Shah S.R.; Khalid M.R.; Memon R.S.; Hameed
I.
Institution
(Nasir, Ikram, Usman, Sarwar, Ahmed) Department of Internal Medicine, Dow
University of Health Sciences, Karachi, Pakistan
(Hamza) Department of Internal Medicine, Guthrie Medical Group, Cortland,
NY, United States
(Farhan) Department of Surgery, Ohio State University, Columbus, OH,
United States
(Siddiqi) Department of Internal Medicine, University of Toledo, Ohio,
United States
(Qadar) Department of Internal Medicine, St Vincent's Medical Center,
Bridgeport, CT, United States
(Shah) Division of Cardiovascular Medicine, University of Louisville,
Louisville, Kentucky, United States
(Khalid) Department of Internal Medicine, Texas Health Presbyterian
Hospital, Denton, Texas, United States
(Memon) Department of Internal Medicine, Jacobi Medical Center-New York
City Health + Hospitals Corporation/Albert Einstein College of Medicine,
Bronx, NY, United States
(Hameed) Division of Cardiac Surgery, Yale University School of Medicine,
New Haven, Connecticut, United States
Publisher
Elsevier Inc.
Abstract
Aortic stenosis is a common and significant valve condition requiring
bioprosthetic heart valves with transcatheter aortic valve replacement
(TAVR) being strongly recommended for high-risk patients or patients over
75 years. This meta-analysis aimed to pool existing data on postprocedural
clinical as well as echocardiographic outcomes comparing valve-in-valve
(ViV)-TAVR to redo-surgical aortic valve replacement to assess the
short-term and medium-term outcomes for both treatment methods. A
systematic literature search on Cochrane Central, Scopus, and Medline
(PubMed interface) electronic databases from inception to August 2023. We
used odds ratios (OR) for dichotomous outcomes and mean differences (MD)
for continuous outcomes. Twenty-four studies (25,216 patients) were pooled
with a mean follow-up of 16.4 months. The analysis revealed that ViV-TAVR
group showed a significant reduction in 30-day mortality (OR 0.50, 95%
confidence interval [CI] 0.43 to 0.58, p <0.00001), new-onset atrial
fibrillation (OR 0.34, 95% CI 0.17 to 0.67, p = 0.002), major bleeding
event (OR 0.28, 95% CI 0.17 to 0.45, p <0.00001) and lower rate of device
success (OR 0.25, 95% CI 0.12 to 0.53, p = 0.0003). There were no
significant differences between either group when assessing 1-year
mortality, stroke, myocardial infarction, postoperative left ventricular
ejection fraction, and effective orifice area. ViV-TAVR cohort showed a
significantly increased incidence of paravalvular leaks, aortic
regurgitation, and increased mean aortic valve gradient. ViV-TAVR is a
viable short-term option for older patients with high co-morbidities and
operative risks, reducing perioperative complications and improving 30-day
mortality with no significant cardiovascular adverse events. However, both
treatment methods present similar results on short-term to medium-term
complications assessment.<br/>Copyright &#xa9; 2024 Elsevier Inc.

<28>
[Use Link to view the full text]
Accession Number
2033271463
Title
Effectiveness of the Bilateral and Bilevel Erector Spinae Plane Block
(ESPB) in Pediatric Idiopathic Scoliosis Surgery: A Randomized,
Double-Blinded, Controlled Trial.
Source
Journal of Pediatric Orthopaedics. 44(7) (pp e634-e640), 2024. Date of
Publication: 01 Aug 2024.
Author
Domagalska M.; Ciftsi B.; Janusz P.; Reysner T.; Daroszewski P.; Kowalski
G.; Wieczorowska-Tobis K.; Kotwicki T.
Institution
(Domagalska, Reysner, Kowalski, Wieczorowska-Tobis) Department of
Palliative Medicine, Poznan University of Medical Sciences, Poznan, Poland
(Ciftsi) Department of Spine Disorders and Pediatric Orthopedics, Poznan
University of Medical Sciences, Poznan, Poland
(Janusz, Kotwicki) Department of Organization and Management in Health
Care, Poznan University of Medical Sciences, Poznan, Poland
(Daroszewski) Department of Anesthesiology and Reanimation, Istanbul
Medipol University, Istanbul, Turkey
Publisher
Lippincott Williams and Wilkins
Abstract
Background: This study aimed to compare the effect of the
ultrasound-guided bilateral and bilevel erector spinae plane block (ESPB)
on pain scores, opioid requirement, intraoperative motor-evoked potentials
(MEPs), and stress response to surgery expressed by the
neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio
(PLR) versus standard analgesia methods following idiopathic scoliosis
surgery. <br/>Method(s): This was a prospective, double-blinded,
randomized controlled trial. Sixty patients aged 10 to 18 years and
physical status ASA 1 or 2 were randomized into 2 equal groups, each
receiving an ESPB or sham block. The primary outcome was the pain scores
(Numerical Rating Scale, NRS) within 48 hours after spinal correction and
fusion surgery for idiopathic thoracic scoliosis. The secondary outcomes
were total opioid consumption, NLR, and PLR levels at 12 and 24 hours
postoperatively and intraoperative MEPs. <br/>Result(s): ESPB patients
presented lower NRS scores, signifying less pain, at all time points (30,
60, 90, 120 min; and 6, 12, 24, and 48 h after surgery), all P<0.0001. The
total opioid consumption, the incidence of nausea or vomiting, and the
need for remifentanil and propofol during surgery were significantly lower
in the ESPB group. The surgery-induced stress response expressed by NLR
and PLR was considerably lower in the ESPB group. ESPB did not affect the
intraoperative MEP's amplitude. <br/>Conclusion(s): ESPB is effective for
postoperative analgesia, can reduce opioid consumption in patients
undergoing scoliosis surgery, and reduces the stress response to surgery.
ESPB does not interfere with neuromonitoring.<br/>Copyright &#xa9; 2024
The Author(s).

<29>
[Use Link to view the full text]
Accession Number
2033271449
Title
Incidence of Intraoperative Cardiothoracic Intervention during Open
Surgery Following Acute Posterior Sternoclavicular Joint Injury: A Case
Series and Review of the Literature.
Source
Journal of Pediatric Orthopaedics. 44(7) (pp 421-426), 2024. Date of
Publication: 01 Aug 2024.
Author
Galina J.M.; Miller S.D.; Whelan T.J.; Pavlesen S.; Ferrick M.R.
Institution
(Galina, Whelan, Pavlesen, Ferrick) Department of Orthopaedic Surgery,
University at Buffalo, Jacobs School of Medicine and Biomedical Sciences,
Buffalo, NY, United States
(Miller) Eastern Virginia Medical School, Norfolk, VA, United States
Publisher
Lippincott Williams and Wilkins
Abstract
Background: Acute posterior sternoclavicular joint injuries are rare but
potentially lethal injuries - signs of mediastinal compression range from
nonspecific to neurovascular compromise. Currently, orthopaedic experts
recommend a cardiothoracic surgeon be placed on standby during open
surgery for potential intraoperative complications. However, few studies
have reported on how often cardiothoracic intervention is required.
<br/>Method(s): First, we identified patients in our institution by CPT
codes 23530, 23525, and 23532 from January 1, 2002 to May 1, 2023.
Demographic variables and intraoperative cardiothoracic intervention rates
were collected. Second, we systematically reviewed the literature to
identify articles on acute posterior sternoclavicular injury using PubMed,
Embase, and CINAHL databases (through August 20, 2023). Exclusion criteria
included conservative treatment, successful closed reduction, chronic
injury (>6 wk) cadaver studies, reviews, and nonavailable text.
<br/>Result(s): Thirteen local patients underwent open surgery for an
acute posterior sternoclavicular joint injury, 11 males and 2 females with
an average age of 18.2 years old (range: 15 to 32.4). The most common
mechanism of injury was sports (n=9; 69.2%). Four (30.8%) patients had
physical or radiographic evidence of mediastinal compression. No patients
required intraoperative cardiothoracic intervention in our institution.
The literature search yielded 132 articles and 512 open surgeries for
acute posterior sternoclavicular joint injuries. Four patients required
intraoperative cardiothoracic intervention, all of whom presented with
polytrauma and/or clinical or radiographic signs of neurovascular
compromise, giving a combined overall rate of 0.76%. <br/>Conclusion(s):
Expert opinion commonly recommends cardiothoracic backup during open
surgery for acute posterior sternoclavicular joint injuries. On the basis
of our local data and systematic literature review, we found an overall
cardiothoracic intervention rate of 0.76%. In the presence of polytrauma
and/or findings of neurovascular compromise, we suggest having
cardiothoracic surgery on close standby during the procedure. However, a
patient with an isolated acute posterior sternoclavicular joint injury and
no clinical or radiographic findings of neurovascular compromise does not
appear to require a cardiothoracic surgeon on standby. Ultimately, the
decision to involve cardiothoracic backup during open surgery for an acute
posterior sternoclavicular injury should be made on a case-by-case basis
after a thorough physical and radiographic evaluation of the
patient.<br/>Copyright &#xa9; 2024 Wolters Kluwer Health, Inc. All rights
reserved.

<30>
Accession Number
2033144565
Title
Norepinephrine weaning guided by the Hypotension Prediction Index in
vasoplegic shock after cardiac surgery: Protocol for a single-centre,
open-label randomised controlled trial - The NORAHPI study.
Source
BMJ Open. 14(6) (no pagination), 2024. Article Number: e084499. Date of
Publication: 26 Jun 2024.
Author
Beyls C.; Lefebvre T.; Mollet N.; Boussault A.; Meynier J.; Abou-Arab O.;
Mahjoub Y.
Institution
(Beyls, Mollet, Abou-Arab, Mahjoub) CHU Amiens-Picardie Pole Coeur Thorax
Vaisseaux, Amiens, France
(Lefebvre) Department of Anesthesiology and Critical Care, Amiens-Picardy
University Hospital, Amiens, France
(Boussault, Meynier) Amiens-Picardy University Hospital, Amiens, France
Publisher
BMJ Publishing Group
Abstract
Introduction Norepinephrine (NE) is the first-line recommended vasopressor
for restoring mean arterial pressure (MAP) in vasoplegic syndrome (vs)
following cardiac surgery with cardiopulmonary bypass. However, solely
focusing on target MAP values can lead to acute hypotension episodes
during NE weaning. The Hypotension Prediction Index (HPI) is a machine
learning algorithm embedded in the Acumen IQ device, capable of detecting
hypotensive episodes before their clinical manifestation. This study
evaluates the clinical benefits of an NE weaning strategy guided by the
HPI. Material and analysis The Norahpi trial is a prospective, open-label,
single-centre study that randomises 142 patients. Inclusion criteria
encompass adult patients scheduled for on-pump cardiac surgery with
postsurgical NE administration for vs patient randomisation occurs once
they achieve haemodynamic stability (MAP>65 mm Hg) for at least 4 hours on
NE. Patients will be allocated to the intervention group (n=71) or the
control group (n=71). In the intervention group, the NE weaning protocol
is based on MAP>65 mmHg and HPI<80 and solely on MAP>65 mm Hg in the
control group. Successful NE weaning is defined as achieving NE weaning
within 72 hours of inclusion. An intention-to-treat analysis will be
performed. The primary endpoint will compare the duration of NE
administration between the two groups. The secondary endpoints will
include the prevalence, frequency and time of arterial hypotensive events
monitored by the Acumen IQ device. Additionally, we will assess cumulative
diuresis, the total dose of NE, and the number of protocol weaning
failures. We also aim to evaluate the occurrence of postoperative
complications, the length of stay and all-cause mortality at 30 days.
Ethics and dissemination Ethical approval has been secured from the
Institutional Review Board (IRB) at the University Hospital of Amiens
(IRB-ID:2023-A01058-37). The findings will be shared through peer-reviewed
publications and presentations at national and international conferences.
Trial registration number NCT05922982.<br/>Copyright &#xa9; 2024 BMJ
Publishing Group. All rights reserved.

<31>
Accession Number
2032817248
Title
The Impact of Acute Kidney Injury on Chronic Kidney Disease After Cardiac
Surgery: A Systematic Review and Meta-analysis.
Source
Journal of Cardiothoracic and Vascular Anesthesia. 38(8) (pp 1760-1768),
2024. Date of Publication: August 2024.
Author
Lindhardt R.B.; Rasmussen S.B.; Riber L.P.; Lassen J.F.; Ravn H.B.
Institution
(Lindhardt, Rasmussen, Ravn) Department of Anesthesiology and Intensive
Care, Odense University Hospital, Odense, Denmark
(Lindhardt, Rasmussen, Riber, Lassen, Ravn) Department of Clinical
Research, Health Faculty, University of Southern Denmark, Odense, Denmark
(Riber) Department of Cardiac, Thoracic and Vascular Surgery, Odense
University Hospital, Odense, Denmark
(Lassen) Department of Cardiology, Odense University Hospital, Odense,
Denmark
Publisher
W.B. Saunders
Abstract
Objectives: To evaluate the impact of acute kidney injury on transition to
chronic kidney disease (CKD) after cardiac surgery and to determine
frequency of incident CKD in these patients. <br/>Design(s): A systematic
review and meta-analysis of observational studies. <br/>Setting(s):
Electronic databases Medline and Embase were systematically searched from
1974 to February 6, 2023. <br/>Participant(s): Eligible studies were
original observational studies on adult cardiac surgery patients, written
in the English language, and with clear kidney disease definitions.
Exclusion criteria were studies with previously transplanted populations,
populations with preoperative kidney impairment, ventricular assist device
procedures, endovascular procedures, a kidney follow-up period of <90
days, and studies not presenting necessary data for effect size
calculations. <br/>Intervention(s): Patients developing postoperative
acute kidney injury after cardiac surgery were compared with patients who
did not develop acute kidney injury. <br/>Measurements and Main Results:
The search identified 4,329 unique studies, 87 underwent full-text review,
and 12 were included for analysis. Mean acute kidney injury occurrence
across studies was 16% (minimum-maximum: 8-50), while mean occurrence of
CKD was 24% (minimum-maximum: 3-35), with high variability depending on
definitions and follow-up time. Acute kidney injury was associated with
increased odds of CKD in all individual studies. The pooled odds ratio
across studies was 5.67 (95% confidence interval, 3.34-9.64; p < 0.0001).
<br/>Conclusion(s): Acute kidney injury after cardiac surgery was
associated with a more than 5-fold increased odds of developing CKD.
New-onset CKD occurred in almost 1 in 4 patients in the years after
surgery.<br/>Copyright &#xa9; 2024 The Authors

<32>
Accession Number
2032636089
Title
Anti-Xa-guided Anticoagulation With Unfractionated Heparin and Thrombosis
During Extracorporeal Membrane Oxygenation Support: A Systematic Review
and Meta-analysis.
Source
Journal of Cardiothoracic and Vascular Anesthesia. 38(8) (pp 1662-1672),
2024. Date of Publication: August 2024.
Author
Rajsic S.; Breitkopf R.; Treml B.; Jadzic D.; Innerhofer N.; Eckhardt C.;
Oberleitner C.; Nawabi F.; Bukumiric Z.
Institution
(Rajsic, Breitkopf, Treml, Innerhofer, Eckhardt, Oberleitner, Nawabi)
Department of Anesthesiology and Intensive Care Medicine, Medical
University Innsbruck, Innsbruck 6020, Austria
(Jadzic) Anesthesia and Intensive Care Department, Pain Therapy Service,
Cagliari University, Cagliari, Italy
(Bukumiric) Institute of Medical Statistics and Informatics, Faculty of
Medicine, University of Belgrade, Belgrade 11000, Serbia
Publisher
W.B. Saunders
Abstract
Objective: The initiation of extracorporeal membrane oxygenation (ECMO)
triggers complex coagulation processes necessitating systemic
anticoagulation. Therefore, anticoagulation monitoring is crucial to avoid
adverse events such as thrombosis and hemorrhage. The main aim of this
work was to analyze the association between anti-Xa levels and thrombosis
occurrence during ECMO support. <br/>Design(s): Systematic literature
review and meta-analysis (Scopus and PubMed, up to July 29, 2023).
<br/>Setting(s): All retrospective and prospective studies.
<br/>Participant(s): Patients receiving ECMO support.
<br/>Intervention(s): Anticoagulation monitoring during ECMO support.
<br/>Measurements and Main Results: A total of 16 articles with 1,968
patients were included in the review and 7 studies in the meta-analysis (n
= 374). Patients with thrombosis had significantly lower mean anti-Xa
values (standardized mean difference -0.36, 95% confidence interval [CI]
-0.62 to -0.11, p < 0.01). Furthermore, a positive correlation was
observed between unfractionated heparin infusion and anti-Xa levels
(pooled estimate of correlation coefficients 0.31, 95% CI 0.19 to 0.43, p
< 0.001). The most common adverse events were major bleeding (42%) and any
kind of hemorrhage (36%), followed by thromboembolic events (30%) and
circuit or oxygenator membrane thrombosis (19%). More than half of the
patients did not survive to discharge (52%). <br/>Conclusion(s): This work
revealed significantly lower levels of anti-Xa in patients experiencing
thromboembolic events and a positive correlation between anti-Xa and
unfractionated heparin infusion. Considering the contemplative limitations
of conventional monitoring tools, further research on the role of anti-Xa
is warranted. New trials should be encouraged to confirm these findings
and determine the most suitable monitoring strategy for patients receiving
ECMO support.<br/>Copyright &#xa9; 2024 The Author(s)

<33>
Accession Number
2032635632
Title
Effect of volatile versus propofol anaesthesia on major complications and
mortality after cardiac surgery: a multicentre randomised trial.
Source
British Journal of Anaesthesia. 133(2) (pp 296-304), 2024. Date of
Publication: August 2024.
Author
Deng X.-Q.; Wang W.-J.; Wu Q.-L.; Wei H.; Deng J.-S.; Li Z.-J.; Wu J.-Z.;
Yang J.-J.; Zheng X.-M.; Wei J.-J.; Fan S.-S.; Zou X.-H.; Shi J.; Zhang
F.-X.; Wu D.-Q.; Kou D.-P.; Wang T.; Wang E.; Ye Z.; Zheng X.; Chen G.;
Chen Y.; Wei X.; Chai X.-Q.; Huang W.-Q.; Wang L.; Li K.; Li L.; Zhang Y.;
Li R.; Jiao J.-L.; Yu H.; Liu J.
Institution
(Deng, Yu, Yu, Liu) Department of Anaesthesiology, West China Hospital,
Sichuan University, Chengdu, China
(Wang, Wu) Department of Anaesthesiology, The First Affiliated Hospital of
Wenzhou Medical University, Wenzhou, China
(Wei, Deng) Department of Anaesthesiology, Gaozhou People's Hospital,
Guangdong, China
(Li, Wu) Department of Anaesthesiology, Second Xiangya Hospital, Central
South University, Changsha, China
(Yang, Zheng) Department of Anaesthesiology, Pain and Perioperative
Medicine, The First Affiliated Hospital of Zhengzhou University,
Zhengzhou, China
(Wei, Fan) Department of Anaesthesiology, Cardiovascular Hospital (The 7th
People's Hospital of Zhengzhou), Zhengzhou, China
(Zou, Shi) Department of Anaesthesiology, Affiliated Hospital of Guizhou
Medical University, Guiyang, China
(Zhang, Wu) Department of Anaesthesiology, Guizhou Provincial People's
Hospital, Guiyang, China
(Kou, Wang) Department of Anaesthesiology, Tianjin Chest Hospital, Tian
Jin, China
(Wang, Ye) Department of Anaesthesiology, Xiangya Hospital of Central
South University, National Clinical Research Centre for Geriatric
Disorders, Central South University, Changsha, China
(Zheng, Chen) Department of Anaesthesiology, Sir Run Run Shaw Hospital,
Zhejiang University, Hangzhou, China
(Huang, Chen) Department of Anaesthesiology, The First Affiliated
Hospital, Sun Yat-sen University, Guangzhou, China
(Wei, Chai) Department of Anaesthesiology, Anhui Provincial Hospital,
Hefei, China
(Huang, Wang) Department of Anaesthesiology, Wuhan Asia Heart Hospital,
Wuhan, China
(Li, Li) Department of Anaesthesiology, China Japan Union Hospital, Jilin
University, Changchun, China
(Zhang, Li) Department of Anaesthesiology and Perioperative Medicine, The
Second Affiliated Hospital of Anhui Medical University, Hefei, China
(Jiao) Institute of Translational Medicine, Shanghai Jiao Tong University,
Shanghai, China
Publisher
Elsevier Ltd
Abstract
Background: The comparative effectiveness of volatile anaesthesia and
total intravenous anaesthesia (TIVA) in terms of patient outcomes after
cardiac surgery remains a topic of debate. <br/>Method(s): Multicentre
randomised trial in 16 tertiary hospitals in China. Adult patients
undergoing elective cardiac surgery were randomised in a 1:1 ratio to
receive volatile anaesthesia (sevoflurane or desflurane) or propofol-based
TIVA. The primary outcome was a composite of predefined major
complications during hospitalisation and mortality 30 days after surgery.
<br/>Result(s): Of the 3123 randomised patients, 3083 (98.7%; mean age 55
yr; 1419 [46.0%] women) were included in the modified intention-to-treat
analysis. The composite primary outcome was met by a similar number of
patients in both groups (volatile group: 517 of 1531 (33.8%) patients vs
TIVA group: 515 of 1552 (33.2%) patients; relative risk 1.02 [0.92-1.12];
P=0.76; adjusted odds ratio 1.05 [0.90-1.22]; P=0.57). Secondary outcomes
including 6-month and 1-yr mortality, duration of mechanical ventilation,
length of ICU and hospital stay, and healthcare costs, were also similar
for the two groups. <br/>Conclusion(s): Among adults undergoing cardiac
surgery, we found no difference in the clinical effectiveness of volatile
anaesthesia and propofol-based TIVA. Clinical trial registration: Chinese
Clinical Trial Registry (ChiCTR-IOR-17013578).<br/>Copyright &#xa9; 2024
British Journal of Anaesthesia

<34>
Accession Number
2032393508
Title
Dexmedetomidine mitigates acute kidney injury after coronary artery bypass
grafting: a prospective clinical trial.
Source
Revista Espanola de Cardiologia. 77(8) (pp 645-655), 2024. Date of
Publication: August 2024.
Author
Zhang C.; Zhang Y.; Liu D.; Mei M.; Song N.; Zhuang Q.; Jiang Y.; Guo Y.;
Liu G.; Li X.; Ren L.
Institution
(Zhang, Zhang, Liu, Mei, Song, Zhuang, Liu, Li) Department of
Anesthesiology, First Affiliated Hospital of Bengbu Medical University,
Anhui, Bengbu, China
(Jiang) Department of Cardiac Surgery, First Affiliated Hospital of Bengbu
Medical University, Anhui, Bengbu, China
(Guo) Department of Urology, First Affiliated Hospital of Bengbu Medical
University, Anhui, Bengbu, China
(Ren) School of Laboratory Medicine, Bengbu Medical University, Anhui,
Bengbu, China
(Zhang, Zhang, Liu) Estos autores han contribuido por igual a este
estudio.
Publisher
Ediciones Doyma, S.L.
Abstract
Introduction and objectives: To evaluate the impact of dexmedetomidine
impact on cardiac surgery-associated acute kidney injury (CSA-AKI), kidney
function, and metabolic and oxidative stress in patients undergoing
coronary artery bypass grafting with heart-lung machine support.
<br/>Method(s): A randomized double-masked trial with 238 participants
(50-75 years) undergoing coronary artery bypass grafting was conducted
from January 2021 to December 2022. The participants were divided into Dex
(n = 119) and NS (n = 119) groups. Dex was administered at 0.5 mcg/kg over
10 minutes, then 0.4 mcg/kg/h until the end of surgery; the NS group
received equivalent saline. Blood and urine were sampled at various time
points pre- and postsurgery. The primary outcome measure was the incidence
of CSA-AKI, defined as the occurrence of AKI within 96 hours after
surgery. <br/>Result(s): The incidence of CSA-AKI was significantly lower
in the Dex group than in the NS group (18.26% vs 32.46%; P = .014).
Substantial increases were found in estimated glomerular filtration rate
value at T4-T6 (P < .05) and urine volume 24 hours after surgery (P <
.01). Marked decreases were found in serum creatinine level, blood glucose
level at T1-T2 (P < .01), blood urea nitrogen level at T3-T6 (P < .01),
free fatty acid level at T2-T3 (P < .01), and lactate level at T3-T4 (P <
.01). <br/>Conclusion(s): Dex reduces CSA-AKI, potentially by regulating
metabolic disorders and reducing oxidative stress. Registered with the
Chinese Clinical Study Registry (No. ChiCTR2100051804).<br/>Copyright
&#xa9; 2024 Sociedad Espanola de Cardiologia

<35>
Accession Number
2030563154
Title
Overview of Cochrane Systematic Reviews on Interventions for
Rehabilitation in People with Ischemic Heart Disease: A Mapping Synthesis.
Source
Journal of Clinical Medicine. 13(13) (no pagination), 2024. Article
Number: 3662. Date of Publication: July 2024.
Author
Del Furia M.J.; Arienti C.; Cattadori G.; Di Marco S.; Kiekens C.
Institution
(Del Furia) Department of Biomedical, Surgical and Dental Sciences,
University of Milan, Milan 20122, Italy
(Del Furia) Department of Mental and Physical Health and Preventive
Medicine, University of Campania Luigi Vanvitelli, Naples 80138, Italy
(Del Furia, Kiekens) IRCCS Istituto Ortopedico Galeazzi, Milan 20157,
Italy
(Arienti) Clinical Epidemiology and Research Center, Department of
Biomedical Sciences, Humanitas University, Piave Emanuele, Milan 20090,
Italy
(Cattadori) Department of Clinical Sciences and Community Health,
University of Milan, Milan 20122, Italy
(Cattadori, Di Marco) IRCCS MultiMedica, Milan 20138, Italy
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Objectives: This overview of Cochrane Systematic Reviews (CSRs) reports on
current evidence and its certainty of the effectiveness of interventions
for the rehabilitation of people with ischemic heart disease (IHD),
included in the World Health Organization Rehabilitation Programme Package
of Interventions for Rehabilitation. <br/>Method(s): We included all the
CSRs relevant to people with IHD. We used a mapping synthesis to group
outcomes and comparisons of included CSRs, indicating the effectiveness of
interventions for rehabilitation and the certainty of evidence.
<br/>Result(s): The evidence map included a total of 13 CSRs. The effect
of the interventions varied across comparisons, and the certainty of
evidence was inconsistent, ranging from high to very low. We found the
best evidence for exercise-based cardiac rehabilitation in the reduction
of fatal and non-fatal myocardial infarction and all-cause hospital
admission up to 12 months follow-up. Also, combined interventions
(work-directed interventions, physical conditioning interventions, and
psychological interventions) reduce the days needed for returning to work.
<br/>Conclusion(s): The current effect and certainty of evidence for
several comparisons investigated support the role of exercise-based
cardiac rehabilitation in the management of people with IHD, specifically
reducing the risk of fatal and non-fatal myocardial infarction and
hospitalisation. However, our findings highlight the lack of
high-certainty evidence about hard endpoints, particularly total
mortality. Future research should prioritise these primary endpoints to
enhance the credibility of cardiac rehabilitation.<br/>Copyright &#xa9;
2024 by the authors.

<36>
Accession Number
2030258610
Title
Clinical outcomes associated with the use of sacubitril/valsartan in the
perioperative period of patients undergoing cardiac surgery: a systematic
review.
Source
REC: CardioClinics. 59(3) (pp 169-176), 2024. Date of Publication: 01 Jul
2024.
Author
Gilon L.; Davila V.; Munoz O.; Garcia A.; Caceres E.
Institution
(Gilon, Davila, Munoz) Departamento de Medicina Interna, Pontificia
Universidad Javeriana, Bogota, Colombia
(Munoz) Departamento de Medicina Interna, Hospital Universitario San
Ignacio, Bogota, Colombia
(Garcia, Caceres) Unidad de Cardiologia, Hospital Universitario San
Ignacio, Bogota, Colombia
Publisher
Elsevier Espana S.L.U
Abstract
Introduction and objectives: Sacubitril/valsartan (SV) is recommended in
patients with heart failure, especially in reduced ejection fraction. So
far, the safety of its use in perioperative cardiac surgery is uncertain
but given its mechanism of action and possible blood pressure lowering
effect, some guidelines recommend discontinuation, without clear evidence.
This systematic review aims to assess clinical outcomes of use SV in the
perioperative period compared with never having used it or its withdrawal.
<br/>Method(s): Systematic literature review in MedLine, Cochrane, EMBASE
and LILACs of studies published in English and Spanish. We included
randomized clinical trials and non-randomized studies evaluating adult
patients undergoing cardiac surgery that compared the use of SV up to the
day of surgery versus stopping or not starting it prior to the procedure.
In-hospital and 30-day mortality, length of stay in general ward and
intensive care unit stay, orotracheal intubation, postoperative vasoplegia
and need for renal replacement therapy were assessed. Quality was assessed
using the ROBINS tool. <br/>Result(s): Three non-randomized studies were
included, one single-arm. There were fewer cases of in-hospital and 30-day
mortality in the group in which SV was not discontinued, with no
statistically significant difference. There was no difference in length of
hospital or intensive care unit stay, orotracheal intubation, need for
renal replacement therapy, or frequency of postoperative vasoplegia (OR,
0.77; 95%CI, 0.23-2.98). <br/>Conclusion(s): The current evidence is
scarce and of low quality so a recommendation regarding the use of SV
prior to cardiac surgery cannot be generated, further studies are
required.<br/>Copyright &#xa9; 2024 Sociedad Espanola de Cardiologia

<37>
Accession Number
2033208430
Title
Comparison of Propofol-Based Total Intravenous Anesthesia versus Volatile
Anesthesia with Sevoflurane for Postoperative Delirium in Adult Coronary
Artery Bypass Grafting Surgery: A Prospective Randomized Single-Blinded
Study.
Source
Journal of Cardiothoracic and Vascular Anesthesia. (no pagination), 2024.
Date of Publication: 2024.
Author
Varsha A.V.; Unnikrishnan K.P.; Saravana Babu M.S.; Raman S.P.; Koshy T.
Institution
(Varsha, Unnikrishnan, Saravana Babu, Raman, Koshy) Cardiothoracic and
Vascular Anaesthesiology Division, Sree Chitra Tirunal Institute for
Medical Sciences and Technology, Thiruvananthapuram, India
Publisher
W.B. Saunders
Abstract
Objectives: To compare the incidence of delirium and early (at 1 week)
postoperative cognitive dysfunction (POCD) between propofol-based total
intravenous anesthesia (TIVA) and volatile anesthesia with sevoflurane in
adult patients undergoing elective coronary artery bypass graft surgery
(CABG) with cardiopulmonary bypass (CPB). <br/>Design(s): This was a
prospective randomized single-blinded study. <br/>Setting(s): The study
was conducted at a single institution, the Sree Chitra Tirunal Institute
for Medical Sciences and Technology, a tertiary care institution and
university-level teaching hospital. <br/>Participant(s): Seventy-two
patients undergoing elective CABG under CPB participated in this study.
<br/>Intervention(s): This study was conducted on 72 adult patients (>18
years) undergoing elective CABG under CPB who were randomized to receive
propofol or sevoflurane. Anesthetic depth was monitored to maintain the
bispectral index between 40 and 60. Delirium was assessed using the
Confusion Assessment Method for the Intensive Care Unit. Early POCD was
diagnosed when there was a reduction of >2 points in the Montreal
Cognitive Assessment score compared to baseline. Cerebral oximetry changes
using near-infrared spectroscopy (NIRS), atheroma grades, and
intraoperative variables were compared between the 2 groups. Measurements
& Main Results: Seventy-two patients were randomized to receive propofol
(n = 36) or sevoflurane (n = 36). The mean patient age was 59.4 +/- 8.6
years. The baseline and intraoperative variables, including atheroma
grades, NIRS values, hemoglobin, glycemic control, and oxygenation, were
comparable in the 2 groups. Fifteen patients (21.7%) patients developed
delirium, and 31 patients (44.9%) had early POCD. The incidence of
delirium was higher with sevoflurane (n = 12; 34.2%) compared to propofol
(n = 3; 8.8%) (odds ratio [OR], 1.72; 95% confidence interval [CI],
1.13-2.62; p = 0.027)*. POCD was higher with sevoflurane (n = 20; 57.1%)
compared to propofol (n = 11; 32.3%) (OR, 1.63; 95% CI, 1.01-2.62; p =
0.038)*. In patients aged >65 years, delirium was higher with sevoflurane
(7/11; 63.6%) compared to propofol (1/7; 14.2%) (p = 0.03)*.
<br/>Conclusion(s): Propofol-based TIVA was associated with a lower
incidence of delirium and POCD compared to sevoflurane in this cohort of
patients undergoing CABG under CPB. Large-scale, multicenter randomized
trials with longer follow-up are needed to substantiate the clinical
relevance of this observation.<br/>Copyright &#xa9; 2024

<38>
Accession Number
2033208334
Title
Analgesic Effect and Sleep Quality of Low-Dose Dexmedetomidine in Cardiac
Surgical Patients After Ultrafast-Track Extubation: A Randomized Clinical
Trial.
Source
Journal of Cardiothoracic and Vascular Anesthesia. (no pagination), 2024.
Date of Publication: 2024.
Author
Lertkovit S.; Vacharaksa K.; Khamtuikrua C.; Tocharoenchok T.;
Chartrungsan A.; Sangarunakul N.; Suphathamwit A.
Institution
(Lertkovit, Vacharaksa, Khamtuikrua, Suphathamwit) Division of
Cardiothoracic Anesthesia, Department of Anesthesiology, Faculty of
Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
(Tocharoenchok, Chartrungsan) Division of Cardiothoracic Surgery,
Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol
University, Bangkok, Thailand
(Sangarunakul) Integrated Perioperative Geriatric Excellent Research
Center, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok,
Thailand
Publisher
W.B. Saunders
Abstract
Objective: To compare the analgesic and sleep quality effects of
dexmedetomidine infusion versus placebo in patients undergoing cardiac
surgery with ultra-fast track extubation. <br/>Design(s): The randomized,
double-blind clinical trial study. <br/>Setting(s): At a single academic
center hospital. <br/>Participant(s): We included patients aged 25 to 65
scheduled for elective cardiac surgery under general anesthesia with
cardiopulmonary bypass from October 2021 to December 2022.
<br/>Intervention(s): After immediate extubation in the operating room,
the patients who were allocated at first after providing their consent to
either the dexmedetomidine group (Dex) or the placebo group (Placebo)
received continuous infusion of dexmedetomidine (0.2 mug/kg/h) or saline
for 12 hours postoperatively. <br/>Measurements and Main Results: The
groups' demographic and perioperative variables were not statistically
significant. Total morphine consumption in milligrams at 12 and 24 hours
after administered study drug, total sleep time in hours by BIS value
<=85, and sleep quality with the Richard-Campbell Sleep Questionnaire were
compared. The analysis included 22 Dex and 23 Placebo patients. The
consumption of morphine was not statistically different between the Dex
and Placebo groups at 12 and 24 hours (p = 0.707 and p = 0.502,
respectively). The Dex group had significantly longer sleep time (8.7 h
[7.8, 9.5]) than the Placebo group (5.8 h [2.9, 8.5]; p = 0.007). The Dex
group also exhibited better sleep quality (7.9 [6.7, 8.7] vs 6.6 [5.2,
8.0]; p = 0.038). <br/>Conclusion(s): Sedation with low-dose
dexmedetomidine infusion for ultra-fast track extubation following cardiac
surgery enhances sleep duration and quality.<br/>Copyright &#xa9; 2024
Elsevier Inc.

<39>
Accession Number
2030550990
Title
Hypertrophic Cardiomyopathy: From Medical Treatment to Advanced Heart
Failure Therapies.
Source
Current Cardiology Reports. (no pagination), 2024. Date of Publication:
2024.
Author
Mazur M.; Braksator W.; Popjes E.
Institution
(Mazur) Heart and Vascular Institute, Kaufman Center for Heart Failure,
Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195,
United States
(Braksator) Department of Cardiology and Noninvasive Cardiovascular
Imaging, Faculty of Medicine, Medical University of Warsaw, Warsaw, Poland
(Popjes) Heart and Vascular Institute, Pennsylvania State Health Milton S.
Hershey Medical Center, Hershey, PA, United States
Publisher
Springer
Abstract
Purpose of Review: There has been much debate surrounding novel medical
therapies and heart transplantation listing challenges in patients with
hypertrophic cardiomyopathy (HCM). Recent Findings: Recent clinical trials
led to FDA approval of mavacamten (a cardiac myosin inhibitor), offering
symptom relief and potentially delaying/avoiding invasive septal reduction
therapies for some patients with HCM and left ventricular outflow
obstruction (LVOTO). For those with refractory symptoms and end-stage
heart failure, heart transplantation remains the gold standard. However,
the concern for the organ allocation system failing to prioritize those
individuals persists. <br/>Summary: HCM is a heterogeneous genetic
condition with variable penetration and clinical presentation. Even though
a large portion of patients remain asymptomatic, an important minority
develops debilitating symptoms refractory to medical therapy. Post-HT
short- and long-term outcomes are favorable. However, HT waitlist
mortality remains high. For highly selected patients with HCM, a left
ventricular assist device is a viable option.<br/>Copyright &#xa9; The
Author(s), under exclusive licence to Springer Science+Business Media,
LLC, part of Springer Nature 2024.

<40>
Accession Number
2030550767
Title
Intentional coronary revascularization versus conservative therapy in
patients after peripheral artery revascularization due to critical limb
ischemia: the INCORPORATE trial.
Source
Clinical Research in Cardiology. (no pagination), 2024. Date of
Publication: 2024.
Author
Toth G.G.; Brodmann M.; Kanoun Schnur S.S.; Bartus S.; Vrsalovic M.;
Krestianinov O.; Kala P.; Bil J.; Gil R.; Kanovsky J.; Di Serafino L.;
Paolucci L.; Barbato E.; Mangiacapra F.; Ruzsa Z.
Institution
(Toth, Kanoun Schnur) Department of Cardiology, University Heart Center
Graz, Medical University Graz, Graz, Austria
(Brodmann) Division of Angiology, Department of Internal Medicine, Medical
University Graz, Graz, Austria
(Kanoun Schnur, Ruzsa) Department of Cardiology, Faculty of Medicine,
Doctoral School of Clinical Medicine, University of Szeged, Szeged,
Hungary
(Kanoun Schnur) Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
(Bartus) II Dept of Cardiology, Medical College, Jagiellonian University,
Krakow, Poland
(Vrsalovic) Department of Cardiology, University of Zagreb School of
Medicine, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia
(Krestianinov) E. Meshalkin National Medical Research Center of the
Ministry of Health of the Russian Federation, Novosibirsk, Russian
Federation
(Kala, Kanovsky) University Hospital Brno and Medical Faculty of Masaryk
University, Brno, Czechia
(Bil) Department of Invasive Cardiology, Centre of Postgraduate Medical
Education, Warsaw, Poland
(Gil) National Medical Institute of the Internal Affairs and
Administration Ministry, Warsaw, Poland
(Di Serafino) Department of Advanced Biomedical Sciences, University of
Naples Federico II, Naples, Italy
(Paolucci, Mangiacapra) Department of Medicine and Surgery, Research Unit
of Cardiovascular Science, Universita Campus Bio-Medico Di Roma and
Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy
(Barbato) Department of Clinical and Molecular Medicine, Sapienza
University of Rome, Rome, Italy
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Objectives: INCORPORATE trial was designed to evaluate whether default
coronary-angiography (CA) and ischemia-targeted revascularization is
superior compared to a conservative approach for patients with treated
critical limb ischemia (CLI). Registered at clinicaltrials.gov
(NCT03712644) on October 19, 2018. <br/>Background(s): Severe peripheral
artery disease is associated with increased cardiovascular risk and poor
outcomes. <br/>Method(s): INCORPORATE was an open-label, prospective 1:1
randomized multicentric trial that recruited patients who had undergone
successful CLI treatment. Patients were randomized to either a
conservative or invasive approach regarding potential coronary artery
disease (CAD). The conservative group received optimal medical therapy
alone, while the invasive group had routine CA and fractional flow
reserve-guided revascularization. The primary endpoint was myocardial
infarction (MI) and 12-month mortality. <br/>Result(s): Due to COVID-19
pandemic burdens, recruitment was halted prematurely. One hundred
eighty-five patients were enrolled. Baseline cardiac symptoms were scarce
with 92% being asymptomatic. Eighty-nine patients were randomized to the
invasive approach of whom 73 underwent CA. Thirty-four percent had
functional single-vessel disease, 26% had functional multi-vessel disease,
and 90% achieved complete revascularization. Conservative and invasive
groups had similar incidences of death and MI at 1 year (11% vs 10%;
hazard ratio 1.21 [0.49-2.98]). Major adverse cardiac and cerebrovascular
events (MACCE) trended for hazard in the Conservative group (20 vs 10%;
hazard ratio 1.94 [0.90-4.19]). In the per-protocol analysis, the primary
endpoint remained insignificantly different (11% vs 7%; hazard ratio 2.01
[0.72-5.57]), but the conservative approach had a higher MACCE risk (20%
vs 7%; hazard ratio 2.88 [1.24-6.68]). <br/>Conclusion(s): This trial
found no significant difference in the primary endpoint but observed a
trend of higher MACCE in the conservative arm. Graphical Abstract: A
graphical abstract illustrating the key highlights of the design and
comparisons (Figure presented.)<br/>Copyright &#xa9; The Author(s) 2024.

<41>
Accession Number
2030550707
Title
Off-pump Versus On-pump Coronary Artery Bypass Grafting in Diabetic
patients: A Meta-analysis of Observational Studies with a Propensity-Score
Analysis.
Source
Cardiovascular Drugs and Therapy. (no pagination), 2024. Date of
Publication: 2024.
Author
Ren Q.; Li G.; Chu T.; Liu Q.; Huang Y.; Liu K.; Pan J.; Wu Z.
Institution
(Ren, Li, Chu, Liu, Huang, Liu, Pan, Wu) Department of Cardiac Surgery,
First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
(Ren, Li, Chu, Liu, Huang, Liu, Pan, Wu) NHC Key Laboratory of Assisted
Circulation, Sun Yat-Sen University, Guangzhou, China
Publisher
Springer
Abstract
Purpose: The debate between off-pump coronary artery bypass grafting
(OPCAB) and on-pump coronary artery bypass grafting (ONCAB) in diabetic
patients remains. This meta-analysis aimed to investigate outcomes after
OPCAB versus ONCAB for patients with diabetes. <br/>Method(s): Literature
research was conducted up to December 2023 using Ovid Medline, EMBASE, and
the Cochrane Library. Eligible studies were observational studies with a
propensity-score analysis of OPCAB versus ONCAB. The primary outcomes were
early mortality and mid-term survival. The secondary outcomes were
cerebrovascular accidents, reoperation for bleeding, incomplete
revascularization, myocardial infarction, low cardiac output, and renal
replacement therapy. <br/>Result(s): Our research identified seven
observational studies with a propensity-score analysis enrolling 13,085
patients. There was no significant difference between OPCAB and ONCAB for
early mortality, mid-term survival, myocardial infarction, low cardiac
output, and renal replacement therapy. OPCAB was associated with a lower
risk of cerebrovascular accidents (OR 0.43; 95% CI, 0.24-0.76, P = 0.004)
and reoperation for bleeding (OR 0.60; 95% CI, 0.41-0.88, P = 0.009).
However, OPCAB was associated with a higher risk of incomplete
revascularization (OR 2.07; 95% CI, 1.60-2.68, P < 0.00001).
<br/>Conclusion(s): Among patients with diabetes, no difference in early
mortality and mid-term survival was observed. However, OPCAB was
associated with a lower incidence of morbidity, including cerebrovascular
accidents and reoperation for bleeding.<br/>Copyright &#xa9; The Author(s)
2024.

<42>
Accession Number
2030535280
Title
Clinical and biological effects of different energetic surgical devices
currently used for mini-invasive anatomical lung resections for the
treatment of NSCLC: a prospective interventional study.
Source
Surgical Endoscopy. (no pagination), 2024. Date of Publication: 2024.
Author
Catelli C.; D'Alessandro M.; Mathieu F.; Addamo E.; Franchi F.; Paladini
P.; Luzzi L.
Institution
(Catelli, Luzzi) Lung Transplant Unit, Azienda Ospedaliero-Universitaria
Senese, University of Siena, Siena, Italy
(D'Alessandro) Respiratory Diseases and Lung Transplant Unit, Department
of Medical and Surgical Sciences and Neurosciences, University of Siena,
Siena 53100, Italy
(Mathieu, Addamo, Paladini) Thoracic Surgery Unit, University Hospital of
Siena, Siena, Italy
(Franchi) Department of Medicine, Surgery and Neuroscience, Anesthesiology
and Intensive Care, University Hospital of Siena, Siena, Italy
Publisher
Springer
Abstract
Background: This study aims to compare three commonly used energy devices
for dissection during Video-Assisted Thoracoscopic Surgery (VATS)
lobectomy: monopolar hook, advanced bipolar, and ultrasonic device, in
terms of duration of the surgical procedure and clinical intra- and
post-operative outcomes. <br/>Material(s) and Method(s): In this
prospective single-center study, 75 patients undergoing VATS lobectomy for
non-small cell lung cancer between January 2022 and May 2023 were enrolled
and divided into 3 groups based on the device used during the surgical
procedure (Group 1: Ultrasonic Device, Group 2: Advanced Bipolar, Group 3:
Monopolar Hook). The duration of the surgical procedure, daily pleural
fluid production, post-operative pain, length of hospital stay, and
occurrence of post-operative complications were compared for each group.
In a subgroup of 20 patients (10 from Group 1 and 10 from Group 3),
concentrations of inflammatory cytokines in pleural fluid at 3 h and 48 h
post-surgery were analyzed. <br/>Result(s): Pleural fluid production on
the first and second post-operative days was significantly lower in
patients treated with the Ultrasonic device compared to the other two
groups (p < 0.001). The duration of the surgical procedure was
significantly shorter when using the Ultrasonic device (p < 0.001). There
were no significant differences in length of hospital stay (p = 0.975),
pain on the first and second post-operative days (p = 0.147 and p = 0.755,
respectively), and blood hemoglobin levels on the first post-operative day
(p = 0.709) and at discharge (p = 0.795). No differences were observed in
terms of post-operative complications, although the incidence of
post-operative cardiac arrhythmias was borderline significant (p = 0.096),
with no cases of arrhythmias recorded in Group 1. IL-10 levels in pleural
fluid of patients in Group 3 peaked at 3 h post-surgery, with a
significant reduction at 48 h (p = 0.459). <br/>Discussion(s): The use of
the ultrasonic device during VATS lobectomy may reduce pleural fluid
production and shorten the duration of the surgical procedure compared to
using a monopolar hook or advanced bipolar device. The choice of energy
device may influence the local inflammatory response, although further
studies are needed to confirm these results.<br/>Copyright &#xa9; The
Author(s), under exclusive licence to Springer Science+Business Media,
LLC, part of Springer Nature 2024.

<43>
Accession Number
2030534962
Title
The Current State of Coronary Revascularization: Coronary Artery Bypass
Graft Surgery Versus Percutaneous Coronary Interventions.
Source
Current Cardiology Reports. (no pagination), 2024. Date of Publication:
2024.
Author
Krittanawong C.; Rizwan A.; Khawaja M.; Newman N.; Escobar J.; Virk
H.U.H.; Alam M.; Al-Azzam F.; Yong C.M.; Jneid H.
Institution
(Krittanawong) Cardiology Division, NYU Langone Health and NYU School of
Medicine, New York, NY, United States
(Rizwan) Department of Medicine, Baylor College of Medicine, Houston, TX
77030, United States
(Khawaja, Newman) Division of Cardiology, Emory University School of
Medicine, Atlanta, GA 30322, United States
(Escobar) Division of Cardiology, Harlem Cardiology, NY 10035, United
States
(Virk) Harrington Heart & amp; Vascular Institute, Case Western Reserve
University, University Hospitals, Cleveland Medical Center, Cleveland,
United States
(Alam) Division of Cardiology, The Texas Heart Institute, Baylor College
of Medicine, Houston, TX 77030, United States
(Al-Azzam) Division of Cardiovascular Surgery, Mayo Clinic, Rochester, MN
55905, United States
(Yong) VA Palo Alto Medical Center, Department of Medicine, Stanford,
University and Stanford Cardiovascular Institute, Palo AltoStanford, CA,
United States
(Jneid) Division of Cardiology, University of Texas Medical Branch,
Houston, TX 77030, United States
Publisher
Springer
Abstract
Purpose of Review: The optimal revascularization strategy for coronary
artery disease depends on various factors, such as disease complexity,
patient characteristics, and preferences. Including a heart team in
complex cases is crucial to ensure optimal outcomes. Decision-making
between percutaneous coronary intervention and coronary artery bypass
grafting must consider each patient's clinical profile and coronary
anatomy. While current practice guidelines offer some insight into the
optimal revascularization approach for the various phenotypes of coronary
artery disease, the evidence to support either strategy continues to
evolve and grow. Given the large amount of contemporary data on
revascularization, this review aims to comprehensively summarize the
literature on coronary artery bypass grafting and percutaneous coronary
intervention in patients across the spectrum of coronary artery disease
phenotypes. Recent Findings: Contemporary evidence suggests that for
patients with triple vessel disease, coronary artery bypass grafting is
preferred over percutaneous coronary intervention due to better long-term
outcomes, including lower rates of death, myocardial infarction, and
target vessel revascularization. Similarly, for patients with left main
coronary artery disease, both percutaneous coronary intervention and
coronary artery bypass grafting can be considered, as they have shown
similar efficacy in terms of major adverse cardiac events, but there may
be a slightly higher risk of death with percutaneous coronary
intervention. For proximal left anterior descending artery disease, both
percutaneous coronary intervention and coronary artery bypass grafting are
viable options, but coronary artery bypass grafting has shown lower rates
of repeat revascularization and better relief from angina. The Synergy
Between PCI with Taxus and Cardiac Surgery score can help in
decision-making by predicting the risk of adverse events and guiding the
choice between percutaneous coronary intervention and coronary artery
bypass grafting. European and American guidelines both agree with
including a heart team that can develop and lay out individualized,
optimal treatment options with respect for patient preferences.
<br/>Summary: The debate between coronary artery bypass grafting versus
percutaneous coronary intervention in multiple different scenarios will
continue to develop as technology and techniques improve for both
procedures. Risk factors, pre, peri, and post-procedural complications
involved in both revascularization strategies will continue to be
mitigated to optimize outcomes for those patients for which coronary
artery bypass grafting or percutaneous coronary intervention provide
ultimate benefit. Methods to avoid unnecessary revascularization continue
to develop as well as percutaneous technology that may allow patients to
avoid surgical intervention when possible. With such changes,
revascularization guidelines for specific patient populations may change
in the coming years, which can serve as a limitation of this time-dated
review.<br/>Copyright &#xa9; The Author(s), under exclusive licence to
Springer Science+Business Media, LLC, part of Springer Nature 2024.

<44>
Accession Number
2029352246
Title
Single versus dual antiplatelet therapy following percutaneous left atrial
appendage closure-A systematic review and meta-analysis.
Source
European Journal of Clinical Investigation. 54(8) (no pagination), 2024.
Article Number: e14209. Date of Publication: August 2024.
Author
Continisio S.; Montonati C.; Angelini F.; Bocchino P.P.; Carbonaro C.;
Giacobbe F.; Dusi V.; DeFilippo O.; Ielasi A.; Giannino G.; Boldi E.;
Fabris T.; D'Ascenzo F.; DeFerrari G.M.; Tarantini G.
Institution
(Continisio, Boldi) Division of Cardiology, Clinica S. Rocco di
Franciacorta, Brescia, Italy
(Montonati, Ielasi) Division of Cardiology, IRCCS Hospital
Galeazzi-Sant'Ambrogio, Milan, Italy
(Angelini, Bocchino, Dusi, De Filippo, D'Ascenzo, De Ferrari) Division of
Cardiology, Cardiovascular and Thoracic Department, 'Citta della Salute e
della Scienza' Hospital, Turin, Italy
(Carbonaro, Giacobbe, Dusi, Giannino, D'Ascenzo, De Ferrari) Department of
Medical Sciences, University of Turin, Turin, Italy
(Fabris, Tarantini) Department of Cardiac, Thoracic, Vascular Sciences and
Public Health, University of Padua Medical School, Padua, Italy
Publisher
John Wiley and Sons Inc
Abstract
Background: In the last few years, percutaneous LAA occlusion (LAAO) has
become a plausible alternative in atrial fibrillation (AF) patients with
contraindications to anticoagulation therapy. Nevertheless, the optimal
antiplatelet strategy following percutaneous LAAO remains to be defined.
<br/>Method(s): Studies comparing single antiplatelet therapy (SAPT)
versus dual antiplatelet therapy (DAPT) following LAAO were systematically
searched and screened. The outcomes of interest were ischemic stroke,
device-related thrombus (DRT) and major bleeding. A random-effect
meta-analysis was performed comparing outcomes in both groups. The
moderator effect of baseline characteristics on outcomes was evaluated by
univariate meta-regression analyses. <br/>Result(s): Sixteen observational
studies with 3255 patients treated with antiplatelet therapy (SAPT, n =
1033; DAPT, n = 2222) after LAAO were included. Mean age was 74.5 +/- 8.3
years, mean CHA<inf>2</inf>DS<inf>2</inf>-VASc and HAS-BLED scores were
4.3 +/- 1.5 and 3.2 +/- 1.0, respectively. At a weighted mean follow-up of
12.7 months, the occurrence of stroke (RR 1.33; 95% CI 0.64-2.77; p =.44),
DRT (RR 1.52; 95% CI 0.90-2.58; p =.12), and the composite of stroke and
DRT (RR 1.26; 95% CI 0.67-2.37; p =.47) did not differ significantly
between SAPT and DAPT groups. The rate of major bleedings was also not
different between groups (RR 1.41; 95% CI 0.64-3.12; p =.39).
<br/>Conclusion(s): Among AF patients at high bleeding risk undergoing
percutaneous LAAO, a post-procedural minimalistic antiplatelet strategy
with SAPT did not significantly differ from DAPT regimens regarding the
rate of stroke, DRT and major bleeding.<br/>Copyright &#xa9; 2024
Stichting European Society for Clinical Investigation Journal Foundation.
Published by John Wiley & Sons Ltd.

<45>
Accession Number
2029244284
Title
Prognostic significance of echocardiographic deformation imaging in adult
congenital heart disease.
Source
European Journal of Clinical Investigation. 54(8) (no pagination), 2024.
Article Number: e14200. Date of Publication: August 2024.
Author
van Rosendael P.J.; Taha K.; Guglielmo M.; Teske A.J.; van der Harst P.;
Sieswerda G.; Cramer M.J.; van der Zwaan H.B.
Institution
(van Rosendael, Taha, Guglielmo, Teske, van der Harst, Sieswerda, Cramer,
van der Zwaan) Department of Cardiology, University Medical Center
Utrecht, Utrecht, Netherlands
(Guglielmo) Department of Cardiology, Haga Teaching Hospital, The Hague,
Netherlands
Publisher
John Wiley and Sons Inc
Abstract
Background: Due to medical and surgical advancements, the population of
adult patients with congenital heart disease (ACHD) is growing. Despite
successful therapy, ACHD patients face structural sequalae, placing them
at increased risk for heart failure and arrhythmias. Left and right
ventricular function are important predictors for adverse clinical
outcomes. In acquired heart disease it has been shown that
echocardiographic deformation imaging is of superior prognostic value as
compared to conventional parameters as ejection fraction. However, in
adult congenital heart disease, the clinical significance of deformation
imaging has not been systematically assessed and remains unclear.
<br/>Method(s): According to the Preferred Reporting Items for Systematic
Reviews checklist, this systematic review included studies that reported
on the prognostic value of echocardiographic left and/or right ventricular
strain by 2-dimensional speckle tracking for hard clinical end-points
(death, heart failure hospitalization, arrhythmias) in the most frequent
forms of adult congenital heart disease. <br/>Result(s): In total, 19
contemporary studies were included. Current data shows that left
ventricular and right ventricular global longitudinal strain (GLS) predict
heart failure, transplantation, ventricular arrhythmias and mortality in
patients with Ebstein's disease and tetralogy of Fallot, and that GLS of
the systemic right ventricle predicts heart failure and mortality in
patients post atrial switch operation or with a congenitally corrected
transposition of the great arteries. <br/>Conclusion(s): Deformation
imaging can potentially impact the clinical decision making in ACHD
patients. Further studies are needed to establish disease-specific
reference strain values and ranges of impaired strain that would indicate
the need for medical or structural intervention.<br/>Copyright &#xa9; 2024
The Authors. European Journal of Clinical Investigation published by John
Wiley & Sons Ltd on behalf of Stichting European Society for Clinical
Investigation Journal Foundation.

<46>
Accession Number
2031046249
Title
Effect of Seated Cervical Spinal Manipulation on Autonomic Nervous System
Activity as Measured by Heart Rate Variability and Plasma Norepinephrine
Levels: A randomized Pre- and Poststudy.
Source
Journal of Manipulative and Physiological Therapeutics. 46(4) (pp
220-228), 2023. Date of Publication: May 2023.
Author
Budgell B.S.; Injeyan H.S.; Teodorczyk-Injeyan J.
Institution
(Budgell) Canadian Memorial Chiropractic College, Toronto, ON, Canada
(Injeyan, Teodorczyk-Injeyan) Department of Research and Innovation,
Canadian Memorial Chiropractic College, Toronto, ON, Canada
Publisher
Elsevier Inc.
Abstract
Objective: The objective of this study was to determine whether seated
cervical manipulation produced changes in autonomic nervous system
activity, as measured by heart rate variability and plasma norepinephrine
levels. <br/>Method(s): Ninety-five healthy young adults (ages 20-48
years) were recruited into a single-blinded physiological study, with 47
randomized to a seated cervical manipulation and 44 randomized to a sham
procedure. Heart rate variability in the frequency domain, and plasma
norepinephrine levels were measured prior to, immediately following, and 5
minutes following the intervention. <br/>Result(s): Electrocardiograms
were obtained from 39 subjects in the sham group and 43 subjects in the
manipulation group. No statistically significant changes were found in
measures of heart rate variability in the frequency domain in either the
manipulation or sham groups. Blood samples were obtained from 22 subjects
in the sham group and 27 subjects in the manipulation group. Plasma
norepinephrine levels, as measured by spectrophotometry, declined in both
groups from pre- to immediately postintervention, and they remained at
decreased levels 5 minutes after the interventions. There were no
statistically significant differences between groups in pre- or
postintervention norepinephrine levels. <br/>Conclusion(s): Measures of
heart rate variability and plasma norepinephrine levels did not show that
seated cervical manipulation produced short-term changes in autonomic
nervous system activity compared to a sham procedure in healthy young
adults.<br/>Copyright &#xa9; 2024

<47>
Accession Number
644728521
Title
Coronary artery disease management in older adults: revascularization and
exercise training.
Source
European heart journal. (no pagination), 2024. Date of Publication: 10
Jul 2024.
Author
Pavasini R.; Biscaglia S.; Kunadian V.; Hakeem A.; Campo G.
Institution
(Pavasini, Biscaglia, Campo) Cardiology Unit, Azienda Ospedaliero
Universitaria di Ferrara, Via Aldo Moro 8, Ferrara 44124, Italy
(Kunadian) Translational and Clinical Research Institute, Newcastle
University and Cardiothoracic Centre, Freeman Hospital, Newcastle upon
Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
(Hakeem) National Institute of Cardiovascular Diseases (NICVD), Karachi,
Pakistan
Abstract
The mean age of patients with coronary artery disease (CAD) is steadily
increasing. In older patients, there is a tendency to underutilize
invasive approach, coronary revascularization, up-to-date pharmacological
therapies, and secondary prevention strategies, including cardiac
rehabilitation. Older adults with CAD commonly exhibit atypical symptoms,
multi-vessel disease involvement, complex coronary anatomy, and a higher
presence of risk factors and comorbidities. Although both invasive
procedures and medical treatments are characterized by a higher risk of
complications, avoidance may result in a suboptimal outcome. Often,
overlooked factors, such as coronary microvascular disease, malnutrition,
and poor physical performance, play a key role in determining prognosis,
yet they are not routinely assessed or addressed in older patients.
Historically, clinicians have relied on sub-analyses or observational
findings to make clinical decisions, as older adults were frequently
excluded or under-represented in clinical studies. Recently, dedicated
evidence through randomized clinical trials has become available for older
CAD patients. Nevertheless, the management of older CAD patients still
raises several important questions. This review aims to comprehensively
summarize and critically evaluate this emerging evidence, focusing on
invasive management and coronary revascularization. Furthermore, it seeks
to contextualize these interventions within the framework of improved risk
stratification tools for older CAD patients, through user-friendly scales
along with emphasizing the importance of promoting physical activity and
exercise training to enhance the outcomes of invasive and medical
treatments. This comprehensive approach may represent the key to improving
prognosis in the complex and growing patient population of older CAD
patients.<br/>Copyright &#xa9; The Author(s) 2024. Published by Oxford
University Press on behalf of the European Society of Cardiology. All
rights reserved. For commercial re-use, please contact reprints@oup.com
for reprints and translation rights for reprints. All other permissions
can be obtained through our RightsLink service via the Permissions link on
the article page on our site-for further information please contact

<48>
Accession Number
644727463
Title
Correction to: Effect of home-based prehabilitation on objectively
measured physical activity in patients undergoing elective major cardiac
and non-cardiac surgery. Data from a randomized controlled trial.
Source
European journal of preventive cardiology. (no pagination), 2024. Date of
Publication: 10 Jul 2024.
Author
Anonymous

<49>
Accession Number
2033192240
Title
Preoperative Nonselective Chest Computed Tomography Prior to Primary
Cardiac Surgery Results in Meaningful Change to Surgical Management:
Systematic Review and Pooled Prevalence Meta-Analysis.
Source
Heart Lung and Circulation. (no pagination), 2024. Date of Publication:
2024.
Author
Indja B.; Chang J.; Flynn C.D.; Vallely M.
Institution
(Indja, Chang, Flynn, Vallely) Department of Cardiothoracic Surgery, St
George Hospital, Kogarah, NSW, Australia
(Vallely) Department of Cardiothoracic Surgery, Macquarie University
Hospital, Macquarie University, NSW, Australia
Publisher
Elsevier Ltd
Abstract
Background: Routine screening chest computed tomography (CT) prior to
primary cardiac surgery is advocated by some surgeons due to the purported
benefits of identifying significant aortic calcification that impacts
ongoing management, such as performing anaortic off-pump surgery or
adjusting cannulation strategy. Additionally, axial imaging can identify
incidental findings that may require concomitant or staged procedures such
as ascending aortic dilatation or pulmonary lesions. The objective of this
study was to quantify the impact that nonselective chest CT prior to
primary cardiac surgery had on subsequent management. <br/>Method(s): A
systematic review and pooled prevalence meta-analyses were performed in
accordance with Preferred Reporting Items for Systematic Reviews and
Meta-analyses guidelines. Included studies performed non-selective chest
CT prior to primary cardiac surgery. <br/>Result(s): A total of eight
studies, including 2,250 patients were included. The rate of mortality and
stroke was low (1% and 2%, respectively). Calcification of the ascending
aorta was identified in 15% of patients (95% confidence interval [CI]
5.0-26.0). A significant change to the surgical plan such as cannulation
strategy, off-pump surgery, cancellation, or an additional procedure was
required in 7% (95% CI 2.0-12.0). Clinically relevant incidental findings
requiring in-patient management or follow-up were identified in 10% (95%
CI 6.0-14.0). <br/>Conclusion(s): Nonselective CT chest prior to primary
cardiac surgery identifies clinically relevant findings that result in a
modification of the surgical plan in a significant population of patients
to address the risk of stroke associated with aortic calcification as well
as the identification of important incidental findings such as pulmonary
lesions.<br/>Copyright &#xa9; 2024 Australian and New Zealand Society of
Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of
Australia and New Zealand (CSANZ)

<50>
Accession Number
2033192060
Title
Concomitant Tricuspid Valve Ring Annuloplasty During Mitral Valve Surgery
Versus Mitral Valve Surgery Alone: A Systematic Review and Meta-Analysis.
Source
Heart Lung and Circulation. (no pagination), 2024. Date of Publication:
2024.
Author
Poon S.S.; Chan J.; Ahmed Y.; Aslam U.; Cianci V.; Sharma S.; Kumar P.
Institution
(Poon, Ahmed, Aslam, Cianci, Sharma, Kumar) Department of Cardiothoracic
Surgery, Morriston Hospital, Wales, Swansea, United Kingdom
(Chan) Department of Cardiothoracic Surgery, Bristol Royal Infirmary,
Bristol, United Kingdom
Publisher
Elsevier Ltd
Abstract
Aim: Although current guidelines recommend concomitant tricuspid
annuloplasty for moderate or greater tricuspid regurgitation (TR) and/or
dilated annulus, there remains significant variation in undertaking
concomitant tricuspid valve surgery (TVA) across different centres. This
meta-analysis aimed to compare the clinical outcomes of concomitant
tricuspid valve surgery for patients with moderate or greater TR and/or
dilated annulus at the time of mitral valve (MV) surgery. <br/>Method(s):
A systematic review of the literature using six databases. Eligible
studies include comparative studies on TVA concomitant with MV surgery
versus MV surgery alone. A meta-analysis was performed on studies
reporting outcomes of interest to quantify the effects of concomitant
tricuspid ring annuloplasty. <br/>Result(s): Two randomised controlled
trials and six cohort studies were included in the analysis. 1,941
patients were included in the analysis, of whom, 1,090 underwent
concomitant TVA and 851 underwent MV surgery alone. Pooled analysis
demonstrated that there was less progression of moderate/severe TR in the
concomitant group (3.0% vs 9.6%; odds ratio [OR] 0.29; 95% confidence
interval [CI] 0.13-0.55; p=0.0001). There was no significant difference in
in-hospital mortality (3.0% vs 3.8%; OR 0.79; 95% CI 0.47-1.34; p=0.38).
The rate of permanent pacemaker implantation was higher in the concomitant
group although this did not reach statistical significance (7.6% vs 5.3%;
OR 1.30; 95% CI 0.85-1.98; p=0.23). Cardiopulmonary bypass was longer in
the concomitant TVA group by 20 minutes (mean difference 13.9-26.0;
p<0.00001). <br/>Conclusion(s): Our study demonstrated that concomitant
tricuspid ring annuloplasty at the time of MV surgery is associated with a
significantly lower rate of TR progression without increasing the
operative mortality. There is a trend towards a higher permanent pacemaker
implantation rate although this did not reach statistical
significance.<br/>Copyright &#xa9; 2024

<51>
Accession Number
2030575481
Title
Antithrombotic Therapy in Patients Undergoing Transcatheter Aortic Valve
Implantation.
Source
Journal of Clinical Medicine. 13(13) (no pagination), 2024. Article
Number: 3636. Date of Publication: July 2024.
Author
Pallante F.; Costa F.; Garcia Ruiz V.; Vizzari G.; Iannello P.; Teresi L.;
Carciotto G.; Lo Giudice S.; Iuvara G.; Laterra G.; Regueiro A.; Giustino
G.; Alonso Briales J.H.; Hernandez J.M.; Barbanti M.; Micari A.; Patane F.
Institution
(Pallante, Vizzari, Teresi, Carciotto, Lo Giudice, Iuvara) Department of
Clinical and Experimental Medicine, University of Messina, Messina 98122,
Italy
(Costa, Micari, Patane) Department of Biomedical and Dental Sciences and
of Morphological and Functional Images, University of Messina, Messina
98122, Italy
(Costa, Garcia Ruiz, Alonso Briales, Hernandez) Departamento de Medicina
UMA, Area del Corazon, Hospital Universitario Virgen de la Victoria,
CIBERCV, IBIMA Plataforma BIONAND, Malaga 29010, Spain
(Iannello, Patane) Cardiology Division, Papardo Hospital, Messina 98158,
Italy
(Laterra, Barbanti) Faculty of Medicine and Surgery, Universita degli
Studi di Enna "Kore", Enna 94100, Italy
(Regueiro) Hospital Clinic, Cardiovascular Institute, Institut
D'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Barcelona
08036, Spain
(Giustino) Icahn School of Medicine at Mount Sinai, New York, NY 10029,
United States
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Transcatheter aortic valve implantation (TAVI) now represents the mainstay
of treatment for severe aortic stenosis. Owing to its exceptional
procedural efficacy and safety, TAVI has been extended to include patients
at lower surgical risk, thus now encompassing a diverse patient population
receiving this treatment. Yet, long-term outcomes also depend on optimal
medical therapy for secondary vascular prevention, with antithrombotic
therapy serving as the cornerstone. Leveraging data from multiple
randomized controlled trials, the current guidelines generally recommend
single antithrombotic therapy, with either single antiplatelet therapy
(SAPT) or oral anticoagulation (OAC) alone in those patients without or
with atrial fibrillation, respectively. Yet, individualization of this
pattern, as well as specific case uses, may be needed based on individual
patient characteristics and concurrent procedures. This review aims to
discuss the evidence supporting antithrombotic treatments in patients
treated with TAVI, indications for a standardized treatment, as well as
specific considerations for an individualized approach to
treatment.<br/>Copyright &#xa9; 2024 by the authors.

<52>
[Use Link to view the full text]
Accession Number
2033271429
Title
Angiographic Characteristics and Clinical Outcomes in Patients with
Chronic Kidney Disease Undergoing Impella-Supported High-Risk Percutaneous
Coronary Intervention: Insights from the cVAD PROTECT III Study.
Source
Circulation: Cardiovascular Interventions. 17(7) (pp e013503), 2024. Date
of Publication: 01 Jul 2024.
Author
Bharadwaj A.S.; Abu-Much A.; Maini A.S.; Zhou Z.; Li Y.; Batchelor W.B.;
Grines C.L.; Baron S.J.; Redfors B.; Lansky A.J.; Basir M.B.; O'Neill W.W.
Institution
(Bharadwaj) Division of Cardiology, Loma Linda University Medical Center,
CA, United States
(Abu-Much, Maini, Zhou, Li, Redfors) Clinical Trials Center,
Cardiovascular Research Foundation, New York, NY, United States
(Batchelor) Inova Center of Outcomes Research, Inova Heart and Vascular
Institute, Falls Church, VA, United States
(Grines) Department of Cardiology, Northside Hospital Cardiovascular
Institute, Atlanta, GA, United States
(Baron) Massachusetts General Hospital, Boston, United States
(Baron) Baim Institute for Clinical Research, Boston, MA, United States
(Redfors) Department of Cardiology, Sahlgrenska University Hospital,
Gothenburg, Sweden
(Lansky) Yale University, School of Medicine, New Haven, CT, United States
(Lansky) Barts Heart Centre, Queen Mary University, London, United Kingdom
(Basir, O'Neill) Division of Cardiology, Center for Structural Heart
Disease, Henry Ford Health System, Detroit, MI, United States
Publisher
Lippincott Williams and Wilkins
Abstract
BACKGROUND: Prior studies have found that patients with chronic kidney
disease (CKD) have worse outcomes following percutaneous coronary
intervention (PCI). There are no data about patients with advanced CKD
undergoing Impella-supported high-risk PCI. We, therefore, aimed to
evaluate angiographic characteristics and clinical outcomes in patients
with CKD who received Impella-supported high-risk PCI as part of the
catheter-based ventricular assist device PROTECT III study (A Prospective,
Multi-Center, Randomized Controlled Trial of the IMPELLA RECOVER LP 2.5
System Versus Intra Aortic Balloon Pump [IABP] in Patients Undergoing Non
Emergent High Risk PCI). <br/>METHOD(S): Patients enrolled in the PROTECT
III study were analyzed according to their baseline estimated glomerular
filtration rate (eGFR). The primary outcome was 90-day major adverse
cardiovascular and cerebrovascular events (the composite of all-cause
death, myocardial infarction, stroke/transient ischemic attack, and repeat
revascularization). <br/>RESULT(S): Of 1237 enrolled patients, 1052
patients with complete eGFR baseline assessment were evaluated: 586 with
eGFR >=60 mL/min per 1.73 m², 190 with eGFR >=45 to <60, 105
with eGFR >=30 to <45, and 171 with eGFR <30 or on dialysis. Patients with
lower eGFR (all groups with eGFR <60) were more frequently females and had
a higher prevalence of hypertension, diabetes, anemia, and peripheral
artery disease. The baseline Synergy Between PCI With Taxus and Cardiac
Surgery score was similar between groups (28.2+/-12.6 for all groups).
Patients with lower eGFR were more likely to have severe coronary
calcifications and higher usage of atherectomy. There were no differences
in individual PCI-related coronary complications between groups, but the
rates of overall PCI complications were less frequent among patients with
lower eGFR. Major adverse cardiovascular and cerebrovascular events at 90
days and 1-year mortality were significantly higher among patients with
eGFR <30 mL/min per 1.73 m² or on dialysis. <br/>CONCLUSION(S):
Patients with advanced CKD undergoing Impella-assisted high-risk PCI tend
to have higher baseline comorbidities, severe coronary calcification, and
higher atherectomy usage, yet CKD was not associated with a higher rate of
immediate PCI-related complications. However, 90-day major adverse
cardiovascular and cerebrovascular events and 1-year mortality were
significantly higher among patients with eGFR<30 mL/min per 1.73
m² or on dialysis. Future studies of strategies to improve
intermediate and long-term outcomes of these high-risk patients are
warranted.<br/>Copyright &#xa9; 2024 The Authors.

<53>
Accession Number
2033211805
Title
Real changes in left atrial appendage occlusion practice in Denmark over
time or inappropriate use of registry data?.
Source
International Journal of Cardiology. 412 (no pagination), 2024. Article
Number: 132350. Date of Publication: 01 Oct 2024.
Author
Nielsen-Kudsk J.E.; Korsholm K.; Andersen A.; Jensen J.M.; Norgaard B.L.
Institution
(Nielsen-Kudsk, Korsholm, Andersen, Jensen, Norgaard) Department of
Cardiology, Aarhus University Hospital, Aarhus, Denmark
Publisher
Elsevier Ireland Ltd

<54>
Accession Number
2030527850
Title
Comprehensive meta-analysis of surgical procedure for congenital
diaphragmatic hernia: thoracoscopic versus open repair.
Source
Pediatric Surgery International. 40(1) (no pagination), 2024. Article
Number: 182. Date of Publication: December 2024.
Author
Shibuya S.; Paraboschi I.; Giuliani S.; Tsukui T.; Matei A.; Olivos M.;
Inoue M.; Clarke S.A.; Yamataka A.; Zani A.; Eaton S.; De Coppi P.
Institution
(Shibuya, Eaton, De Coppi) Stem Cell and Regenerative Medicine Section,
Developmental Biology and Cancer Research & amp; Teaching Department,
Zayed Centre for Research Into Rare Disease in Children, Great Ormond
Street Institute of Child Health, University College London, 30 Guilford
Street, London WC1N 1E, United Kingdom
(Shibuya, Tsukui, Yamataka) Department of Pediatric General and Urogenital
Surgery, Juntendo University School of Medicine, 3-1-3 Hongo, Bunkyo City,
Tokyo 113-8431, Japan
(Paraboschi) Department of Biomedical and Clinical Science, University of
Milano, Milan, Italy
(Giuliani, Zani, De Coppi) Department of Specialist Neonatal and
Paediatric Surgery, Great Ormond Street Hospital for Children, NHS
Foundation Trust, London, United Kingdom
(Matei) Division of General and Thoracic Surgery, The Hospital for Sick
Children, Toronto, ON, Canada
(Olivos, Clarke) Chelsea and Westminster NHS Foundation Trust, London,
United Kingdom
(Inoue) Department of Pediatric Surgery, Fujita Health University, Aichi,
Japan
(Zani) Department of Surgery, University of Toronto, Toronto, ON, Canada
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Purpose: Previous studies have shown a higher recurrence rate and longer
operative times for thoracoscopic repair (TR) of congenital diaphragmatic
hernia (CDH) compared to open repair (OR). An updated meta-analysis was
conducted to re-evaluate the surgical outcomes of TR. <br/>Method(s): A
comprehensive literature search comparing TR and OR in neonates was
performed in accordance with the PRISMA statement (PROSPERO:
CRD42020166588). <br/>Result(s): Fourteen studies were selected for
quantitative analysis, including a total of 709 patients (TR: 308 cases,
OR: 401 cases). The recurrence rate was higher [Odds ratio: 4.03, 95% CI
(2.21, 7.36), p < 0.001] and operative times (minutes) were longer [Mean
Difference (MD): 43.96, 95% CI (24.70, 63.22), p < 0.001] for TR compared
to OR. A significant reduction in the occurrence of postoperative bowel
obstruction was observed in TR (5.0%) compared to OR (14.8%) [Odds ratio:
0.42, 95% CI (0.20, 0.89), p = 0.02]. <br/>Conclusion(s): TR remains
associated with higher recurrence rates and longer operative times.
However, the reduced risk of postoperative bowel obstruction suggests
potential long-term benefits. This study emphasizes the importance of
meticulous patient selection for TR to mitigate detrimental effects on
patients with severe disease.<br/>Copyright &#xa9; The Author(s) 2024.

<55>
Accession Number
2029986644
Title
Usefulness and drawbacks of comparing balloon-expandable and
self-expanding TAV.
Source
Catheterization and Cardiovascular Interventions. 104(1) (pp 172-173),
2024. Date of Publication: 01 Jul 2024.
Author
De Backer O.; Van Belle E.
Institution
(De Backer) The Heart Centre, Rigshospitalet, Copenhagen University
Hospital, Copenhagen, Denmark
(Van Belle) Institut Coeur et Poumon, CHU Lille, Lille, France
Publisher
John Wiley and Sons Inc

<56>
Accession Number
2029867193
Title
Balloon predilation or direct valve implantation in TAVI for women:
Insights from the DIRECTAVI study.
Source
Catheterization and Cardiovascular Interventions. 104(1) (pp 97-104),
2024. Date of Publication: 01 Jul 2024.
Author
Robert P.; Akodad M.; Lattuca B.; Gandet T.; Meunier P.A.; Macia J.-C.;
Schmutz L.; Steinecker M.; Roubille F.; Cayla G.; Leclercq F.
Institution
(Robert, Lattuca, Schmutz, Cayla) Department of cardiology, Nimes
University Hospital, Nimes, France
(Akodad) Ramsay Generale de Sante, Institut Cardiovasculaire Paris Sud,
Massy, France
(Gandet) Department of Cardiovascular Surgery, Montpellier University
Hospital, Montpellier, France
(Meunier, Macia, Steinecker, Roubille, Leclercq) Department of Cardiology,
Montpellier University Hospital, Montpellier, France
Publisher
John Wiley and Sons Inc
Abstract
Background: The randomized DIRECTAVI trial demonstrated safety and
feasibility of transcatheter aortic valve implantation (TAVI) without
balloon aortic valvuloplasty (BAV) using SAPIEN 3 balloon-expandable
devices. However, the female population with smaller anatomy may have
potential higher risk of residual gradient and/or mismatch.
<br/>Purpose(s): We assessed the impact of BAV on the procedural success
rate and clinical outcomes in the female population of the DIRECTAVI
trial. <br/>Method(s): Between May 2016 and May 2018, 91 of the 250
patients included in the DIRECTAVI trial were women (38.6%), 45 of them
(49.5%) were enrolled in the BAV group and 46 of them (50.5%) in the
direct TAVI group. The primary endpoint was procedural success rate in
women (Valve Academic Research Consortium-2 criteria). The secondary
endpoint included evaluation of PPM and 1-month major adverse events
according to the implantation stategy in women and comparison between men
and women regarding major endpoints. <br/>Result(s): The primary endpoint
occurred in 29 women (64.4%) in the BAV group and in 34 women (73.9%) in
the direct TAVI group (mean difference 9.47%; 95% confidence interval:
6.5%-25.4%; p = 0.045 for non-inferiority of the direct strategy).
One-month major adverse events were similar between the 2 women groups.
Procedural success was lower in women vs men (p = 0.01) due to higher
incidence of moderate mismatches in women (p = 0.001) but with no
significant difference regarding the implantation strategy (p = 0.4).
<br/>Conclusion(s): Direct implantation of the balloon-expandable SAPIEN 3
valve was non-inferior to predilatation on procedural success in women.
Incidence of moderate mismatch was higher in women but was not related to
the implantation strategy.<br/>Copyright &#xa9; 2024 The Author(s).
Catheterization and Cardiovascular Interventions published by Wiley
Periodicals LLC.

<57>
Accession Number
2029724981
Title
Current alternatives to traditional radial approach for coronary
interventions: A randomized prospective study of the ulnar and distal
radial approaches.
Source
Catheterization and Cardiovascular Interventions. 104(1) (pp 44-53), 2024.
Date of Publication: 01 Jul 2024.
Author
Elwany M.; Dawood M.; Shakhlab A.; Sadaka M.; Sobhy M.
Institution
(Elwany, Dawood, Shakhlab, Sadaka, Sobhy) Department of Cardiology and
Angiology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
Publisher
John Wiley and Sons Inc
Abstract
Background: The radial artery is the standard access for coronary
intervention; however, it is essential to have alternative accesses as it
may be used as a conduit during coronary artery bypass grafting or for
dialysis fistula. Ulnar and distal radial artery accesses have emerged as
alternative accesses for traditional radial artery. <br/>Aim(s): To
compare distal radial artery access and ulnar artery access as
alternatives to traditional radial artery access regarding safety,
efficacy, and success rate. <br/>Method(s): Two-hundred patients were
included (100 traditional radial [TRA], 50 distal radial [DRA] and 50
ulnar). Access artery follow up ultrasound was performed up to 28 days.
<br/>Result(s): Procedural success rate was 97%, 74%, and 92% in the TRA,
DRA and ulnar groups, respectively (p < 0.001). Crossover occurred in 3
patients (3%) in TRA, 13 patients (26%) in DRA and 4 cases (8%) in ulnar
group (p < 0.001). The most common cause of crossover was failure of
artery cannulation. Regarding cannulation time, the mean access time in
seconds was 80.19 +/- 25.98, 148.4 +/- 29.60, 90.5 +/- 21.84 in TRA, DRA
and ulnar groups, respectively (p < 0.001). <br/>Conclusion(s): Our study
concluded that these new approaches proved to be potential alternatives to
traditional radial approach; however, ulnar artery access proved to be
superior to distal radial artery access as regards success rate and
cannulation time.<br/>Copyright &#xa9; 2024 Wiley Periodicals LLC.

<58>
Accession Number
2029554075
Title
Upper extremity versus lower extremity for secondary access during
transcatheter aortic valve implantation: rationale and design of the
randomised TAVI XS trial.
Source
Netherlands Heart Journal. 32(7-8) (pp 270-275), 2024. Date of
Publication: August 2024.
Author
Rooijakkers M.J.P.; Versteeg G.A.A.; Hemelrijk K.I.; Aarts H.M.; Overduin
D.C.; van Ginkel D.-J.; Vlaar P.J.; van Wely M.H.; van Nunen L.X.; van
Geuns R.J.; van Garsse L.A.F.M.; Geuzebroek G.S.C.; Verkroost M.W.A.;
Rodwell L.; Heijmen R.H.; Tonino P.A.L.; ten Berg J.M.; Delewi R.; van
Royen N.
Institution
(Rooijakkers, Versteeg, van Wely, van Nunen, van Geuns, van Royen)
Department of Cardiology, Radboud University Medical Centre, Nijmegen,
Netherlands
(Hemelrijk, Aarts, Delewi) Department of Cardiology, Amsterdam University
Medical Centre, Amsterdam, Netherlands
(Overduin, van Ginkel, ten Berg) Department of Cardiology, St. Antonius
Hospital, Nieuwegein, Netherlands
(Vlaar, Tonino) Department of Cardiology, Catharina Hospital, Eindhoven,
Netherlands
(van Garsse, Geuzebroek, Verkroost, Heijmen) Department of Cardiothoracic
Surgery, Radboud University Medical Centre, Nijmegen, Netherlands
(Rodwell) Department of Health Sciences, Section Biostatistics, Radboud
Institute for Health Sciences, Nijmegen, Netherlands
(ten Berg) Cardiovascular Research Institute Maastricht, Maastricht,
Netherlands
Publisher
Bohn Stafleu van Loghum
Abstract
Background: During transcatheter aortic valve implantation (TAVI),
secondary access is required for angiographic guidance and temporary
pacing. The most commonly used secondary access sites are the femoral
artery (angiographic guidance) and the femoral vein (temporary pacing). An
upper extremity approach using the radial artery and an upper arm vein
instead of the lower extremity approach using the femoral artery and
femoral vein may reduce clinically relevant secondary access site-related
bleeding complications, but robust evidence is lacking. Trial design: The
TAVI XS trial is a multicentre, randomised, open-label clinical trial with
blinded evaluation of endpoints. A total of 238 patients undergoing
transfemoral TAVI will be included. The primary endpoint is the incidence
of clinically relevant bleeding (i.e. Bleeding Academic Research
Consortium (BARC) type 2, 3 or 5 bleeding) of the randomised secondary
access site (either diagnostic or pacemaker access, or both) within 30
days after TAVI. Secondary endpoints include time to mobilisation after
TAVI, duration of hospitalisation, any BARC type 2, 3 or 5 bleeding, and
early safety at 30 days according to Valve Academic Research Consortium-3
criteria. <br/>Conclusion(s): The TAVI XS trial is the first randomised
trial comparing an upper extremity approach to a lower extremity approach
with regard to clinically relevant secondary access site-related bleeding
complications. The results of this trial will provide important insights
into the safety and efficacy of an upper extremity approach in patients
undergoing transfemoral TAVI.<br/>Copyright &#xa9; The Author(s) 2024.

<59>
Accession Number
2029501178
Title
Device regulation and surveillance in vascular care: Challenges and
opportunities.
Source
Catheterization and Cardiovascular Interventions. 104(1) (pp 84-91), 2024.
Date of Publication: 01 Jul 2024.
Author
Pyun A.J.; Goodney P.P.; Eldrup-Jorgensen J.; Wadzinski J.; Secemsky E.A.;
Cigarroa J.E.
Institution
(Pyun) Division of Vascular Surgery and Endovascular Therapy, Keck Medical
Center of University of Southern California, Los Angeles, CA, United
States
(Goodney) Heart and Vascular Center, Dartmouth Health, Lebanon, NH, United
States
(Goodney, Eldrup-Jorgensen, Wadzinski) The Society for Vascular Surgery's
Patient Safety Organization (SVS-PSO) and Vascular Quality Initiative
(VQI), Chicago, IL, United States
(Secemsky) Division of Vascular Interventions, Beth Israel Deaconess
Medical Center, Boston, MA, United States
(Cigarroa) Division of Cardiovascular Medicine, Department of Medicine,
Oregon Health Sciences University (OHSU), Portland, OR, United States
Publisher
John Wiley and Sons Inc
Abstract
Cardiovascular devices are essential for the treatment of cardiovascular
diseases including cerebrovascular, coronary, valvular, congenital,
peripheral vascular and arrhythmic diseases. The regulation and
surveillance of vascular devices in real-world practice, however, presents
challenges during each individual product's life cycle. Four examples
illustrate recent challenges and questions regarding safety, appropriate
use and efficacy arising from FDA approved devices used in real-world
practice. We outline potential pathways wherein providers, regulators and
payors could potentially provide high-quality cardiovascular care,
identify safety signals, ensure equitable device access, and study
potential issues with devices in real-world practice.<br/>Copyright &#xa9;
2024 Wiley Periodicals LLC.

<60>
Accession Number
2028653427
Title
Aorta Segmentation in 3D CT Images by Combining Image Processing and
Machine Learning Techniques.
Source
Cardiovascular Engineering and Technology. 15(3) (pp 359-373), 2024. Date
of Publication: June 2024.
Author
Mavridis C.; Economopoulos T.L.; Benetos G.; Matsopoulos G.K.
Institution
(Mavridis, Economopoulos, Matsopoulos) Department of Electrical and
Computer Engineering, National Technical University of Athens, Athens
15780, Greece
(Benetos) Department of CT and MRI, Lefkos Stavros Clinic, Athens 11528,
Greece
Publisher
Springer
Abstract
Purpose: Aorta segmentation is extremely useful in clinical practice,
allowing the diagnosis of numerous pathologies, such as dissections,
aneurysms and occlusive disease. In such cases, image segmentation is
prerequisite for applying diagnostic algorithms, which in turn allow the
prediction of possible complications and enable risk assessment, which is
crucial in saving lives. The aim of this paper is to present a novel fully
automatic 3D segmentation method, which combines basic image processing
techniques and more advanced machine learning algorithms, for detecting
and modelling the aorta in 3D CT imaging data. <br/>Method(s): An initial
intensity threshold-based segmentation procedure is followed by a
classification-based segmentation approach, based on a Markov Random Field
network. The result of the proposed two-stage segmentation process is
modelled and visualized. <br/>Result(s): The proposed methodology was
applied to 16 3D CT data sets and the extracted aortic segments were
reconstructed as 3D models. The performance of segmentation was evaluated
both qualitatively and quantitatively against other commonly used
segmentation techniques, in terms of the accuracy achieved, compared to
the actual aorta, which was defined manually by experts.
<br/>Conclusion(s): The proposed methodology achieved superior
segmentation performance, compared to all compared segmentation
techniques, in terms of the accuracy of the extracted 3D aortic model.
Therefore, the proposed segmentation scheme could be used in clinical
practice, such as in treatment planning and assessment, as it can speed up
the evaluation of the medical imaging data, which is commonly a lengthy
and tedious process.<br/>Copyright &#xa9; The Author(s) under exclusive
licence to Biomedical Engineering Society 2024.

<61>
Accession Number
2030547771
Title
Usability and accuracy of two different aortic annulus sizing software
programs in patients undergoing transcatheter aortic valve replacement.
Source
Journal of Cardiovascular Imaging. 32(1) (no pagination), 2024. Article
Number: 1. Date of Publication: December 2024.
Author
Spanke J.; Nubel J.; Holschermann F.; Tambor G.; Kiessling C.; Kaneko H.;
Haase-Fielitz A.; Butter C.
Institution
(Spanke, Nubel, Holschermann, Tambor, Haase-Fielitz, Butter) Department of
Cardiology, Heart Centre Brandenburg Bernau & amp; Faculty of Health
Sciences Brandenburg, Brandenburg Medical School (MHB) Theodor Fontane,
Ladeburger Strase 17, Bernau bei Berlin 16321, Germany
(Kiessling) Personal and Interpersonal Development in Health Care
Education, University Witten/Herdecke, Witten, Germany
(Kaneko) Department of Cardiovascular Medicine, The University of Tokyo
Hospital, Tokyo, Japan
(Haase-Fielitz) Institute of Social Medicine and Health Care Systems
Research, Otto Von Guericke University Magdeburg, Magdeburg, Germany
Publisher
BioMed Central Ltd
Abstract
Background: Semi-automated software is essential for planning and
prosthesis selection prior transcatheter aortic valve replacement (TAVR).
Reliable data on the usability of software programs for planning a TAVR is
missing. The aim of this study was to compare software programs 'Valve
Assist 2' (GE Healthcare) and 3mensio 'Structural Heart' (Pie Medical
Imaging) regarding usability and accuracy of prosthesis size selection in
program-inexperienced users. <br/>Method(s): Thirty-one participants (n =
31) were recruited and divided into program-inexperienced users
(beginners) (n = 22) and experts (n = 9). After software training,
beginners evaluated 3 patient cases in 129 measurements (n = 129) using
either Valve Assist 2 (n = 11) or Structural Heart (n = 11) on 2 test days
(T1, T2). System Usability Scale (SUS) and ISONORM 9241/110-S (ISONORM)
questionnaire were used after the test. The valve size selected by each
beginner was compared with the valve size selected from expert group.
<br/>Result(s): Valve Assist 2 had higher SUS Score: median 78.75 (25th,
75th percentile: 67.50, 85.00) compared to Structural Heart: median 65.00
(25th, 75th percentile: 47.50, 73.75), (p < 0,001, r = 0.557). Also, Valve
Assist 2 showed a higher ISONORM score: median 1.05 (25th, 75th
percentile: - 0.19, 1.71) compared to Structural Heart with a median 0.05
(25th, 75th percentile: - 0.49, 0.13), (p = 0.036, r = 0.454). Correctly
selected valve sizes were stable over time using Valve Assist 2: 72.73% to
69.70% compared to Structural Heart program: 93.94% to 40%
(chi² (1) = 21.10, p < 0.001, phi = 0.579). <br/>Conclusion(s):
The study shows significant better usability scores for Valve Assist 2
compared to 3mensio Structural Heart in program-inexperienced
users.<br/>Copyright &#xa9; The Author(s) 2024.

<62>
Accession Number
2029901532
Title
Benefits and Risks of Antihyperlipidemic Medication in Adults with
Different Low-Density Lipoprotein Cholesterol Based on the Number Needed
to Treat.
Source
American Journal of Cardiovascular Drugs. 24(4) (pp 557-568), 2024. Date
of Publication: July 2024.
Author
Wang H.-F.; Mao Y.-C.; Qi S.-F.; Xu X.-Y.; Zhang Z.-Y.; Geng C.; Song K.;
Tian Q.-B.
Institution
(Wang, Mao, Qi, Zhang, Geng, Song, Tian) Department of Epidemiology and
Statistics, School of Public Health, Hebei Medical University,
Shijiazhuang, China
(Wang, Mao, Qi, Zhang, Geng, Song, Tian) Hebei Key Laboratory of
Environment and Human Health, Shijiazhuang, China
(Xu) Postdoctoral Research Station in Basic Medicine, Hebei Medical
University, Shijiazhuang, China
(Xu) School of Nursing, Hebei Medical University, Shijiazhuang, China
Publisher
Adis
Abstract
Purpose: The objective of this investigation is to examine the benefits
and potential risks of these drugs in individuals by varying baseline
low-density lipoprotein cholesterol (LDL-C) values, utilizing the concept
of the number needed to treat (NNT). <br/>Method(s): We extensively
searched electronic databases, such as PubMed, EMBASE, Cochrane, and Web
of Science, up to 6 August 2023. Baseline LDL-C values were stratified
into four categories: < 100, 100-129, 130-159, and >= 160 mg/dL. Risk
ratios (RRs) and NNT values were computed. <br/>Result(s): This analysis
incorporated data from 46 randomized controlled trials (RCTs),
encompassing a total of 237,870 participants. The meta-regression analysis
demonstrated an incremental diminishing risk of major adverse
cardiovascular events (MACE) with increasing baseline LDL-C values.
Statins exhibited a significant reduction in MACE [number needed to treat
to benefit (NNTB) 31, 95% confidence interval (CI) 25-37], but this effect
was observed only in individuals with baseline LDL-C values of 100 mg/dL
or higher. Ezetimibe and PCSK9 inhibitors also were effective in reducing
MACE (NNTB 18, 95% CI 11-41, and NNTB 18, 95% CI 16-24). Notably, the
safety outcomes of statins and ezetimibe did not reach statistical
significance, while the incidence of injection-site reactions with PCSK9
inhibitors was statistically significant [number needed to treat to harm
(NNTH) 41, 95% CI 80-26]. <br/>Conclusion(s): Statins, ezetimibe, and
PCSK9 inhibitors demonstrated a substantial capacity to reduce MACE,
particularly among individuals whose baseline LDL-C values were relatively
higher. The NNT visually demonstrates the gradient between baseline LDL-C
and cardiovascular disease (CVD) risk. Systematic Review Registration:
Registration: PROSPERO identifier number: CRD42023458630.<br/>Copyright
&#xa9; The Author(s), under exclusive licence to Springer Nature
Switzerland AG 2024.

<63>
Accession Number
2024911917
Title
Transcatheter aortic valve implantation versus surgical aortic valve
replacement in chronic kidney disease: Meta-analysis of reconstructed
time-to-event data.
Source
Trends in Cardiovascular Medicine. 34(5) (pp 317-324), 2024. Date of
Publication: July 2024.
Author
Jacquemyn X.; Van den Eynde J.; Iwens Q.; Billiau J.; Jabagi H.;
Serna-Gallegos D.; Chu D.; Sultan I.; Sa M.P.
Institution
(Jacquemyn, Van den Eynde) Department of Cardiovascular Sciences, KU
Leuven, Leuven, Belgium
(Jacquemyn, Van den Eynde, Iwens, Billiau) Faculty of Medicine, KU Leuven,
Leuven, Belgium
(Jabagi) Department of Cardiothoracic Surgery, Valley Heart and Vascular
Institute, Ridgewood, NJ, United States
(Serna-Gallegos, Chu, Sultan, Sa) Department of Cardiothoracic Surgery,
University of Pittsburgh, Pittsburgh, PA, United States
(Serna-Gallegos, Chu, Sultan, Sa) Heart and Vascular Institute, University
of Pittsburgh Medical Center, Pittsburgh, PA, United States
Publisher
Elsevier Inc.
Abstract
Background: Patients with advanced chronic kidney disease (CKD) are a
challenging and understudied population. Specifically, the late outcomes
following surgical aortic valve replacement (SAVR) or transcatheter aortic
valve implantation (TAVI) in patients with CKD remains uncertain.
<br/>Objective(s): To compare overall mortality risk in patients with
moderate-to-severe CKD following TAVI versus SAVR. <br/>Method(s):
Study-level meta-analysis of reconstructed time-to-event data from
Kaplan-Meier curves of studies published by August 2022. <br/>Result(s):
Nine studies met our inclusion criteria. Patients who underwent TAVI had a
higher 5-year mortality compared with patients undergoing SAVR in the
overall population (HR 1.56, 95% CI 1.44-1.69, P < 0.001) and in
populations with similar risk scores (HR 1.15, 95% CI 1.01-1.31, P =
0.035). The landmark analysis revealed a lower risk of 30-day mortality
with TAVI (HR 0.62, 95% CI 0.41-0.94, P = 0.023), followed by similar risk
until 7.5 months (HR 1, 95% CI 0.78-1.27, P = 0.978). In contrast, the
landmark analysis beyond 7.5 months yielded a reversal of the HR in favor
of SAVR (TAVI with HR 1.27, 95% CI 1.08-1.49 P = 0.003).
<br/>Conclusion(s): In patients with CKD, TAVI provides an initial
survival benefit over SAVR. However, in the long run, a significant
survival benefit of SAVR over TAVI was observed. Our findings highlight
the need for randomized controlled trials to investigate outcomes in this
special population.<br/>Copyright &#xa9; 2023 Elsevier Inc.

<64>
Accession Number
2024766599
Title
Surgical vs transcatheter aortic valve replacement in bicuspid aortic
valve stenosis: A systematic review and meta-analysis.
Source
Trends in Cardiovascular Medicine. 34(5) (pp 304-313), 2024. Date of
Publication: July 2024.
Author
Kang J.J.; Fialka N.M.; EL-Andari R.; Watkins A.; Hong Y.; Mathew A.;
Bozso S.J.; Nagendran J.
Institution
(Kang, EL-Andari, Hong, Bozso, Nagendran) Division of Cardiac Surgery,
Department of Surgery, Minimally Invasive and Transcatheter Valve Surgery,
Mazankowski Alberta Heart Institute, University of Alberta, 4-108A Li Ka
Shing Health Research Center, 8602 - 112 Street, Edmonton, AB T6G 2E1,
Canada
(Fialka, Watkins) Faculty of Medicine and Dentistry, University of
Alberta, Edmonton, AB, Canada
(Mathew) Division of Cardiology, Department of Medicine, University of
Alberta, Edmonton, AB, Canada
Publisher
Elsevier Inc.
Abstract
This systematic review and meta-analysis aim to provide a comprehensive
analysis of the literature directly comparing the outcomes of surgical
aortic valve replacement (SAVR) and TAVR in patients with BAV stenosis.
Medline, PubMed, and Scopus were systematically searched for articles
published between 2000 and 2023, 1862 studies were screened, and 6
retrospective studies met the inclusion criteria. We included 6550
patients in the final analyses: 3,292 and 3,258 in the SAVR and TAVR
groups, respectively. Both groups have similar rates of in-hospital
mortality (odds ratio (OR) 1.11; 95% CI 0.59-2.10; p = 0.75) and stroke
(OR 1.25; 95% CI 0.85-1.86; p = 0.26. Patients who underwent SAVR
experienced lower rates of permanent pacemaker implantation (OR 0.54; 95%
CI 0.35-0.83; p = 0.005) and paravalvular leak (OR 0.47; 95% CI 0.26-0.86;
p = 0.02). On the other hand, patients who underwent TAVR displayed lower
rates of acute kidney injury (OR 1.81; 95% CI 1.15-2.84; p = 0.010), major
bleeding (OR 3.76; 95% CI 2.18-6.49; p < 0.00001), and pulmonary
complications (OR 7.68; 95% CI 1.21-48.84; p = 0.03). Despite the early
mortality data suggesting that TAVR may be a reasonable strategy for
patients with bicuspid AS with low to intermediate surgical risk, the
increased risk of PPI and PVL is concerning. A prospective, randomized,
controlled trial reporting long-term outcomes with pre-defined subgroup
analyses based on BAV morphology is paramount. In the interim, caution
should be exercised in the widespread adoption of TAVR in lower
surgical-risk patients.<br/>Copyright &#xa9; 2023

<65>
[Use Link to view the full text]
Accession Number
2033156296
Title
A meta-analysis supporting the superiority of staged carotid artery
stenting and coronary artery bypass grafting in patients with concurrent
severe coronary and carotid artery stenosis.
Source
Medicine (United States). 103(27) (pp e38665), 2024. Date of Publication:
05 Jul 2024.
Author
Hao D.; Jiang Y.; Wang P.; Mao L.
Institution
(Hao, Mao) Department of Geriatrics, Liaocheng People's Hospital,
Liaocheng, China
(Jiang) Department of Cardiology, Liaocheng People's Hospital, Liaocheng,
China
(Wang) Department of Neurosurgery, Liaocheng People's Hospital, Liaocheng,
China
Publisher
Lippincott Williams and Wilkins
Abstract
Background: This study sought to ascertain whether a staged approach
involving carotid artery stenting (CAS) and coronary artery bypass
grafting (CABG) holds superiority over the synchronous (Syn) strategy of
CAS or carotid endarterectomy (CEA) and CABG in patients necessitating
combined revascularization for concurrent carotid and coronary artery
disease. <br/>Method(s): Studies were identified through 3 databases:
PubMed, EMBASE, and the Cochrane Library. Statistical significance was
defined as a P value of less than .05 for all analyses, conducted using
STATA version 12.0. <br/>Result(s): In the comparison between staged
versus Syn CAS and CABG for patients with concomitant severe coronary and
carotid stenosis, 4 studies were analyzed. The staged procedure was
associated with a lower rate of 30-day stroke (OR = 8.329, 95% CI =
1.017-69.229, P = .048) compared to Syn CAS and CABG. In the comparison
between staged CAS and CABG versus Syn CEA and CABG for patients with
concomitant severe coronary and carotid stenosis, 5 studies were examined.
The staged CAS and CABG procedure was associated with a lower rate of
mortality (OR = 2.046, 95% CI = 1.304-3.210, P = .002) compared to Syn CEA
and CABG. <br/>Conclusion(s): The Syn CAS and CABG was linked to a higher
risk of peri-operative stroke compared to staged CAS and CABG.
Additionally, patients undergoing staged CAS and CABG exhibited a
significantly decreased risk of 30-day mortality compared to Syn CEA and
CABG. Future randomized trials or prospective cohorts are essential to
confirm and validate these findings.<br/>Copyright &#xa9; 2024 the
Author(s).

<66>
[Use Link to view the full text]
Accession Number
2033126328
Title
ICU management of cardiogenic shock before mechanical support.
Source
Current Opinion in Critical Care. 30(4) (pp 362-370), 2024. Date of
Publication: 01 Aug 2024.
Author
Schaubroeck H.; Rossberg M.; Thiele H.; Poss J.
Institution
(Schaubroeck) Intensive Care Department, Ghent University Hospital, Ghent,
Belgium
(Rossberg, Thiele, Poss) Department of Cardiology, Heart Center Leipzig,
University of Leipzig, Leipzig, Germany
Publisher
Lippincott Williams and Wilkins
Abstract
Purpose of review Treatment of cardiogenic shock remains largely driven by
expert consensus due to limited evidence from randomized controlled
trials. In this review, we aim to summarize the approach to the management
of patients with cardiogenic shock in the ICU prior to mechanical
circulatory support (MCS). Recent findings Main topics covered in this
article include diagnosis, monitoring, initial management and key aspects
of pharmacological therapy in the ICU for patients with cardiogenic shock.
Summary Despite efforts to improve therapy, short-term mortality in
patients with cardiogenic shock is still reaching 40-50%. Early
recognition and treatment of cardiogenic shock are crucial, including
early revascularization of the culprit lesion with possible staged
revascularization in acute myocardial infarction (AMI)-CS. Optimal volume
management and vasoactive drugs titrated to restore arterial pressure and
perfusion are the cornerstone of cardiogenic shock therapy. The choice of
vasoactive drugs depends on the underlying cause and phenotype of
cardiogenic shock. Their use should be limited to the shortest duration
and lowest possible dose. According to recent observational evidence,
assessment of the complete hemodynamic profile with a pulmonary artery
catheter (PAC) was associated with improved outcomes and should be
considered early in patients not responding to initial therapy or with
unclear shock. A multidisciplinary shock team should be involved early in
order to identify potential candidates for temporary and/or durable
MCS.<br/>Copyright &#xa9; 2024 Wolters Kluwer Health, Inc. All rights
reserved.

<67>
Accession Number
2033195378
Title
Effects of the discontinuation of antihypertensive treatment on
neuropsychiatric symptoms and quality of life in nursing home residents
with dementia (DANTON): a multicentre, open-label, blinded-outcome,
randomised controlled trial.
Source
Age and Ageing. 53(7) (no pagination), 2024. Article Number: afae133. Date
of Publication: 01 Jul 2024.
Author
Bogaerts J.M.K.; Gussekloo J.; de Jong-Schmit B.E.M.; Le Cessie S.;
Mooijaart S.P.; van der Mast R.C.; Achterberg W.P.; Poortvliet R.K.E.
Institution
(Bogaerts, Gussekloo, de Jong-Schmit, Achterberg, Poortvliet) Department
of Public Health and Primary Care, Leiden University Medical Center,
Albinusdreef 2, Leiden 2333 ZA, Netherlands
(Bogaerts, Gussekloo, de Jong-Schmit, Le Cessie, Mooijaart, van der Mast,
Achterberg, Poortvliet) LUMC Center for Medicine for Older People, Leiden
University Medical Center, Albinusdreef 2, Leiden 2333 ZA, Netherlands
(Gussekloo, Mooijaart) Department of Internal Medicine, Section
Gerontology and Geriatrics, Leiden University Medical Center, Albinusdreef
2, Leiden 2333 ZA, Netherlands
(Le Cessie) Department of Clinical Epidemiology, Leiden University Medical
Center, Albinusdreef 2, Leiden 2333 ZA, Netherlands
(Le Cessie) Department of Biomedical Datasciences, Section Medical
Statistics, Leiden University Medical Center, Albinusdreef 2, Leiden 2333
ZA, Netherlands
(van der Mast) Department of Psychiatry, Leiden University Medical Center,
Albinusdreef 2, Leiden 2333 ZA, Netherlands
(van der Mast) Department of Psychiatry, The Collaborative Antwerp
Psychiatric Research Institute (CAPRI), Faculty of Medicine and Health
Sciences, University of Antwerp, Campus Drie Eiken, S.033,
Universiteitsplein 1, Wilrijk 2610, Belgium
(Achterberg) University Network for the Care sector South Holland, Leiden
University Medical Center, Albinusdreef 2, Leiden 2333 ZA, Netherlands
Publisher
Oxford University Press
Abstract
Background: Based on observational studies and randomised controlled
trials (RCTs), the benefit-harm balance of antihypertensive treatment in
older adults with dementia is unclear. <br/>Objective(s): To assess
whether discontinuing antihypertensive treatment reduces neuropsychiatric
symptoms (NPSs) and maintains quality of life (QoL) in nursing home
residents with dementia. <br/>Design(s): Open-label, blinded-outcome RCT.
Randomisation 1:1, stratified by nursing home organisation and baseline
NPS. Trial registration: NL7365. Subjects: Dutch long-term care residents
with moderate-to-severe dementia and systolic blood pressure (SBP) <=160
mmHg during antihypertensive treatment. Exclusion criteria included heart
failure NYHA-class-III/IV, recent cardiovascular events/procedures or life
expectancy <4 months (planned sample size n = 492). Measurements:
Co-primary outcomes NPS (Neuropsychiatric Inventory-Nursing Home [NPI-NH])
and QoL (Qualidem) at 16 weeks. <br/>Result(s): From 9 November 2018 to 4
May 2021, 205 participants (median age 85.8 [IQR 79.6-89.5] years; 79.5%
female; median SBP 134 [IQR 123-146] mmHg) were randomised to either
antihypertensive treatment discontinuation (n = 101) or usual care (n =
104). Safety concerns, combined with lacking benefits, prompted the data
safety and monitoring board to advice a premature cessation of
randomisation. At 16-week follow-up, no significant differences were found
between groups for NPI-NH (adjusted mean difference 1.6 [95% CI -2.3 to
5.6]; P = 0.42) or Qualidem (adjusted mean difference - 2.5 [95% CI -6.0
to 1.0]; P = 0.15). Serious adverse events (SAEs) occurred in 36%
(discontinuation) and 24% (usual care) of the participants (adjusted
hazard ratio 1.65 [95% CI 0.98-2.79]). All 32-week outcomes favoured usual
care. <br/>Conclusion(s): Halfway through this study, a non-significant
increased SAE risk associated with discontinuing antihypertensive
treatment was observed, and an associated interim analysis showed that
significant worthwhile health gain for discontinuation of antihypertensive
treatment was unlikely. This unbeneficial benefit-harm balance shows that
discontinuation of antihypertensive treatment in this context does not
appear to be either safe or beneficial enough to be recommended in older
adults with dementia.<br/>Copyright &#xa9; The Author(s) 2024. Published
by Oxford University Press on behalf of the British Geriatrics Society.

<68>
Accession Number
2033195085
Title
Rationale and design of the early valve replacement in severe asymptomatic
aortic stenosis trial.
Source
American Heart Journal. 275 (pp 119-127), 2024. Date of Publication:
September 2024.
Author
Richardson C.; Gilbert T.; Aslam S.; Brookes C.L.; Singh A.; Newby D.E.;
Dweck M.R.; Stewart R.A.H.; Myles P.S.; Briffa T.; Selvanayagam J.; Chow
C.K.; Murphy G.J.; Akowuah E.F.; Lord J.; Barber S.; Paola A.S.D.; McCann
G.P.; Hillis G.S.
Institution
(Richardson, Aslam, Brookes, Singh, Murphy, Barber, Paola, McCann) College
of Life Sciences, University of Leicester, Leicester, United Kingdom
(Gilbert, Hillis) Medical School, University of Western Australia, Perth,
Australia
(Newby, Dweck) British Heart Foundation Centre for Cardiovascular Science,
University of Edinburgh, Edinburgh, United Kingdom
(Stewart) Green Lane Cardiovascular Service, Auckland City Hospital,
University of Auckland, Auckland, New Zealand
(Myles) Department of Anaesthesiology and Perioperative Medicine, Alfred
Health and Monash University, Melbourne, Australia
(Briffa) School of Population and Global Health, University of Western
Australia, Perth, Australia
(Selvanayagam) Department of Cardiovascular Medicine, Flinders Medical
Centre, Adelaide, Australia
(Chow) Faculty of Medicine and Health, University of Sydney, Sydney,
Australia
(Akowuah) Department of Cardiac Surgery, the James Cook University
Hospital, South Tees Hospitals NHS Foundation Trust, Middlesbrough, United
Kingdom
(Lord) Southampton Health Technology Assessments Centre, University of
Southampton, Southampton, United Kingdom
(Hillis) Department of Cardiology, Royal Perth Hospital, Perth, Australia
(Richardson, Gilbert) These 2 authors contributed equally to this work.
(McCann, Hillis, Hillis) These 2 authors are joint senior authors and
co-CIs taking joint responsibility.
Publisher
Elsevier Inc.
Abstract
Background: Aortic valve replacement in asymptomatic severe aortic
stenosis is controversial. The Early valve replacement in severe
ASYmptomatic Aortic Stenosis (EASY-AS) trial aims to determine whether
early aortic valve replacement improves clinical outcomes, quality of life
and cost-effectiveness compared to a guideline recommended strategy of
'watchful waiting'. <br/>Method(s): In a pragmatic international, open
parallel group randomized controlled trial (NCT04204915), 2844 patients
with severe aortic stenosis will be randomized 1:1 to either a strategy of
early (surgical or transcatheter) aortic valve replacement or aortic valve
replacement only if symptoms or impaired left ventricular function
develop, or other cardiac surgery becomes nessessary. Exclusion criteria
include other severe valvular disease, planned cardiac surgery, ejection
fraction <50%, previous aortic valve replacement or life expectancy <2
years. The primary outcome is a composite of cardiovascular mortality or
heart failure hospitalization. The primary analysis will be undertaken
when 663 primary events have accrued, providing 90% power to detect a
reduction in the primary endpoint from 27.7% to 21.6% (hazard ratio 0.75).
Secondary endpoints include disability-free survival, days alive and out
of hospital, major adverse cardiovascular events and quality of life.
<br/>Result(s): Recruitment commenced in March 2020 and is open in the UK,
Australia, New Zealand, and Serbia. Feasibility requirements were met in
July 2022, and the main phase opened in October 2022, with additional
international centers in set-up. <br/>Conclusion(s): The EASY-AS trial
will establish whether a strategy of early aortic valve replacement in
asymptomatic patients with severe aortic stenosis reduces cardiovascular
mortality or heart failure hospitalization and improves other important
outcomes.<br/>Copyright &#xa9; 2024 The Authors

<69>
Accession Number
2033186628
Title
Cardiopulmonary Protection of Modified Remote Ischemic Preconditioning in
Mitral Valve Replacement Surgery: A Randomized Controlled Trial.
Source
Cardiovascular Therapeutics. 2024 (no pagination), 2024. Article Number:
9889995. Date of Publication: 2024.
Author
Zhang L.; Zhou K.; Gu T.; Xu J.; Shi M.; Zhu J.; Liu J.
Institution
(Zhang, Zhu) Department of Anesthesiology, The Second Affiliated Hospital
of Soochow University, Jiangsu, Soochow 215008, China
(Zhou, Gu, Xu, Shi, Liu) Jiangsu Province Key Laboratory of
Anesthesiology, Xuzhou Medical University, Jiangsu, Xuzhou 221004, China
(Liu) Department of Anesthesiology, The Affiliated Hospital of Xuzhou
Medical University, Jiangsu, Xuzhou 221004, China
Publisher
Hindawi Limited
Abstract
Background: Remote ischemic preconditioning (RIPC) is reported to have
early-phase and delayed-phase organ-protective effects. Previous studies
have focused on the organ protection of a single RIPC protocol, and the
clinical outcomes remain uncertain. Whether the modified RIPC (mRIPC)
protocol performed repeatedly provides cardiopulmonary protection is still
uncertain. <br/>Method(s): In this single-center, randomized, controlled
trial, 86 patients undergoing elective mitral valve replacement (MVR)
surgery were randomized 1:1 to receive either mRIPC or no ischemic
preconditioning (control). Three cycles of 5 min ischemia and 5 min
reperfusion induced by a blood pressure cuff served as the RIPC stimulus.
mRIPC was induced at the following three time points: 24 h, 12 h, and 1 h
before surgery. Blood samples were withdrawn at 10 min after intubation
(T0), at 1 h after aortic declamping (T1), and at 6 h (T2), 12 h (T3), and
24 h (T4) after surgery to measure the serum concentrations of myocardial
enzymes and other biomarkers, including cardiac troponin I (cTnI), which
was the primary endpoint of this study. Creatine kinase isoenzyme (CK-MB),
lactate dehydrogenase (LDH), inotropic score (IS), and inflammatory
mediators were also measured. Blood gas analysis was conducted to
calculate the PaO2/FiO2 ratio and A-aDO2, and the incidence of acute lung
injury (ALI) was also recorded. <br/>Result(s): mRIPC significantly
decreased the serum concentrations of cTnI, CK-MB, and LDH at T2, T3, and
T4 (p<0.01), and the IS decreased compared with that in the control group
(12.0+/-1.0 vs. 14.2+/-1.1, p<0.01). In addition, the incidence of ALI in
the mRIPC group was decreased (32.6% vs. 51.2%, p=0.039), and the
PaO2/FiO2 was higher at T4 (p<0.05). Compared with those in the control
group, the levels of interleukin-6 (IL-6) and tumor necrosis factor-alpha
(TNF-alpha) were decreased at T1, T2, T3, and T4 (p<0.05) in the mRIPC
group, and the level of IL-10 increased at the same time.
<br/>Conclusion(s): mRIPC decreased the incidence of myocardial and lung
injury in MVR surgery, providing new evidence for the clinical application
of RIPC in valve surgery.Trial Registration: ClinicalTrials.gov
(NCT01406678).<br/>Copyright &#xa9; 2024 Lianqin Zhang et al.

<70>
Accession Number
2033175162
Title
Continuous Glucose Monitoring and the Effect of Liraglutide in Cardiac
Surgery Patients: A Substudy of the Randomized Controlled GLOBE Trial.
Source
Journal of Cardiothoracic and Vascular Anesthesia. (no pagination), 2024.
Date of Publication: 2024.
Author
Oosterom-Eijmael M.J.P.; Hermanides J.; van Raalte D.H.; Kouw I.W.K.;
DeVries J.H.; Hulst A.H.
Institution
(Oosterom-Eijmael, Hermanides, Hulst) Department of Anesthesiology,
Amsterdam University Medical Center, Amsterdam, Netherlands
(Oosterom-Eijmael, van Raalte, DeVries) Department of Endocrinology,
Amsterdam University Medical Center, Amsterdam, Netherlands
(Oosterom-Eijmael, van Raalte, Hulst) Amsterdam Cardiovascular Sciences
Research Institute, Amsterdam, Netherlands
(Hermanides) Amsterdam Public Health Research Institute, Amsterdam,
Netherlands
(Kouw) Department of Intensive Care Medicine, Intensive Care Research,
Gelderse Vallei Hospital, Ede, Netherlands
(Kouw) Wageningen University & Research, Division of Human Nutrition and
Health, Wageningen, Netherlands
(DeVries, Hulst) Amsterdam Gastroenterology Endocrinology Metabolism,
Amsterdam, Netherlands
Publisher
W.B. Saunders
Abstract
Objectives: The objectives of the current research were to evaluate the
accuracy and reliability of continuous glucose monitoring (CGM) in
patients undergoing cardiac surgery and assess the impact of preoperative
liraglutide administration on perioperative glucose control as captured by
CGM. <br/>Design(s): This was a prospective, single-center, prespecified
analysis of the GLOBE trial, a randomized controlled trial comparing
preoperative liraglutide treatment to placebo in patients undergoing
cardiac surgery. <br/>Setting(s): The work took place at a single-center
academic hospital in the Netherlands. <br/>Participant(s): Twenty-five
patients undergoing cardiac surgery were recruited from the hospital's
cardiac surgery department. <br/>Intervention(s): Participants received
the Dexcom G5 CGM system from the day before surgery until discharge from
the intensive care unit after surgery. Additionally, participants were
randomized to receive either preoperative liraglutide or placebo.
<br/>Measurements and Main Results: Arterial blood gas (ABG) glucose
measurements were collected as a reference and matched to CGM readings to
assess accuracy and reliability. In 240 paired CGM-ABG glucose
measurements, the mean absolute relative difference was 14.4 +/- 12.5%.
Temporary sensor interruption occurred mainly intraoperatively (92% of
patients). The median duration of intraoperative sensor interruption was
65 (48-95) minutes. Liraglutide increased glycemic time in range 72%
versus 47% in the control group (absolute difference 25%, 95% confidence
interval -41.4 to -8.9, p =.004). <br/>Conclusion(s): Despite
intraoperative sensor interruption, CGM seems an accurate method for
semi-invasive, real-time assessment of blood glucose levels. CGM can
provide a detailed observation of the pre- and postoperative glycemic
trajectory, demonstrating increased time in range following perioperative
liraglutide treatment compared with placebo.<br/>Copyright &#xa9; 2024 The
Author(s)

<71>
Accession Number
2030563341
Title
Mechanical Valves: Past, Present, and Future-A Review.
Source
Journal of Clinical Medicine. 13(13) (no pagination), 2024. Article
Number: 3768. Date of Publication: July 2024.
Author
Leviner D.B.; Abraham D.; Ronai T.; Sharoni E.
Institution
(Leviner, Abraham, Ronai, Sharoni) Department of Cardiothoracic Surgery,
Carmel Medical Center, Haifa 3436212, Israel
(Abraham, Ronai) The Ruth & Baruch Rappaport Faculty of Medicine, Haifa,
Technion 3525433, Israel
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
The mechanical valve was first invented in the 1950s, and since then, a
wide variety of prostheses have been developed. Although mechanical valves
have outstanding durability, their use necessitates life-long treatment
with anticoagulants, which increases the risk of bleeding and
thromboembolic events. The current guidelines recommend a mechanical
prosthetic valve in patients under 50-60 years; however, for patients aged
50-70 years, the data are conflicting and there is not a clear-cut
recommendation. In recent decades, progress has been made in several
areas. First, the On-X mechanical valve was introduced; this valve has a
lower anticoagulant requirement in the aortic position. Second, a
potential alternative to vitamin K-antagonist treatment, rivaroxaban, has
shown encouraging results in small-scale trials and is currently being
tested in a large randomized clinical trial. Lastly, an innovative
mechanical valve that eliminates the need for anticoagulant therapy is
under development. We attempted to review the current literature on the
subject with special emphasis on the role of mechanical valves in the
current era and discuss alternatives and future innovations.<br/>Copyright
&#xa9; 2024 by the authors.

<72>
Accession Number
2030563175
Title
Dobutamine in the Management of Advanced Heart Failure.
Source
Journal of Clinical Medicine. 13(13) (no pagination), 2024. Article
Number: 3782. Date of Publication: July 2024.
Author
Ahmad T.; Manohar S.A.; Stencel J.D.; Le Jemtel T.H.
Institution
(Ahmad, Manohar, Stencel, Le Jemtel) John W. Deming Department of
Medicine, Tulane University, 131 S., New Orleans, LA 70112, United States
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Background: The potential harm and clinical benefits of inotropic therapy
in patients with decompensated heart failure with reduced ejection
fraction or advanced heart failure were debated for three decades.
Nonetheless, confronted with a dismal quality of life in the last months
to years of life, continuous home inotropic therapy has recently gained
traction for palliative therapy in patients who are not candidates for
left ventricular mechanical circulatory support or heart transplantation.
<br/>Method(s): As continuous inotropic therapy is only considered for
patients who experience symptomatic relief and display objective evidence
of improvement, clinical equipoise is no longer present, and randomized
controlled trials are hard to conduct. <br/>Result(s): We first outline
the transient use of inotropic therapy in patients with decompensated
heart failure with reduced ejection fraction and emphasize the hemodynamic
requisite for inotropic therapy, which is a demonstration of a low cardiac
output through a low mixed venous oxygen saturation. Lastly, we review the
current experience with the use of home inotropic therapy in patients who
are not candidates or are awaiting mechanical circulatory support or heart
transplantation. <br/>Conclusion(s): Evidence-based clinical data are
needed to guide inotropic therapy for refractory decompensated heart
failure with reduced ejection fraction in patients who are ineligible or
awaiting mechanical circulatory support or heart
transplantation.<br/>Copyright &#xa9; 2024 by the authors.

<73>
Accession Number
644713804
Title
Effect of flow-optimized pressure control ventilation-volume guaranteed
(PCV-VG) on postoperative pulmonary complications: a consort study.
Source
Journal of cardiothoracic surgery. 19(1) (pp 425), 2024. Date of
Publication: 08 Jul 2024.
Author
Sun T.T.; Chen K.X.; Tao Y.; Zhang G.W.; Zeng L.; Lin M.; Huang J.; Hu Y.
Institution
(Sun, Chen, Tao, Zhang, Zeng, Lin, Huang, Hu) Department of Anesthesia
Operation, First People's Hospital of Shuangliu District (West China
Airport Hospital of Sichuan University), Chengbei Street ,Dongsheng
Street, Chengdu 610200, China
Abstract
BACKGROUND: Postoperative pulmonary complications (PPCs) after one-lung
ventilation (OLV) significantly impact patient prognosis and quality of
life. <br/>OBJECTIVE(S): To study the impact of an optimal inspiratory
flow rate on PPCs in thoracic surgery patients. <br/>METHOD(S): One
hundred eight elective thoracic surgery patients were randomly assigned to
2 groups in this consort study (control group: n=53 with a fixed
inspiratory expiratory ratio of 1:2; and experimental group [flow rate
optimization group]: n=55). Measurements of Ppeak, Pplat, PETCO2, lung
dynamic compliance (Cdyn), respiratory rate, and oxygen concentration were
obtained at the following specific time points: immediately after
intubation (T0); immediately after starting OLV (T1); 30 min after OLV
(T2); and 10 min after 2-lung ventilation (T4). The PaO2:FiO2 ratio was
measured using blood gas analysis 30 min after initiating one-lung
breathing (T2) and immediately when OLV ended (T3). The lung ultrasound
score (LUS) was assessed following anesthesia and resuscitation (T5). The
occurrence of atelectasis was documented immediately after the surgery.
PPCs occurrences were noted 3 days after surgery. <br/>RESULT(S): The
treatment group had a significantly lower total prevalence of PPCs
compared to the control group (3.64% vs. 16.98%; P=0.022). There were no
notable variations in peak airway pressure, airway plateau pressure,
dynamic lung compliance, PETCO2, respiratory rate, and oxygen
concentration between the two groups during intubation (T0). Dynamic lung
compliance and the oxygenation index were significantly increased at T1,
T2, and T4 (P<0.05), whereas the CRP level and number of inflammatory
cells decreased dramatically (P<0.05). <br/>CONCLUSION(S): Optimizing
inspiratory flow rate and utilizing pressure control ventilation -volume
guaranteed (PCV-VG) mode can decrease PPCs and enhance lung dynamic
compliance in OLV patients.<br/>Copyright &#xa9; 2024. The Author(s).

<74>
Accession Number
2033296955
Title
Randomized Trial of Cholesterol Lowering With Evolocumab for Cardiac
Allograft Vasculopathy in Heart Transplant Recipients.
Source
JACC: Heart Failure. (no pagination), 2024. Date of Publication: 2024.
Author
Broch K.; Lemstrom K.B.; Gustafsson F.; Eiskjaer H.; Karason K.; Gjesdal
G.; Fagerland M.W.; Pentikainen M.; Lommi J.; Gude E.; Andreassen A.K.;
Clemmensen T.S.; Christiansen E.H.; Bjorkelund E.; Berg E.S.; Arora S.;
Gullestad L.
Institution
(Broch, Gude, Andreassen, Bjorkelund, Berg, Gullestad) Oslo University
Hospital Rikshospitalet, Oslo, Norway
(Broch, Gullestad) KG Jebsen Center for Cardiac Research, University of
Oslo, Oslo, Norway
(Lemstrom, Pentikainen, Lommi) Helsinki University Hospital Heart and Lung
Center and University of Helsinki, Helsinki, Finland
(Gustafsson) Rigshospitalet-Copenhagen University Hospital, Copenhagen,
Denmark
(Eiskjaer, Clemmensen, Christiansen) Aarhus University Hospital, Aarhus,
Denmark
(Karason) Transplant Institute, Sahlgrenska University Hospital and
Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
(Gjesdal) Cardiology Unit, Department of Clinical Sciences, Lund
University and Department of Heart and Lung Medicine, Skane University
Hospital, Lund, Sweden
(Fagerland) Oslo Center for Biostatistics and Epidemiology, Research
Support Services, Oslo University Hospital, Oslo, Norway
(Arora) Faculty of Medicine, University of Oslo, Oslo, Norway
Publisher
Elsevier Inc.
Abstract
Background: Cardiac allograft vasculopathy is characterized by increased
coronary intimal thickness and is a leading cause of death in heart
transplant (HTx) recipients despite the routine use of statins. The
experience with inhibitors of proprotein convertase subtilisin-kexin type
9 in HTx recipients is limited. Our hypothesis was that lowering
cholesterol with the proprotein convertase subtilisin-kexin type
9inhibitor evolocumab would reduce coronary intimal thickness in these
patients without compromising safety. <br/>Objective(s): This double
blind, randomized trial was conducted to test whether evolocumab reduces
the burden of cardiac allograft vasculopathy. <br/>Method(s): Patients who
had received a cardiac allograft at one of the Nordic transplant centers
within the prior 4 to 8 weeks were randomized to monthly subcutaneous
injections of evolocumab 420 mg or matching placebo. The primary endpoint
was the baseline-adjusted maximal intimal thickness as measured by
intracoronary ultrasound after 12 months' treatment. <br/>Result(s): The
trial enrolled 128 patients between June 2019 and May 2022. Matched pairs
of coronary ultrasound images were available for 56 patients assigned to
evolocumab and 54 patients assigned to placebo. At 12 months, the adjusted
mean difference in the maximal intimal thickness between the 2 arms was
0.017 mm (95% CI: -0.006 to 0.040; P = 0.14). The mean reduction in
low-density lipoprotein cholesterol with evolocumab compared with placebo
was 1.11 mmol/L (95% CI: 0.86-1.37 mmol/L). The use of evolocumab was not
associated with an increase in adverse events. <br/>Conclusion(s): Twelve
months of treatment with evolocumab substantially reduced low-density
lipoprotein cholesterol but did not reduce maximal coronary intimal
thickness in HTx recipients. (Cholesterol Lowering With EVOLocumab to
Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant
Recipients [EVOLVD]; NCT03734211)<br/>Copyright &#xa9; 2024 The Authors

<75>
Accession Number
2030495621
Title
Comparative effectiveness of mesenchymal stem cell versus bone-marrow
mononuclear cell transplantation in heart failure: a meta-analysis of
randomized controlled trials.
Source
Stem Cell Research and Therapy. 15(1) (no pagination), 2024. Article
Number: 202. Date of Publication: December 2024.
Author
Hosseinpour A.; Kamalpour J.; Dehdari Ebrahimi N.; Mirhosseini S.A.;
Sadeghi A.; Kavousi S.; Attar A.
Institution
(Hosseinpour, Kamalpour, Attar) Department of Cardiovascular Medicine,
Shiraz University of Medical Sciences, Shiraz, Iran, Islamic Republic of
(Hosseinpour, Sadeghi, Kavousi) School of Medicine, Shiraz University of
Medical Sciences, Shiraz, Iran, Islamic Republic of
(Dehdari Ebrahimi) Transplant Research Center, Shiraz University of
Medical Sciences, Shiraz, Iran, Islamic Republic of
(Mirhosseini) MD-MPH Department, School of Medicine, Shiraz University of
Medical Sciences, Shiraz, Iran, Islamic Republic of
Publisher
BioMed Central Ltd
Abstract
Background: There is no clear evidence on the comparative effectiveness of
bone-marrow mononuclear cell (BMMNC) vs. mesenchymal stromal cell (MSC)
stem cell therapy in patients with chronic heart failure (HF).
<br/>Method(s): Using a systematic approach, eligible randomized
controlled trials (RCTs) of stem cell therapy (BMMNCs or MSCs) in patients
with HF were retrieved to perform a meta-analysis on clinical outcomes
(major adverse cardiovascular events (MACE), hospitalization for HF, and
mortality) and echocardiographic indices (including left ventricular
ejection fraction (LVEF)) were performed using the random-effects model. A
risk ratio (RR) or mean difference (MD) with corresponding 95% confidence
interval (CI) were pooled based on the type of the outcome and subgroup
analysis was performed to evaluate the potential differences between the
types of cells. <br/>Result(s): The analysis included a total of 36 RCTs
(1549 HF patients receiving stem cells and 1252 patients in the control
group). Transplantation of both types of cells in patients with HF
resulted in a significant improvement in LVEF (BMMNCs: MD (95% CI) = 3.05
(1.11; 4.99) and MSCs: MD (95% CI) = 2.82 (1.19; 4.45), between-subgroup p
= 0.86). Stem cell therapy did not lead to a significant change in the
risk of MACE (MD (95% CI) = 0.83 (0.67; 1.06), BMMNCs: RR (95% CI) = 0.59
(0.31; 1.13) and MSCs: RR (95% CI) = 0.91 (0.70; 1.19), between-subgroup p
= 0.12). There was a marginally decreased risk of all-cause death (MD (95%
CI) = 0.82 (0.68; 0.99)) and rehospitalization (MD (95% CI) = 0.77 (0.61;
0.98)) with no difference among the cell types (p > 0.05).
<br/>Conclusion(s): Both types of stem cells are effective in improving
LVEF in patients with heart failure without any noticeable difference
between the cells. Transplantation of the stem cells could not decrease
the risk of major adverse cardiovascular events compared with controls.
Future trials should primarily focus on the impact of stem cell
transplantation on clinical outcomes of HF patients to verify or refute
the findings of this study.<br/>Copyright &#xa9; The Author(s) 2024.

<76>
Accession Number
2028886721
Title
Superficial parasternal intercostal plane blocks in cardiac surgery: a
systematic review and meta-analysis.
Source
Canadian Journal of Anesthesia. 71(6) (pp 883-895), 2024. Date of
Publication: June 2024.
Author
Cameron M.J.; Long J.; Kardash K.; Yang S.S.
Institution
(Cameron, Long, Kardash, Yang) Faculty of Medicine, McGill University,
Montreal, QC, Canada
(Cameron) Department of Anesthesia, Jewish General Hospital, K1401-3755
Cote Sainte Catherine, Montreal, QC H3T 1E2, Canada
(Kardash, Yang) Department of Anesthesia, Jewish General Hospital,
Montreal, QC, Canada
(Cameron, Yang) Lady Davis Research Institute, Montreal, QC, Canada
Publisher
Springer
Abstract
Purpose: Traditional multimodal analgesic strategies have several
contraindications in cardiac surgery patients, forcing clinicians to use
alternative options. Superficial parasternal intercostal plane blocks,
anesthetizing the anterior cutaneous branches of the thoracic intercostal
nerves, are being explored as a straightforward method to treat pain after
sternotomy. We sought to evaluate the literature on the effects of
superficial parasternal blocks on pain control after cardiac surgery.
<br/>Method(s): We conducted a systematic review and meta-analysis of
randomized controlled trials (RCTs). We searched MEDLINE, Embase, CENTRAL,
and Web of Science databases for RCTs evaluating superficial parasternal
intercostal plane blocks in adult patients undergoing cardiac surgery via
midline sternotomy published from inception to 11 March 2022. The
prespecified primary outcome was opioid consumption at 12 hr. The risk of
bias was assessed with the Cochrane Collaboration Risk of Bias Tool, and
the quality of evidence was evaluated using the grading of
recommendations, assessments, development, and evaluations. Outcomes were
analyzed with a random-effects model. All subgroups were prespecified.
<br/>Result(s): We reviewed 1,275 citations. Eleven RCTs, comprising 756
patients, fulfilled the inclusion criteria. Only one study reported the
prespecified primary outcome, precluding the possibility of meta-analysis.
This study reported a reduction in opioid consumption (-11.2 mg iv
morphine equivalents; 95% confidence interval [CI], -8.2 to -14.1) There
was a reduction in opioid consumption at 24 hr (-7.2 mg iv morphine
equivalents; 95% CI, -5.6 to -8.7; five trials; 436 participants; moderate
certainty evidence). All five studies measuring complications reported
that none were detected, which included a sample of 196 blocks.
<br/>Conclusion(s): The literature suggests a potential benefit of using
superficial parasternal blocks to improve acute postoperative pain control
after cardiac surgery via midline sternotomy. Future studies specifying
dosing regimens and adjuncts are required. Study registration: PROSPERO
(CRD42022306914); first submitted 22 March 2022.<br/>Copyright &#xa9;
Canadian Anesthesiologists' Society 2024.

<77>
Accession Number
2033166242
Title
Comparison of the effect of telephone follow-up with social network
follow-up program on self-efficacy and depression in patients undergoing
coronary artery bypass graft surgery: A randomized controlled trial.
Source
Internet Interventions. 37 (no pagination), 2024. Article Number: 100757.
Date of Publication: September 2024.
Author
Hassanzadeh A.; Baharestani B.; Dizaji N.N.; Shabani F.; Fathollahi M.S.;
Goli R.; Kouhpayeh M.S.
Institution
(Hassanzadeh, Shabani) Department of Nursing, School of Nursing and
Midwifery, Tehran University of Medical Sciences, Tehran, Iran, Islamic
Republic of
(Dizaji, Goli) Department of nursing, School of Nursing and Midwifery,
Urmia University of Medical Sciences, Urmia, Iran, Islamic Republic of
(Kouhpayeh) Department of Nursing, School of Nursing and Midwifery, Jiroft
University of Medical Sciences, Kerman, Iran, Islamic Republic of
(Hassanzadeh, Baharestani, Shabani) Cardiovascular Research Center, Rajaie
Cardiovascular Medical and Research Center, Iran University of Medical
Sciences, Tehran, Iran, Islamic Republic of
(Fathollahi) Department of Epidemiology and Biostatistics, Faculty of
Medicine, Rajaie Cardiovascular, Medical and Research Center, Iran
University of Medical Sciences, Tehran, Iran, Islamic Republic of
Publisher
Elsevier B.V.
Abstract
Introduction: Coronary artery bypass graft (CABG) surgery is a common
procedure to improve blood flow to the heart muscles, but patients often
face challenges during the recovery period. Self-efficacy and depression
play crucial roles in patient outcomes. Telephone follow-up and social
network follow-up have been introduced as interventions to enhance
self-efficacy. This study aims to compare the effectiveness of telephone
follow-up and social network follow-up on self-efficacy and depression in
CABG patients. <br/>Method(s): The study is a single-blinded, randomized
controlled trial conducted at Shahid Rajaee Heart Hospital in Tehran,
Iran. The sample size was determined to be 99 patients who met the
inclusion criteria. Data were collected using a demographic questionnaire,
Sullivan's cardiac self-efficacy questionnaire, and the Beck Depression
Inventory (BDI). Participants were assigned to three groups: control,
telephone follow-up, and WhatsApp follow-up using randomization. Data were
analyzed using IBM SPSS Statistics for Windows, version 25 (IBM Corp.,
Armonk, N.Y., USA). <br/>Result(s): The results revealed significant
improvements in self-efficacy and reductions in depression scores for both
the telephone and WhatsApp follow-up groups compared to the control group
following the intervention (p < 0.001). Additionally, the mean
self-efficacy score was higher and the mean depression score was lower in
the WhatsApp follow-up group than in the telephone follow-up group after
the intervention (p < 0.001). <br/>Discussion(s): The findings provide
valuable insights for healthcare professionals in choosing appropriate
interventions to enhance patients' self-efficacy levels and improve mental
health outcomes. Both telephone follow-up and social network follow-up
interventions have their own advantages and can be effective in supporting
patients' recovery after CABG surgery.<br/>Copyright &#xa9; 2024 The
Author(s)

<78>
Accession Number
2033144844
Title
Comparison of Transesophageal Echocardiography Probe as Surface Probe with
Vascular Probe During Right Internal Jugular Vein Catheterization in
Cardiac Surgeries.
Source
Annals of Cardiac Anaesthesia. 27(3) (pp 241-245), 2024. Date of
Publication: 2024.
Author
Antony N.R.; Sundarsingh S.; Radhakrishnan A.; Sasidharan S.
Institution
(Antony, Sundarsingh, Radhakrishnan, Sasidharan) Department of Anesthesia,
KIMSHealth, Kerala, Trivandrum, India
Publisher
Wolters Kluwer Medknow Publications
Abstract
Transesophageal echocardiography (TEE) has become an essential monitor for
the management of most patients undergoing cardiothoracic surgery. TEE and
central venous catheter placement are often used during cardiac surgeries.
Here we conducted a study comparing TEE 3D probe as a surface probe with
the ultrasound-guided (USG) vascular probe for guiding right internal
jugular vein (IJV) catheterization. <br/>Context: USG vascular probe and
TEE probe can help during central venous catheterization (CVC) and can
confirm the location of guide wire in the neck vessels. We proposed this
study, as there are only few studies comparing between TEE probe as
surface probe and USG vascular probe for right IJV cannulation.
<br/>Aim(s): To compare the TEE probe as a surface probe and USG vascular
probe during right IJV catheterization in cardiac surgeries. Settings and
Design: Prospective, comparative study. Methods and Material: One
twenty-four patients of either sex posted for major elective cardiac
surgery were included in this study. Patients were divided into two groups
(TEE group and USG group) of 62 by assigning the study participants
alternatively to each group. The goal of this study was to compare the
puncture time, visualization of IJV to first successful puncture, quality
of the imaging with needle tip positioning, and catheter positioning using
both TEE probe and vascular probe. The primary outcome was comparison of
time from visualization of the IJV to successful puncture using both TEE
probe as a surface probe and vascular probe. Secondary outcome was to
compare the quality of image with respect to needle tip positioning and
compare quality of image with respect to catheter position using both
probes. Statistical Analysis Used: Statistical analyses were performed by
using a statistical software package SPSS, version 20.0. <br/>Result(s):
The observation and results of our study clearly show the feasibility of
TEE as surface probe for guiding central venous catheter in right IJV just
like the vascular linear probe. There was no significant difference
between the two groups (P > 0.05). No statistical differences were found
in the puncture time, image quality, needle tip positioning, wire
positioning, and catheter positioning between the two groups. All the P
values were greater than 0.05. <br/>Conclusion(s): The TEE probe can be
used as an alternative method to guide IJV puncturing and catheterization
when the vascular probe is not available. It is feasible especially in
cardiac surgeries where the TEE monitoring machine is a must in modern
anesthesia and readily available than an ultrasound machine.<br/>Copyright
&#xa9; 2024 Annals of Cardiac Anaesthesia.

<79>
Accession Number
2033144843
Title
Continuous Positive Airway Pressure versus Differential Lung Ventilation
during One Lung Ventilation for Thoracic Surgery.
Source
Annals of Cardiac Anaesthesia. 27(3) (pp 235-240), 2024. Date of
Publication: 2024.
Author
Purayil A.P.; Nair S.G.; Abraham J.; Vazhakatt J.D.; Rajmohan N.; Shaji A.
Institution
(Purayil, Nair, Abraham, Vazhakatt, Rajmohan, Shaji) Department of
Anaesthesiology and Critical Care, Aster Medcity, Kuttisahib Road
Cheranalloor, South Chitoor, Kerala, Kochi, India
Publisher
Wolters Kluwer Medknow Publications
Abstract
Introduction: One lung ventilation (OLV) is a technique used during lung
resection surgery to facilitate optimal surgical conditions. However, this
may result in severe hypoxemia due to the right-to-left shunt created in
the collapsed lung. Several techniques are used to overcome hypoxemia, one
of which is continuous positive airway pressure (CPAP) to the
non-dependent lung. Another technique is ventilating the non-dependent
lung with a minimal volume, thus creating differential lung ventilation
(DLV) or split lung ventilation (SLV). In this study, we compared the
efficacy of CPAP to DLV during video-assisted thoracoscopic (VATS) lung
resection. <br/>Material(s) and Method(s): In this single-center
randomized controlled, cross-over study, each patient acted as his control
as well as the study. Patients crossed over from SLV to CPAP (or vice
versa) with an interval period during which only OLV was used (control
period). The primary objective of the study was to observe the changes in
oxygenation, ventilation, and the surgeons' perception of the surgical
field using CPAP or SLV to the non-ventilated lung during the period of
OLV in patients undergoing thoracic surgery. <br/>Result(s): The study
revealed that oxygenation was significantly better when using SLV to the
non-ventilated lung during the period of OLV (P = 0.03). However, the
surgeon found a significantly better surgical field when applying CPAP to
the surgical field. <br/>Conclusion(s): The study showed that using SLV to
the non-ventilated lung during the period of OLV was superior in terms of
oxygenation, although it interfered more with the surgical
field.<br/>Copyright &#xa9; 2024 Annals of Cardiac Anaesthesia.

<80>
Accession Number
2033144842
Title
Effects of Dexmedetomidine on Perioperative Glycemic Control in Adult
Diabetic Patients Undergoing Cardiac Surgery.
Source
Annals of Cardiac Anaesthesia. 27(3) (pp 228-234), 2024. Date of
Publication: 2024.
Author
Panidapu N.; Babu S.; Gadhinglajkar S.V.; Thomas D.; Aspari A.M.; Sen B.
Institution
(Panidapu, Sen) Department of Cardiac Anesthesia, Amrita Institute of
Medical Sciences, Kerala, Kochi, India
(Babu, Gadhinglajkar, Thomas, Aspari) Division of Cardiothoracic and
Vascular Anesthesia, Sree Chitra Tirunal Institute for Medical Sciences
and Technology, Kerala, Trivandrum, India
Publisher
Wolters Kluwer Medknow Publications
Abstract
Background and Objective: To study the effects of dexmedetomidine (DEX) on
perioperative blood glucose levels in adult diabetes mellitus (DM)
patients undergoing cardiac surgery. Methods and Material: A prospective,
observational study was conducted on 100 adult diabetic patients aged
between 18 and 75 years undergoing cardiac surgery with cardiopulmonary
bypass (CPB). The patients were divided into two groups (group D and group
C) of 50 each. Group D patients received DEX infusion, whereas the group C
patients received 0.9% normal saline infusion. <br/>Result(s): The blood
glucose levels, heart rate, mean arterial pressure, and serum potassium
levels at different time points were comparable between the two groups (P
> 0.05). The mean dose of insulin required in the combined population as
well as in both controlled and uncontrolled DM patients was significantly
less in group D than in group C (combined population - 36.03 +/- 22.71 vs
47.82 +/- 30.19 IU, P = 0.0297; uncontrolled DM - 37.36 +/- 23.9 IU vs
48.16 +/- 25.15 IU, P = 0.0301; controlled DM - 34.7 +/- 21.5 IU vs 47.63
+/- 35.25 IU, P = 0.0291). Duration of mechanical ventilation and VIS were
comparable between the two groups. The incidence of arrhythmias (20% vs
46%, P = 0.0059) and delirium (6% vs 20%, P = 0.0384) was significantly
less in group D than in group C. None of the patients in either group had
stroke, myocardial ischemia, and mortality. <br/>Conclusion(s): The
results suggested that DEX infusion during the intraoperative period was
very effective for perioperative glycemic control and reduction of insulin
requirement in DM patients undergoing cardiac surgery.<br/>Copyright
&#xa9; 2024 Annals of Cardiac Anaesthesia.

<81>
Accession Number
2033144838
Title
Effectiveness of Erector Spinae Plane Block as Perioperative Analgesia in
Midline Sternotomies: A Systematic Review and Meta-Analysis of Randomized
Controlled Trials.
Source
Annals of Cardiac Anaesthesia. 27(3) (pp 193-201), 2024. Date of
Publication: 2024.
Author
Patel N.; Fayed M.; Maroun W.; Milad H.; Adlaka K.; Schultz L.; Aiyer R.;
Forrest P.; Mitchell J.D.
Institution
(Patel) Department of Anesthesiology and Pain Medicine, Massachusetts
General Hospital, Boston, MA, United States
(Fayed) Department of Anesthesiology and Pain Medicine, Montefiore Medical
Center, Bronx, NY, United States
(Maroun, Schultz, Forrest, Mitchell) Department of Anesthesiology and Pain
Medicine, Henry Ford Health, Fullerton, Detroit, MI, United States
(Milad, Adlaka) Wayne State University, School of Medicine, Fullerton,
Detroit, MI, United States
(Aiyer) Westside Pain Management, Long Beach, CA, United States
Publisher
Wolters Kluwer Medknow Publications
Abstract
With the advancements in regional anesthesia and ultrasound techniques,
the use of non-neuraxial blocks like the erector spinae plane block (ESPB)
has been increasing in cardiac surgeries with promising outcomes. A total
of 3,264 articles were identified through a literature search.
Intervention was defined as ESPB. Comparators were no regional technique
performed or sham blocks. Four studies with a total of 226 patients were
included. Postoperative opioid consumption was lower in the group that
received ESPB than the group that did not (weighted mean difference [WMD]:
-204.08; 95% CI: -239.98 to -168.19; P < 0.00001). Intraoperative opioid
consumption did not differ between the two groups (WMD: -398.14; 95% CI:
-812.17 to 15.98; P = 0.06). Pain scores at 0 hours were lower in the
group that received ESPB than the group that did not (WMD: -1.27; 95% CI:
-1.99 to -0.56; P = 0.0005). Pain scores did not differ between the two
groups at 4-6 hours (WMD: -0.79; 95% CI: -1.70 to 0.13; P = 0.09) and 12
hours (WMD: -0.83; 95% CI: -1.82 to 0.16; P = 0.10). Duration of
mechanical ventilation in minutes was lower in the group that received
ESPB than the group that did not (WMD: -45.12; 95% CI: -68.82 to -21.43; P
= 0.0002). Given the limited number of studies and the substantial
heterogeneity of measured outcomes and interventions, further studies are
required to assess the benefit of ESPB in midline
sternotomies.<br/>Copyright &#xa9; 2024 Annals of Cardiac Anaesthesia.

<82>
Accession Number
2033144798
Title
Treat-to-target or high-intensity statin treatment in older adults with
coronary artery disease: A post hoc analysis of the LODESTAR trial.
Source
Age and Ageing. 53(7) (no pagination), 2024. Article Number: afae132. Date
of Publication: 01 Jul 2024.
Author
Lee S.-J.; Lee J.-B.; Yang T.-H.; Kang W.C.; Lee J.-Y.; Lee Y.-J.; Hong
S.-J.; Ahn C.-M.; Kim J.-S.; Kim B.-K.; Ko Y.-G.; Hong B.-K.; Choi D.;
Yoon J.; Jang Y.; Hong M.-K.; Kwon H.M.; Kim J.-Y.; Min P.K.; Yoon Y.W.;
Lee B.K.; Rim S.-J.; Choi E.-Y.; Oh P.C.; Kim K.S.; Choi J.Y.; Ryu J.K.;
Kim C.Y.; Cho H.-J.; Ahn M.-S.; Ahn S.G.; Lee J.-W.; Son J.-W.; Yoon
H.-J.; Lee C.H.; Hwang J.; Cho Y.-K.; Hur S.-H.; Han S.; Nam C.-W.; Kim
H.; Park H.-S.; Kim I.-C.; Cho Y.-H.; Jeong H.-J.; Kim J.-H.; Lim C.; Suh
Y.; Hwang E.S.; Lee J.H.; Lee S.Y.; Kwon S.U.; Kim S.-Y.; Park K.-H.; Kim
H.K.
Institution
(Lee, Lee, Hong, Ahn, Kim, Kim, Ko, Choi, Hong) Severance Hospital, Yonsei
University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722,
South Korea
(Lee) Daegu Catholic University Medical Center, Duryugongwon-ro 17-gil,
Nam-gu, Daegu 42472, South Korea
(Yang) Inje University Busan Paik Hospital, Bokji-ro 75, Busanjin-gu,
Busan 47392, South Korea
(Kang) Gachon University College of Medicine, Namdong-daero 774 beon-gil,
Namdong-gu, Incheon 21565, South Korea
(Lee) Kangbuk Samsung Hospital, Sungkyunkwan University School of
Medicine, Saemunan-ro, Jongno-gu, Seoul 03181, South Korea
(Hong) Gangnam Severance Hospital, Eonju-ro, Gangnam-gu, Seoul 06273,
South Korea
(Yoon) Wonju Severance Christian Hospital, Ilsan-ro, Wonju 26426, South
Korea
(Jang) CHA University College of Medicine, Yatap-ro, Bundang-gu, Seongnam
13497, South Korea
Publisher
Oxford University Press
Abstract
Background: The optimal statin treatment strategy that is balanced for
both efficacy and safety has not been clearly determined in older adults
with coronary artery disease (CAD). <br/>Method(s): In the post hoc
analysis of the LODESTAR (low-density lipoprotein cholesterol-targeting
statin therapy versus intensity-based statin therapy in patients with
coronary artery disease) trial, the impact between a treat-to-target
strategy versus a high-intensity statin therapy strategy was compared in
older adults (aged 75 years or older). The goal of treat-to-target
low-density lipoprotein cholesterol (LDL-C) level was 50-70 mg/dl. The
primary endpoint comprised the three-year composite of all-cause death,
myocardial infarction, stroke or coronary revascularisation.
<br/>Result(s): Among 4, 400 patients with CAD enrolled in the LODESTAR
trial, 822 (18.7%) were aged 75 years or older. Poor clinical outcomes and
risk factors for atherosclerosis were more frequently observed in older
adults than in younger population (<75 years old). Among these older
adults with CAD, the prescription rate of high-intensity statin was
significantly lower in the treat-to-target strategy group throughout the
study period (P < 0.001). The mean LDL-C level for three years was 65 +/-
16 mg/dl in the treat-to-target strategy group and 64 +/- 18 mg/dl in the
high-intensity statin group (P = 0.34). The incidence of primary endpoint
occurrence was 10.9% in the treat-to-target strategy group and 12.0% in
the high-intensity statin group (hazard ratio 0.92, 95% confidence
interval 0.61-1.38, P = 0.69). <br/>Conclusion(s): High-intensity statin
therapy is theoretically more necessary in older adults because of worse
clinical outcomes and greater number of risk factors for atherosclerosis.
However, the primary endpoint occurrence with a treat-to-target strategy
with an LDL-C goal of 50-70 mg/dl was comparable to that of high-intensity
statin therapy and reduced utilisation of a high-intensity statin. Taking
efficacy as well as safety into account, adopting a tailored approach may
be considered for this high-risk population. Trial Registration:
ClinicalTrials.gov, NCT02579499.<br/>Copyright &#xa9; 2024 The Author(s).
Published by Oxford University Press on behalf of the British Geriatrics
Society. All rights reserved.

<83>
Accession Number
2033142624
Title
Comparative Profiles of the WATCHMANTM and AmplatzerTM Cardiac
Plug/AmplatzerTM AmuletTM Devices for Left Atrial Appendage Closure in
Non-valvular Atrial Fibrillation: A Comprehensive Systematic Review and
Meta-analysis.
Source
Journal of Innovations in Cardiac Rhythm Management. 15(6) (pp 5917-5929),
2024. Date of Publication: June 2024.
Author
Raja F.; Rani K.; Kumar S.; Someshwar F.; Khan M.A.N.; Abubakar F.; Bhatt
D.; Subedi D.J.; Shadmani S.; Abdullah F.T.Z.
Institution
(Raja) Department of Internal Medicine, Federal Medical and Dental
College, Islamabad, Pakistan
(Rani) Department of Internal Medicine, Chandka Medical College SMBBMU,
Larkana, Pakistan
(Kumar, Someshwar) Department of Internal Medicine, Liaquat National
Hospital and Medical College, Karachi, Pakistan
(Khan, Abubakar) Department of Internal Medicine, King Edward Medical
University, Lahore, Pakistan
(Bhatt) Department of Internal Medicine, American University of Barbados,
Bridgetown, Barbados
(Subedi) Department of Internal Medicine, College of Medical Sciences,
Bharatpur, Nepal
(Shadmani) Department of Internal Medicine, Shaheed Mohtarma Benazir
Bhutto Medical College, Karachi, Pakistan
(Abdullah) Department of Internal Medicine, Allama Iqbal Medical College,
Lahore, Pakistan
Publisher
MediaSphere Medical LLC
Abstract
Atrial fibrillation (AF) is a prevalent cardiac arrhythmia marked by
irregular and frequent tachycardic rhythms in the atria, affecting 1%-2%
of the general population. The WATCHMANTM device from Boston Scientific
(Marlborough, MA, USA) and the AmplatzerTM AmuletTM device from Abbott
(Chicago, IL, USA) are two devices used globally for left atrial appendage
closure (LAAC) in non-valvular AF. A systematic search was conducted in
PubMed, the Cochrane Library, and Elsevier's ScienceDirect literature
databases to identify studies comparing the WATCHMANTM procedure with
AmuletTM device implantation for LAAC in patients with AF. The analyses
were conducted using the random-effects model. A total of 20 studies were
identified, with 18 falling into the category of observational studies and
2 being randomized controlled trials. A total of 6310 participants were
included in this meta-analysis, with 3198 individuals (50.68%) assigned to
the WATCHMANTM procedure group and 3112 individuals (49.32%) allocated to
the AmplatzerTM Cardiac Plug (ACP) group. The analysis revealed a higher
risk of stroke associated with the WATCHMANTM technique (relative risk
[RR], 1.14), albeit without statistical significance. Conversely, the
WATCHMANTM approach led to a significantly lower risk of cardiac death
(RR, 0.44; P = .04). Notably, the risks of all-cause mortality (RR, 0.89;
95% confidence interval [CI], 0.73-1.08; I² = 0%; P = .25) and
major bleeding (RR, 0.93; 95% CI, 0.65-1.33; I² = 31%; P = .70)
were clinically reduced with the WATCHMANTM procedure, although
statistical significance was not achieved. Compared to AmuletTM device
implantation, WATCHMANTM device implantation decreased the risk of cardiac
mortality, while the risks of stroke, systemic embolism, all-cause
mortality, and major bleeding were not statistically
significant.<br/>Copyright &#xa9; 2024 Innovations in Cardiac Rhythm
Management.

<84>
Accession Number
644630038
Title
Intravascular lithotripsy in peripheral lesions with severe calcification
and its use in TAVI procedure - A meta-analysis.
Source
Vasa - European Journal of Vascular Medicine. 53(4) (pp 263-274), 2024.
Date of Publication: 01 Jul 2024.
Author
Sagris M.; Ktenopoulos N.; Soulaidopoulos S.; Dimitriadis K.; Papanikolaou
A.; Tzoumas A.; Terentes-Printzios D.; Lichtenberg M.; Korosoglou G.;
Toutouzas K.; Honton B.; Tousoulis D.; Tsioufis K.
Institution
(Sagris, Ktenopoulos, Soulaidopoulos, Dimitriadis, Papanikolaou,
Terentes-Printzios, Toutouzas, Tousoulis, Tsioufis) First Cardiology
Department, Hippokration General Hospital, National and Kapodistrian
University of Athens, School of Medicine, Athens, Greece
(Tzoumas) Department of Internal Medicine, University of Cincinnati
Medical Center, Cincinnati, OH, United States
(Lichtenberg) Vascular Center Arnsberg, Germany
(Korosoglou) Department of Cardiology, Vascular Medicine and Pneumology,
GRN Hospital, Weinheim, Germany
(Honton) Department of Interventional Cardiology, Clinique Pasteur,
Toulouse, France
Publisher
Hogrefe Verlag GmbH & Co. KG
Abstract
Background: Heavily calcified peripheral artery lesions increase the risk
of vascular complications, constituting a severe challenge for the
operator during catheter-based cardiovascular interventions. Intravascular
Lithotripsy (IVL) technology disrupts subendothelial calcification by
using localized pulsative sonic pressure waves and represents a promising
technique for plaque modification in patients with severe calcification in
peripheral arteries. <br/>Purpose(s): Our aim was to systematically review
and summarize available data regarding the safety and efficacy of IVL in
preparing severely calcified peripheral arteries and its use in
Transcatheter Aortic Valve Implantation (TAVI). <br/>Patients and Methods:
This study was conducted according to the PRISMA guidelines. We
systematically searched PubMed, SCOPUS, and Cochrane databases from their
inception to February 23, 2023, for studies assessing the characteristics
and outcomes of patients undergoing IVL in the peripheral vasculature. The
diameter of the vessel lumen before and after IVL was estimated. The
occurrence of peri-procedural complications was assessed using a
random-effects model. <br/>Result(s): 20 studies with a total of 1,223
patients with heavily calcified peripheral lesions were analysed. The mean
age of the cohort was 70.6 +/- 17.4 years. Successful IVL delivery
achieved in 100% (95% CI: 100%-100%, I² = 0%), with an increase
in the luminal diameter (SMD: 4.66, 95% CI: 3.41- 5.92, I² =
90.8%) and reduction in diameter stenosis (SMD: -4.15, 95% CI: -4.75 to
-3.55, I² = 92.8%), and a concomitant low rate of
complications. The procedure was free from dissection in 97% (95% CI:
91%-100%, I² = 81.4%) while dissections of any type (A, B, C,
or D) were observed in 6% (95% CI: 2%-10%, I² = 85.3%) of the
patients. Several rare cases of abrupt closure, no-reflow phenomenon,
perforation, thrombus formation, and distal embolization were recorded.
Finally, the subgroup analysis of patients who underwent a TAVI with IVL
assistance presented successful implantation in 100% (95% CI: 100%-100%,
I² = 0%) of the cases, with only 4% (95% CI: 0%-12%,
I² = 68.96%) presenting dissections of any sort.
<br/>Conclusion(s): IVL seems to be an effective and safe technique for
modifying severely calcified lesions in peripheral arteries and it is a
promising modality in TAVI settings. Future prospective studies are needed
to validate our results.<br/>Copyright &#xa9; 2024 Hogrefe.

<85>
Accession Number
2033198972
Title
Transcatheter Aortic Valve Replacement in Low Surgical Risk Patients: An
Updated Metanalysis of Extended Follow-Up Randomized Controlled Trials.
Source
American Journal of Cardiology. 224 (pp 56-64), 2024. Date of Publication:
01 Aug 2024.
Author
Di Pietro G.; Improta R.; De Filippo O.; Bruno F.; Birtolo L.I.; Tocci M.;
Fabris T.; Saade W.; Colantonio R.; Celli P.; Sardella G.; Esposito G.;
Tarantini G.; Mancone M.; D'Ascenzo F.
Institution
(Di Pietro, Improta, Birtolo, Tocci, Saade, Colantonio, Sardella, Mancone)
Department of Clinical, Internal, Anesthesiology and Cardiovascular
Sciences, Umberto I Hospital, Sapienza University of Rome, Italy
(Di Pietro, Improta, De Filippo, Bruno, D'Ascenzo) Department of Medical
Science, Division of Cardiology, Molinette Hospital, Turin University,
Italy
(Fabris, Tarantini) Department of Cardiac, Thoracic and Vascular Sciences
and Public Health, University of Padova, Italy
(Celli) Department of General and Specialistic Surgery "Paride Stefanini",
"Sapienza" University of Rome, Rome, Italy
(Esposito) Division of Cardiology, Department of Advanced Biomedical
Sciences, Federico II University of Naples, Naples, Italy
Publisher
Elsevier Inc.
Abstract
The long-term safety and effectiveness of transcatheter aortic valve
replacement (TAVR) compared with surgical aortic valve replacement (SAVR)
in low surgical risk has not been evaluated in a pooled analysis. An
electronic database search was conducted for randomized controlled trials
with a maximal 5 years clinical and echocardiographic follow-up including
low surgical risk patients who underwent TAVR or SAVR. We calculated odds
ratio (OR) and 95% confidence intervals (CIs) using a random-effects
model. Subgroups analysis was performed for permanent pacemaker
implantation and paravalvular leaks. Three randomized controlled trials
were included with a total of 2,611 low surgical risk patients (Society of
Thoracic Surgeons score <4%). Compared with SAVR, the TAVR group had
similar rates of all-cause mortality (OR 0.94,95% CI 0.65 to 1.37, p =
0.75) and disabling stroke (OR 0.84, 95% CI 0.52 to 1.36, p = 0.48). No
significant differences were registered in the TAVR group in terms of
major cardiovascular events (OR 0.96, 95% CI 0.67 to 1.38, p = 0.83),
myocardial infarction (OR 0.69, 95% CI 0.34 to 1.40, p = 0.31), valve
thrombosis (OR 3.11, 95% CI 0.29 to 33.47, p = 0.35), endocarditis (OR
0.71,95% CI 0.35 to 1.48, p = 0.36), aortic valve reintervention (OR 0.93,
95% CI 0.52 to 1.66, p = 0.80), and rehospitalization (OR 0.80, 95% CI
0.52 to 1.02, p = 0.07) compared with SAVR. However, TAVR patients had a
higher risk of paravalvular leaks (OR 8.21, 95% CI 4.18 to 16.14, p
<0.00001), but lower rates of new-onset atrial fibrillation (OR 0.27,95%
CI 0.17 to 0.30, p <0.0001). The rates of permanent pacemaker implantation
were comparable from 1 year up to a maximum of 5 years (OR 1.32, 95% CI
0.88 to 1.97, p = 0.18). Lastly, TAVR had a greater effective orifice area
(0.10 cm²/m², 95% CI 0.05 to 0.15, p = 0.0001), but
similar transvalvular mean gradients (0.60, 95% CI 3.94 to 2.73, p =
0.72). In conclusion, TAVR patients had similar long-term outcomes
compared with SAVR, except for an elevated risk of paravalvular leaks in
the TAVR group and increased rates of atrial fibrillation in the SAVR
cohort.<br/>Copyright &#xa9; 2024 Elsevier Inc.

<86>
Accession Number
2033182878
Title
Cardiovascular disease in adults with a history of out-of-home care during
childhood: a systematic review and meta-analysis of prospective cohort
studies.
Source
The Lancet Regional Health - Europe. 43 (no pagination), 2024. Article
Number: 100984. Date of Publication: August 2024.
Author
Batty G.D.; Kivimaki M.; Almquist Y.B.; Eriksson J.G.; Gissler M.;
Gnanamanickam E.S.; Hamer M.; Jackisch J.; Juon H.-S.; Keski-Santti M.; Li
C.; Mikkola T.M.; Murray E.; Sacker A.; Segal L.; Frank P.
Institution
(Batty, Murray, Sacker, Frank) Department of Epidemiology and Public
Health, University College London, London, United Kingdom
(Kivimaki, Frank) Brain Sciences, University College London, London,
United Kingdom
(Kivimaki, Mikkola) Clinicum, Faculty of Medicine, University of Helsinki,
Helsinki, Finland
(Almquist, Jackisch) Centre for Health Equity Studies, Stockholm
University, Stockholm, Sweden
(Eriksson) Singapore Institute for Clinical Sciences, Singapore
(Eriksson) Department of Obstetrics & Gynaecology and Human Potential
Translational Research Programme, National University of Singapore,
Singapore
(Eriksson, Mikkola) Folkhalsan Research Center, Helsinki, Finland
(Eriksson) Department of General Practice and Primary Health Care,
University of Helsinki, Helsinki, Finland
(Gissler, Keski-Santti) Department of Knowledge Brokers, Finnish Institute
for Health and Welfare, Helsinki, Finland
(Gissler) Academic Primary Health Care Centre, Region Stockholm, Sweden
(Gissler) Department of Molecular Medicine and Surgery, Karolinska
Institutet, Stockholm, Sweden
(Gnanamanickam, Segal) Health Economics and Social Policy Group, Allied
Health & Human Performance, University of South Australia, Adelaide,
Australia
(Hamer) Division of Surgery Interventional Science, University College
London, London, United Kingdom
(Juon) Department of Medical Oncology, Thomas Jefferson University,
Philadelphia, United States
(Li) Department of Epidemiology and Biostatistics, Peking University
Health Science Center, Peking, China
(Mikkola) Population Health Unit, Finnish Institute for Health and
Welfare, Helsinki, Finland
(Murray) Institute of Public Health and Wellbeing, University of Essex,
Colchester, United Kingdom
Publisher
Elsevier Ltd
Abstract
Background: While individuals who were separated from their biological
family and placed into the care of the state during childhood (out-of-home
care) are more prone to developing selected adverse health problems in
adulthood, their risk of cardiovascular disease is uncertain. Our aim was
to explore this association by pooling published and unpublished results
from prospective cohort studies. <br/>Method(s): We used two approaches to
identifying relevant data on childhood care and adult cardiovascular
disease (PROSPERO registration CRD42021254665). First, to locate published
studies, we searched PubMed (Medline) until November 2023. Second, with
the objective of identifying unpublished studies with the potential to
address the present research question, we scrutinised retrieved reviews on
childhood out-of-home care and other adult health outcomes. Included
studies were required to satisfy three criteria: a cohort study in which
the assessment of care was made prospectively pre-adulthood (in the
avoidance of recall bias); data on an unexposed comparator group were
available (for the computation of relative risk); and a diagnosis of adult
cardiovascular disease events (coronary heart disease, stroke, or their
combination) had been made (as opposed to risk factors only).
Collaborating investigators provided study-specific estimates which were
aggregated using random-effects meta-analysis. The Newcastle-Ottawa Scale
was used to assess individual study quality. <br/>Finding(s): Twelve
studies (2 published, 10 unpublished) met the inclusion criteria, and
investigators from nine provided viable results, including updated
analyses of the published studies. Studies comprised 611,601 individuals
(301,129 women) from the US, UK, Sweden, Finland, and Australia. Five of
the nine studies were judged to be of higher methodological quality.
Relative to the unexposed, individuals with a care placement during
childhood had a 51% greater risk of cardiovascular disease in adulthood
(summary rate ratio after age- and sex-adjustment [95% confidence
interval]: 1.51 [1.22, 1.86]; range of study-specific estimates: 1.07 to
2.06; I² = 69%, p = 0.001). This association was attenuated but
persisted after adjustment for socioeconomic status in childhood (8
studies; 1.41 [1.15, 1.72]) and adulthood (9 studies, 1.29 [1.11, 1.51]).
<br/>Interpretation(s): Our findings show that individuals with experience
of out-of-home care in childhood have a moderately raised risk of
cardiovascular disease in adulthood. <br/>Funding(s):Medical Research
Council;National Institute on Aging;Wellcome Trust.<br/>Copyright &#xa9;
2024 The Author(s)

<87>
Accession Number
644701847
Title
Perioperative Transcutaneous Electrical Acupoint Stimulation Reduces
Postoperative Pain in Patients Undergoing Thoracoscopic Surgery: A
Randomized Controlled Trial.
Source
Pain research & management. 2024 (pp 5365456), 2024. Date of Publication:
2024.
Author
Liu J.; Zhang K.; Zhang Y.; Ji F.; Shi H.; Lou Y.; Xu H.
Institution
(Liu, Zhang, Zhang, Ji, Shi, Lou, Xu) Department of Anesthesiology Yueyang
Hospital of Integrated Traditional Chinese and Western Medicine Shanghai
University of Traditional Chinese Medicine, Shanghai 200437, China
(Liu) Department of Anesthesiology Pulmonary Hospital Tongji University,
Shanghai 200433, China
Abstract
Objectives: This study aimed to determine the effects of perioperative
transcutaneous electrical acupoint stimulation (TEAS) on postoperative
pain management in patients undergoing thoracic surgery. <br/>Method(s):
In the prospective, randomized, controlled study, a total of 84 patients
undergoing video-assisted thoracoscopic surgery (VATS) were randomly
allocated to the TEAS group (Group T) or control group (Group C). Patients
in the Group T received TEAS at Neiguan (PC6) and Hegu (LI4) acupoints for
30min before anesthesia induction and 30 min after thoracoscopic surgery.
Patients in the Group C received the same placement of electrodes but
without electrical stimulation. The numeric rating scale (NRS) pain score,
remifentanil consumption, demand for rescue analgesics and incidence of
postoperative nausea and vomiting (PONV), patient satisfaction, and the
levels of plasma beta-endorphin (EP) and IL-6 were recorded.
<br/>Result(s): Patients in the Group T had significantly lower NRS pain
scores at 6h, 12h, 24h, and 48h after surgery than those in the Group C.
Compared with Group C, patients in Group T had lower remifentanil
consumption during operation, lower demand for rescue analgesics and lower
rate of PONV within 24 h after surgery. Patients in Group T also had lower
IL-6 content, higher beta-EP content and higher satisfaction degree than
those in the Group C. <br/>Conclusion(s): Perioperative TEAS significantly
decreased postoperative pain and rescued analgesia requirements and the
incidence of PONV in patients undergoing thoracoscopic surgery, with a
higher patient satisfaction. This trial is registered with
ChiCTR2100051841.<br/>Copyright &#xa9; 2024 Jianming Liu et al.

<88>
Accession Number
2033208584
Title
Use of Intravenous Albumin: A Guideline From the International
Collaboration for Transfusion Medicine Guidelines.
Source
Chest. (no pagination), 2024. Date of Publication: 2024.
Author
Callum J.; Skubas N.J.; Bathla A.; Keshavarz H.; Clark E.G.; Rochwerg B.;
Fergusson D.; Arbous S.; Bauer S.R.; China L.; Fung M.; Jug R.; Neill M.;
Paine C.; Pavenski K.; Shah P.S.; Robinson S.; Shan H.; Szczepiorkowski
Z.M.; Thevenot T.; Wu B.; Stanworth S.; Shehata N.; Flores J.; Frappier
S.; Hou Y.; Jean-Pierre L.; Jomaa D.; Kabir M.; Kadota L.; Lam M.; Ripsman
D.A.; Sandarage R.; Staykov E.; Venes A.; Wan M.; Al Riyami A.; Allard S.;
Brouwers M.; Daly J.; Denomme G.A.; Estcourt L.; Green L.; Greinacher A.;
Hume H.; Kaufman R.; Kim H.; Louw V.; Matsushita T.; Murphy M.; Pink J.;
So-Osman C.; Tobian A.; Wood E.
Institution
(Callum) Department of Pathology and Molecular Medicine, Queen's
University and Kingston Health Sciences Centre, Kingston, ON, Canada
(Clark) Division of Nephrology, University of Ottawa, Ottawa Hospital
Research Institute, Ottawa, ON, Canada
(Fergusson) Department of Medicine, University of Ottawa, Ottawa Hospital
Research Institute, Ottawa, ON, Canada
(Rochwerg) Department of Medicine and Department of Health Research
Methods, Evidence and Impact, Faculty of Health Sciences, McMaster
University, Hamilton, ON, Canada
(Pavenski) Department of Laboratory Medicine and Pathobiology, Mount Sinai
Hospital, Toronto, ON, Canada
(Shah) Institute of Health Policy, Management, and Evaluation, Mount Sinai
Hospital, Toronto, ON, Canada
(Shehata) Department of Medicine, University of Toronto, Mount Sinai
Hospital, Toronto, ON, Canada
(Shah) Department of Pediatrics, Mount Sinai Hospital, Toronto, ON, Canada
(Shehata) Transfusion Medicine Laboratory, Mount Sinai Hospital, Toronto,
ON, Canada
(Bathla, Keshavarz) Canadian Blood Services, Ottawa, ON, Canada
(Skubas) Department of Cardiothoracic Anesthesiology, Anesthesiology
Institute, Cleveland Clinic Lerner College of Medicine of Case Western
Reserve University, Cleveland, OH, United States
(Bauer) Department of Pharmacy, Cleveland Clinic, Cleveland, OH, United
States
(Jug) University of Cincinnati College of Medicine, Cincinnati, OH, United
States
(Fung) Department of Pathology and Laboratory Medicine, University of
Vermont Medical Center, Burlington, VT, United States
(Shan) Department of Pathology, Stanford University School of Medicine,
Palo Alto, CA, United States
(Wu) Department of Internal Medicine, Graduate Medical Education, Loma
Linda University, Loma Linda, CA, United States
(Szczepiorkowski) Department of Pathology and Laboratory Medicine,
Dartmouth-Hitchcock Medical Center, NH, Lebanon
(Paine) Division of Nephrology, Department of Medicine, University of
Washington, Seattle, WA, United States
(Arbous) Department of Critical Care, Leiden University Medical Center,
Leiden, Netherlands
(China) Department of Hepatology and Institute for Liver and Digestive
Health, The Royal Free NHS Trust and University College London, London,
United Kingdom
(Robinson) Department of Clinical Haematology, Guy's and St Thomas' NHS
Foundation Trust, London, United Kingdom
(Stanworth) NHS Blood and Transplant, Oxford, United Kingdom
(Stanworth) Radcliffe Department of Medicine, University of Oxford,
Oxford, United Kingdom
(Stanworth) John Radcliffe Hospital, Oxford University Hospitals NHS
Foundation Trust, Oxford, United Kingdom
(Thevenot) Service d'Hepatologie, Centre Hospitalier Regional et
Universitaire de Besancon, Besancon, France
(Neill) Patient representative
(Flores) University Health Network, Toronto, Canada
(Frappier) University of Ottawa, Ottawa, Canada
(Hou) Trillium Health Partners, Canada
(Jean-Pierre) Carleton University, Canada
(Jomaa) School of Medicine, Queen's University, Kingston, Canada
(Kabir) Bruyere Research Institute, Ottawa, Canada
(Kadota, Sandarage) Faculty of Medicine, University of British Columbia,
Canada
(Lam) CHEO ED SUPPORT Program, Carleton University, Canada
(Ripsman) Department of Neurology, Faculty of Medicine, University of
British Columbia, Canada
(Staykov) Michael G. DeGroote School of Medicine, Hamilton, Canada
(Venes) Department of Biochemistry, Microbiology and Immunology,
University of Ottawa, Ottawa, Canada
(Wan) Department of Family Medicine, Queen's University, Kingston, Canada
(Al Riyami) Sultan Qaboos University Hospital, Oman
(Allard, Green) National Health Service Blood & Transplant, United Kingdom
(Brouwers) University of Ottawa, Canada
(Callum) Sunnybrook Health Sciences Centre and University of Toronto,
Canada
(Daly, Pink) Australian Red Cross Lifeblood, Australia
(Denomme) Versiti Blood Centre of Wisconsin, United States
(Estcourt) National Health Services Blood & Transplant, United Kingdom
(Fergusson) Ottawa Hospital Research Institute, Canada
(Fung) University of Vermont Medical Center, United States
(Greinacher) University of Greifswald, Germany
(Hume) University of Montreal, Canada
(Jug) Canadian Blood Services, Canada
(Kaufman) Brigham & Woman's Hospital Adult Transfusion Service, United
States
(Kim) Seoul National University Hospital, South Korea
(Louw) Groote Schuur Hospital, University of Cape Town, South Africa
(Matsushita) Nagoya University Hospital, Japan
(Murphy) University of Oxford and National Health Service Blood &
Transplant, United Kingdom
(Robinson) Guy's and St. Thomas' NHS Foundation Trust, United Kingdom
(So-Osman) Sanquin and Erasmus Medical Center, Netherlands
(Stanworth) NHS Blood and Transplant and Oxford University, United Kingdom
(Szczepiorkowski) Dartmouth-Hitchcock Medical Center, United States
(Tobian) Johns Hopkins University, United States
(Wood) Monash University, Australia
Publisher
Elsevier Inc.
Abstract
Background: Albumin is used commonly across a wide range of clinical
settings to improve hemodynamics, to facilitate fluid removal, and to
manage complications of cirrhosis. The International Collaboration for
Transfusion Medicine Guidelines developed guidelines for the use of
albumin in patients requiring critical care, undergoing cardiovascular
surgery, undergoing kidney replacement therapy, or experiencing
complications of cirrhosis. Study Design and Methods: Cochairs oversaw the
guideline development process and the panel included researchers,
clinicians, methodologists, and a patient representative. The evidence
informing this guideline arises from a systematic review of randomized
clinical trials and systematic reviews, in which multiple databases were
searched (inception through November 23, 2022). The panel reviewed the
data and formulated the guideline recommendations using Grading of
Recommendations Assessment, Development, and Evaluation methodology. The
guidelines were revised after public consultation. <br/>Result(s): The
panel made 14 recommendations on albumin use in adult critical care (three
recommendations), pediatric critical care (one recommendation), neonatal
critical care (two recommendations), cardiovascular surgery (two
recommendations), kidney replacement therapy (one recommendation), and
complications of cirrhosis (five recommendations). Of the 14
recommendations, two recommendations had moderate certainty of evidence,
five recommendations had low certainty of evidence, and seven
recommendations had very low certainty of evidence. Two of the 14
recommendations suggested conditional use of albumin for patients with
cirrhosis undergoing large-volume paracentesis or with spontaneous
bacterial peritonitis. Twelve of 14 recommendations did not suggest
albumin use in a wide variety of clinical situations where albumin
commonly is transfused. <br/>Interpretation(s): Currently, few
evidence-based indications support the routine use of albumin in clinical
practice to improve patient outcomes. These guidelines provide clinicians
with actionable recommendations on the use of albumin.<br/>Copyright
&#xa9; 2024 The Author(s)

<89>
Accession Number
2033192303
Title
Outcomes and Safety of Transcaval Transcatheter Aortic Valve Replacement:
A Systematic Review and Meta-analysis.
Source
Canadian Journal of Cardiology. (no pagination), 2024. Date of
Publication: 2024.
Author
Salihu A.; Ferlay C.; Kirsch M.; Shah P.B.; Skali H.; Fournier S.; Meier
D.; Muller O.; Hugelshofer S.; Skalidis I.; Tzimas G.; Monney P.; Eeckhout
E.; Arangalage D.; Rancati V.; Antiochos P.; Lu H.
Institution
(Salihu, Ferlay, Fournier, Meier, Muller, Hugelshofer, Skalidis, Tzimas,
Monney, Eeckhout, Arangalage, Antiochos, Lu) Division of Cardiology,
Lausanne University Hospital and University of Lausanne, Lausanne,
Switzerland
(Ferlay) Adult Intensive Care Unit, Lausanne University Hospital and
University of Lausanne, Lausanne, Switzerland
(Ferlay, Kirsch) Division of Cardiac Surgery, Lausanne University Hospital
and University of Lausanne, Lausanne, Switzerland
(Shah, Skali, Lu) Division of Cardiovascular Medicine, Brigham and Women's
Hospital, Harvard Medical School, Boston, MA, United States
(Arangalage) Cardiology Department, AP-HP, Bichat Hospital and Universite
de Paris, Paris, France
(Rancati) Division of Anaesthesiology, Lausanne University Hospital and
University of Lausanne, Lausanne, Switzerland
Publisher
Elsevier Inc.
Abstract
Background: The transcaval (TCv) vascular approach is increasingly used in
transcatheter aortic valve replacement (TAVR) in patients unsuitable for
the gold-standard transfemoral approach. We aimed to evaluate the
efficacy, safety, and clinical outcomes associated with TCv-TAVR.
<br/>Method(s): A systematic review and meta-analysis was conducted by
searching PubMed/Medline, Embase, and the Cochrane Library for all
articles assessing the TCv approach published through December 2023.
Outcomes included 30-day and 1-year all-cause mortality (ACM), 30-day
rehospitalisation, perioperative complications and postoperative
complications at 30 days. The meta-analysis was registered on the PROSPERO
database with the identifier CRD42024501921. <br/>Result(s): A total of 8
studies with 467 patients were included. TCv-TAVR procedures achieved a
success rate of 98.5%. TCv-TAVR was associated with a 30-day ACM rate of
6.1% (95% confidence interval [CI]: 3.9%-8.2%), a 1-year ACM rate of 14.9%
(95% CI 2.3%-27.6%) and a 30-day rehospitalisation rate of 4.2% (95% CI
-2.2% to 10.6%). Postoperative stroke or transient ischemic attack, major
vascular complications, and major or life-threatening bleeding occurred in
3.3%, 8.7%, and 7.5% of cases, respectively. Cumulative meta-analyses
showed a temporal trend of decreasing rates of vascular complications.
<br/>Conclusion(s): The TCv approach in TAVR demonstrated a reassuring
efficacy and safety profile, with mortality and postoperative complication
rates similar to those reported for supra-aortic alternative TAVR access
routes. The temporal decrease in vascular complications suggests potential
improvements in procedural techniques and device technology. These
findings further support the TCv approach as a viable option in patients
ineligible for the transfemoral access. PROSPERO:
CRD42024501921<br/>Copyright &#xa9; 2024 The Authors

<90>
Accession Number
644699570
Title
Platelet inhibitor withdrawal and outcomes after coronary artery surgery:
an individual patient data meta-analysis.
Source
European journal of cardio-thoracic surgery : official journal of the
European Association for Cardio-thoracic Surgery. (no pagination), 2024.
Date of Publication: 05 Jul 2024.
Author
Schoerghuber M.; Kuenzer T.; Biancari F.; Dalen M.; Hansson E.C.; Jeppsson
A.; Schlachtenberger G.; Siegemund M.; Voetsch A.; Pregartner G.; Lindenau
I.; Zimpfer D.; Berghold A.; Mahla E.; Zirlik A.
Institution
(Schoerghuber, Mahla) Division of Anaesthesiology and Intensive Care
Medicine 2, Medical University of Graz, Graz, Austria
(Kuenzer, Pregartner, Berghold) Institute for Medical Informatics,
Statistics and Documentation, Medical University of Graz, Graz, Austria
(Biancari) Department of Internal Medicine, South-Karelia Central
Hospital, University of Helsinki, Lappeenranta, Finland
(Dalen) Department of Cardiac surgery, Karolinska University Hospital,
Sweden
(Dalen) Department of Molecular medicine and surgery, Karolinska
Institutet, Sweden
(Hansson, Jeppsson) Department of Molecular and Clinical Medicine,
Institute of Medicine, Sahlgrenska Academy, University of Gothenburg,
Gothenburg, Sweden
(Hansson, Jeppsson) Department of Cardiothoracic Surgery, Sahlgrenska
University Hospital, Gothenburg, Sweden
(Schlachtenberger) Department of Cardiothoracic Surgery, University
Hospital of Cologne, Cologne, Germany
(Siegemund) Intensive Care Medicine, Department of Acute Medicine,
University Hospital Basel, Basel, Switzerland
(Siegemund) Department of Clinical Research, University of Basel, Basel,
Switzerland
(Voetsch) Department of Cardiovascular and Endovascular Surgery,
Paracelsus Medical University, Salzburg, Austria
(Lindenau) Department of Anaesthesiology and Intensive Care Medicine,
Hospital Oberwart, Oberwart, Austria
(Zimpfer) University Heart Center Graz, Division of Cardiac Surgery,
Medical University of Graz, Graz, Austria
(Zirlik) University Heart Center Graz, Division of Cardiology, Medical
University of Graz, Graz, Austria
Abstract
OBJECTIVE: To evaluate the association between guideline-conforming as
compared to shorter than recommended withdrawal period of P2Y12 receptor
inhibitors prior to isolated on-pump coronary artery bypass grafting
(CABG) and the incidence of severe bleeding and ischemic events.
Randomized controlled trials are lacking in this field. <br/>METHOD(S): We
searched PUBMED, Embase and other suitable databases for studies including
patients on P2Y12 receptor inhibitors undergoing isolated CABG and
reporting bleeding and postoperative ischemic events from 2013 to March
2024. The primary outcome was incidence of Bleeding Academic Research
Consortium type 4 (BARC-4) bleeding defined as any of the following:
perioperative intracranial bleeding, reoperation for bleeding, transfusion
of>=5 units of red blood cells, chest tube output of>=2 liters. The
secondary outcome were postoperative ischemic events according to the
Academic Research Consortium 2 Consensus Document. Patient-level data
provided by each observational trial were synthesized into a single
dataset and analyzed using a two-stage IPD-MA. <br/>RESULT(S): Individual
data of 4,837 patients from 7 observational studies were synthesized.
BARC-4 bleeding, 30-day mortality, and postoperative ischemic events
occurred in 20%, 2.6%, and 5.2% of patients. After adjusting for EuroSCORE
II and cardiopulmonary bypass time, guideline-conforming withdrawal was
associated with decreased BARC-4 bleeding risk in patients on clopidogrel
(adjusted odds ratio [OR] 0.48, 95% confidence intervals (CI) 0.28-0.81,
P=0.006) and a trend toward decreased risk in patients on ticagrelor
(adjusted OR 0.48, 95% CI 0.22-1.05; P=0.067). Guideline-conforming
withdrawal was not significantly associated with 30-day mortality risk
(clopidogrel: adjusted OR 0.70, 95% CI 0.30-1.61; ticagrelor: adjusted OR
0.89, 95% CI 0.37-2.18) but with decreased risk of postoperative ischemic
events in patients on clopidogrel (clopidogrel: adjusted OR 0.50, 95% CI
0.30-0.82; ticagrelor: adjusted OR 0.78, 95% CI 0.45 -1.37). BARC-4
bleeding was associated with 30-day mortality risk (adjusted OR 4.76, 95%
CI 2.67-8.47; P<0.001). <br/>CONCLUSION(S): Guideline-conforming
preoperative withdrawal of ticagrelor and clopidogrel was associated with
a 50% reduced BARC-4 bleeding risk when corrected for EuroSCORE II and
cardiopulmonary bypass time but was not associated with increased risk of
30-day mortality or postoperative ischemic events.<br/>Copyright &#xa9;
The Author(s) 2024. Published by Oxford University Press on behalf of the
European Association for Cardio-Thoracic Surgery.